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ABSTRACT 
Epidemiological studies have implicated that hyperglycemia (HG), even in the absence 
of overt diabetes mellitus (DM) may elicit adverse cardiac outcomes including diastolic 
dysfunction and heart failure (HF), possibly due in part to structural remodelling of the 
myocardium. This study investigated the relationship between HG, left ventricle (LV) 
remodelling and underlying molecular events at 2 ends of the spectrum of glucose 
(dys)metabolic states- in prediabetes and in overt chronic type 2 DM (T2DM) using the 
spontaneously diabetic Goto-Kakizaki (GK) rat as a model of prediabetes that 
progresses to overt T2DM. LV isolations from 2 and 18-month old male Goto-Kakizaki 
(GK) rats and age-matched male Wistar controls grouped on the basis of age, fasting 
plasma glucose and following an oral glucose tolerance test (OGTT) into prediabetic 
and chronic mild T2DM groups were used to assess remodelling changes and 
underlying transforming Growth Factor β1 (TGFβ1) activity, pro-hypertrophic Akt-
p70S6K signalling and gene expression profile of the ECM and Ca
2+
mediators using 
histological, immunohistochemical, immunoblotting and quantitative gene expression 
analyses and compared to age-matched Wistar control rats. LV remodelling in the 
prediabetic GK rat presented with marked hypertrophy of cardiomyocytes and increased 
ECM deposition that altogether translated into increased heart size in the absence of 
ultrastructural changes or fibre disarray. Molecular derangements underlying this 
phenotype included upregulated  TGFβ1 transcription and activity, recapitulation of 
foetal gene phenotype markers B-type natriuretic peptide (BNP) and α-skeletal actin 
(αSKA), activation of the Akt-p70S6K pathway and altered gene expression profile of 
key components (collagen 1α, fibronectin) and modulators i.e matrix metalloproteinases 
(MMP) 2 and 9, connective tissue growth factor (CTGF) of the ECM. Chronic mild 
T2DM produced prominent LV hypertrophy in GK rats, underscored by increased 
myocyte size and LV wall thickness, expression of natriuretic peptides (Atrial natiuretic 
peptide (ANP) and BNP) and Akt phosphorylation. In the absence of caspase-3 
mediated apoptosis, fibrosis proliferation in the GK LV paralleled increased 
transcriptional and biologically active pro-fibrogenic TGFβ1 in the LV with upregulated 
mRNA abundance for key ECM components such as fibronectin, collagen type(s) 1 and 
3α and regulators including MMP 2 and 9, and their tissue inhibitor (TIMP) 4, connexin 
43 (Cx43) and integrin α5. Ageing GK rats also presented with altered mRNA 
expression for cardiac sarcoplasmic reticulum Ca
2+
ATPase 2a (SERCA2a), Na
+
/Ca
2+
 
exchanger and the L-type Ca
2+
 channels which may contribute to the altered Ca
2+
 
transient kinetics previously observed in this model at 18 months of age ( unpaired t 
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test, p<0.05 vs. age-matched Wistar control for all parameters).The present results 
support the clinical relevance and suitability of the GK model of human disease in 
aiding definition of the mechanisms of ventricular decompensation in HF of diabetic 
origin. Additionally, this study demonstrates that a milieu dominated by chronic mild 
HG can produce a hypertrophic myopathy that recapitulates several aspects of the 
failing heart. Data concerning molecular signalling cascades and ECM phenotype may 
be particularly significant as targeting features of structural remodelling may delay 
onset and severity of myocardial complications. 
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FOREWORD 
Understanding the integrative biology of the failing heart in dysglycemic states at 
genetic, molecular and cellular levels is an important focus of current research efforts. 
Although DCM and its consequences on myocardial structure and function has been the 
subject of extensive enquiry, the role of hyperglycemia (HG) in HF pathogenesis by 
way of structural remodelling is still ambiguous. In investigating the relationship 
between HG and its potential contribution to HF pathogenesis in the relative absence of 
traditional cardiovascular risk factors, the approach to the study was 2 pronged by 
design. First, the effects of HG on myocyte contractility and remodelling in the ventricle 
were assessed using the well established STZ-type 1 model of DM. While the results 
demonstrated that HG may indeed result in altered contractile kinetics and structural 
remodelling in the LV, the clinical relevance of the study left much to be desired, 
especially given recently drawn correlations between prediabetes and adverse cardiac 
outcomes. Thus, following this „developmental‟ study, the nature of remodelling 
changes in dysglycemia and cogent molecular events were further investigated using the 
GK rat, a non-obese, non hypertensive model that develops mild T2DM following a 
prediabetic phase. 
In effect, chapter one introduces the relevant functional anatomy of the mammalian 
heart, the significance of remodelling changes in HF pathogenesis, reviews the 
biological basis of the link between DM, HG and HF and presents the rationale for the 
developmental experiments. The second chapter details preliminary experiments on 
myocyte contractility and remodelling in the STZ-induced model and the clinical 
motivation for future experimentation in the GK rat. In the subsequent chapters, 
ventricular remodelling and underlying molecular profile were explored further in 
prediabetes and overt chronic T2DM. As such, each section is dealt with separately for 
clarity but areas of common integration are signposted in the final chapter. In its 
entirety, by focussing on the role of HG alone, this work represents an attempt to 
simplify a complex problem and identifies several avenues for future research. 
 
  
  
 
 
 
 
 
 
 
CHAPTER 1 
 
 
 
 
GENERAL INTRODUCTION 
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For it is the heart by whose virtue and pulse the blood is moved, perfected, made apt to nourish 
and is preserved from corruption and coagulation .... It is indeed the fountain of life, the source 
of all action.’  
 
 William Harvey (1578-1697) 
 
1.1 The Functional Anatomy of the Mammalian Heart 
 
The mammalian heart is a four-chambered muscular organ situated in the anterior 
mediastinum, immediately posterior to the sternum and encapsulated by the 
pericardium. Its pumping ability is central to the functioning of the circulatory system 
wherein blood is pumped through a network of blood vessels namely arteries, veins, 
arterioles, venules and capillaries. These blood vessels can be subdivided into a 
pulmonary circuit carrying blood to and from gas exchange surfaces of the lungs and a 
systemic circuit through which blood is transported to and from the rest of the body 
(Sherwood, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.1: The mammalian heart. Components are described in the text. 
(Image courtesy www.beyondbiology.org) 
 
As given in Figure (Fig) 1, the right and left atria and the right and left ventricles make 
up the four chambers of the mammalian heart. Two chambers of the heart may be 
associated with each circuit; the right atrium receives blood from the systemic circuit 
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through the superior vena cava and the inferior vena cava and allows inflow into the 
right ventricle passing through the right atrioventricular (AV) or tricuspid valve. Blood 
is then pumped into the pulmonary circuit eventually being collected by the left atrium 
and emptied into the LV through the left AV or bicuspid valve. Semilunar valves are 
situated between the ventricles and the major blood vessels of the heart and open and 
close passively due to pressure gradients. Blood pumped from the right atrium into the 
pulmonary trunk passes through the pulmonary valve and blood leaves the left ventricle 
through the aortic valve into the ascending aorta. The atria are separated by the 
interatrial septum and the ventricles by a much thicker interventricular septum that 
houses electrical conduction tissue. Innervation of the heart is by both vagal and 
sympathetic fibres. The SA node and the atria are predominantly innervated by the right 
vagus whereas the left vagus nerve supplies the AV node and the bundle of His (Vander 
et al., 2007). The myocardium in the ventricles is only sparsely innervated by vagal 
efferents. Although rhythmic contraction of the heart is initiated in the SA node, cardiac 
function is mediated by neural activation. Release of noradrenaline by sympathetic 
nerves and subsequent activation of beta adrenergic receptors result in positive 
chronotropy, inotropy and dromotropy whereas parasympathetic stimulation brings 
about opposite effects, secreting acetylcholine that acts on muscarinic receptors. The 
cardiac action potential that initiates contraction is generated in the sinoatrial (SA) node 
and spreads through the atria before converging upon the AV node for distribution to 
the ventricles by the specialised Bundle of His, right and left bundle branches and 
Purkinje fibre network (Koeppen and Stanton, 2008). 
The walls of the atria are thinner than those of the ventricles, particularly the LV whose 
wall is 3-4 times thicker than the right ventricle at a corresponding position (Vander et 
al., 2007).  The wall of the heart is typically described to be made up of 3 layers; the 
outer epicardium (visceral pericardium) is a serous membrane consisting of an exposed 
mesothelium and a layer of smooth connective tissue that is attached to the myocardium 
(Koeppen and Stanton, 2008). The inner surfaces of the heart (including the valves) are 
lined by the endocardium that consists of squamous epithelial cells continuous with the 
endothelium of blood vessels. The myocardium is the middle muscular wall of the heart 
that forms both atria and ventricles. This layer encompasses several types of cells 
including atrial and ventricular contractile „working‟ myocytes that comprise muscle 
fibres, nodal cells, purkinje fibres, smooth muscle cells and fibroblasts (Koeppen and 
Stanton, 2008). Cardiac myocytes account for 70% to 75% of the myocardium by cell 
volume but only 25% to 30% by cell number (Miner and Miller, 2006). Cardiac 
CHAPTER 1                                                           GENERAL INTRODUCTION 
3 
 
fibroblasts that synthesize proteins of the ECM are the most abundant cell type of the 
myocardium 
 
1.1.1   The Extracellular Matrix 
The muscle fibre array of the myocardium is surrounded and interspersed by the ECM, 
a fibrillar, highly differentiated structure consisting of an organised hierarchy of 
connective tissue that provides structural support and functional integrity to the heart. 
The ECM is broadly differentiated into an epimysium encircling the endo- and 
epicardium, a perimysium that groups myofibrils into bundles and an endomysium that 
surrounds individual myocytes and provides connection to the vasculature (Fedak et al., 
2005).  It comprises of a complex network of structural proteins (collagen and elastic 
fibres) and adhesive proteins (fibronectin, laminin) within a hydrated proteoglycan and 
glycosaminoglycan-rich milieu (Graham et al., 2008).  Coiled fibers of the ECM act to 
store energy produced during systole, and hence relengthening of cardiac myocytes 
during diastole (Miner and Miller, 2006). Apart from the provision of a structural 
network that translates developed force in individual myocytes into regular synchronous 
contraction and passive stiffness, the ECM also functions to prevent myocyte slippage, 
overstretch and interstitial oedema. Once considered an inert physical scaffolding, 
ongoing research has established diverse roles of the ECM in transmembrane signalling, 
MAPK activation, growth factor mediation, cytoskeletal rearrangement, modulation of 
cell phenotype among other regulatory roles in hypertrophy and ontogenic development 
(Fedak et al., 2005; Graham et al., 2008; Bowers et al., 2010; Hutchinson et al., 2010). 
Transmembrane mechanoreceptors known as integrins constitute another important 
feature of the ECM that transduces mechanical forces and changes in ECM structure, 
through signals from the extracellular compartment to the cytoskeleton and vice versa.  
Integrins consist of two different chains, α (120±150 kDa) and β (110±190 kDa), linked 
by non covalent bounds. They modulate signals instigated by ionic channels, hormone 
receptors and growth factors, and participate in various transduction processes including 
those concerned with cell motility, division, differentiation and programmed death 
(Spinale, 2007; Graham et al., 2008; Bowers et al., 2010).  
The ECM is a dynamic entity and component proteins are maintained by a finely 
controlled homeostatic balance between deposition and degradation. Different families 
of MMPs that favour or inhibit matrix degradation, regulate the ECM in both normal 
and pathological conditions. Collagenases (MMP1) cleave collagens in fragments which 
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in turn constitute the substrate of proteases including the gelatinases (MMP2, MMP9) 
that are responsible for the degradation of type IV collagen and fibronectin (Bowers et 
al., 2010). These zinc-dependent enzymes are regulated by a class of proteins called 
TIMPs. The ability to synthesize ECM components differs among cells in the heart and 
varies depending upon the inciting stiumulus; myocytes produce type IV and VI 
collagens, laminin and proteoglycans. Collagen type(s) I and III and fibronectin, as well 
as MMPs are synthesised by the surrounding fibroblasts (Banerjee et al. 2006; 2007). 
Integrin activation also induces the synthesis of collagens and gelatinases, which 
regulate the synthesis and type of ECM proteins (Spinale, 2007). Modulation of these 
various components regulates mechanical, chemical and electrical signalling between 
cells (Miner and Miller, 2006).  
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(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.2 Components of the extracellular matrix. Interaction between different cell types 
(A). Electron micrograph of human fibroblast cells (B). Magnification X28, 000. Image 
A from www.visualphotos.com, B from http://www.dr-jacques-imbeau.com/index.html 
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1.1.2   The Cardiomyocyte 
 A ventricular myocyte is an elongated cell containing contractile myofibrils that give it 
a striated appearance (Fig 1.2 A). Ventricular myocytes are typically uni-nucleated, 
have a variable branching morphology, extensive capillary supply and are connected to 
adjacent cardiomyocytes at blunt ends by specialised intercalated discs. The intercalated 
discs of neighbouring cells are physically connected by types of cell junction i.e. gap 
junctions and desmosomes that together orchestrate and integrate cardiac electro-
mechanical activity. As a result, the entire myocardium functions as a single unit known 
as a „syncyctium‟ with a single contraction of the atria followed by a single contraction 
of the ventricles (Vander et al., 2001).  
An exquisitely specialised cardiac microanatomy coordinates the processes of orderly 
spread of action potentials, contraction of cardiac chambers and the pumping action of 
the heart. Similar in many respects to skeletal muscle cells, the fundamental contractile 
unit within the myocyte is the sarcomere containing interdigitating thick and thin 
filaments of the contractile apparatus, namely the proteins actin, myosin, the troponin 
complex and tropomyosin (Tm).  Three proteins, Troponin T, I and C (TnT, TnI, TnC) 
make up the thin filament complex and together mediate the extent of crossbridge 
formation whilst contributing to the structural integrity of the sarcomere (Fig 1.2 B, 
Sherwood, 2008) (Koeppen and Stanton, 2008). Within the cardiomyocyte, each 
myofibril is surrounded by the sarcoplasmic reticulum (SR), a highly organised Ca
2+
 
handling organelle made up of membranous tubules that regulate cytocolic Ca
2+
 flux in 
conjuction with key sarcoplasmic proteins namely SERCA, the regulatory protein of 
SERCA- phospholamban (Plb),
 
and the Ca
2+
 release channels (Fig 1.2 B). Another 
specialised component of the cardiomyocyte is the sarcolemma, a lipid bilayer 
combination of the plasma membrane and the basement membrane that contains 
membrane receptors, pumps and channels that regulate contractility. The sarcolemma 
forms the intercalated disks and penetrates deep into the cell to form the Transverse „T‟ 
tubular system that bring in close proximity ion channels and the SR calcium handling 
proteins, thus playing a pivotal role in cell contractility (Vander et al., 2001) (Fig 1.2 A, 
1.2 C). Integrins are interwoven throughout the sarcolemma and form an important
 
collagen-integrin-cytoskeletal relation.  
Nodal cells differ morphologically from contractile myocytes, being smaller in size with 
fewer contractile elements and gap junctions that appear more dispersed; a feature that 
accommodates protection from hyperpolarisation in the SA node and a slowing of 
conduction in the AV node. The latter feature works to ensure sequential contraction of 
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atria and ventricles. By contrast, gap junctions (made up of Connexins, notably 40 and 
43) are abundant in cells of the His-Purkinje system allowing for rapid conduction of 
electrical impulses (Walker and Spinale, 1999). 
 
 
 Fig 1.3: Functional anatomy of ventricular cardiomyocytes. Representation of EM 
micrograph detailing cardiomyocyte architecture (A). Cardiac myofilaments in cross 
bridge cycle underlying muscle contraction (B). Protein complexes and intracellular 
organelles involved in cardiac excitation–contraction coupling are illustrated (C) Red 
stars indicate proteins encoded by genes that are mutated in primary arrhythmia 
syndromes; many of these proteins form part of macromolecular complexes, so 
mutations in several genes could be responsible for these syndromes. Green stars 
indicate protein complexes in which mutations in multiple genes cause 
cardiomyopathies often associated with arrhythmias; these complexes include the 
sarcomere (in hypertrophic cardiomyopathy), the desmosome (in arrhythmic right 
ventricular cardiomyopathy), and the cytoskeleton, sarcoglycan complex and 
mitochondrion (in dilated cardiomyopathy). Typical ventricular myocyte action 
potential resulting from sarcolemmal protein interactions (D). Structure-function 
relationships between the elements in the figure and further descriptions of each 
component are summarized in the text. Image courtesy:  (A) Koeppen and Stanton, 
2008; (B) available via http://www.ccbm.jhu.edu/doc/courses/BME_580_682; (C) 
Knollmann and Roden, 2008; (D) Adapted from Vander et al., 2007 
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A more complete appreciation of the functional anatomy of myocyte ultrastructure 
comes from placing in it the context of (ventricular) myocyte contraction and relaxation. 
Grossly oversimplified, these processes are described as follows:  
At the resting membrane potential (corresponding to phase 4 of the action potential, Fig 
1.2 D) the sarcolemma is only permeable to K
+
, a condition maintained by the combined 
activities of the inward K
+
 rectifier, Na
+
/K
+
 ATPase and the Na
+
/Ca
2+
 exchanger 
operating in forward mode (Fig 1.2 C, 1.2 D). Depolarisation of the plasma membrane 
beyond an inherent threshold voltage results in the activation of voltage gated Na
+
 and 
Ca
2+
channels. Opening of fast Na
+
 channels results in the rapid upstroke characteristic 
of phase 0 of the action potential whereas the subsequent inward current that maintains 
the plateau of the action potential is primarily due to Ca influx via L-type Ca
2+
 channels, 
with Na
+
/Ca
2+
 exchanger playing a minor role. Rapid inactivation of the fast Na
+
 
channels (2-10 ms) and a transient net outward current of K
+
  along the electrochemical 
gradient contributes to an early, brief repolarisation (notch) during phase 1 of the action 
potential  (Fig 1.2 D). The small influx of Ca
2+
 that enters the cell after initial 
depolarisation triggers Ca
2+
 release from the SR by activating SR Ca
2+
  release channels 
culminating in a transient rise in cytosolic free calcium concentration to micromolar 
concentrations (10 µM/litre) from a resting (diastolic) nanomolar concentration (100 
nanomoles/L). A central feature of this process is the gating of the SR Ca
2+
 release 
channels by ryanodine receptors (RyR) located within terminal cisternae of the SR. This 
„calcium-induced calcium release‟, activates the contractile machinery and initiates 
contraction in the myocyte by a mechanism termed Excitation-Contraction coupling 
(EC coupling) (Vander et al., 2001).  
Under resting conditions, lower intracellular Ca
2+
 favours the shift of the Tn-Tm 
complex towards the outer grooves of the actin filament and thereby blocks actin-
myosin interaction. Rise in Ca
2+
 concentrations during the action potential and 
subsequent binding to TnC strengthens TnC-TnI interaction and detaches TnI from the 
actin molecule by a conformational shift of the Tn-Tm complex, enabling crossbridge 
formation (Fig 1.2 B). The available literature suggests that thin filament activation is 
achieved by the movement of Tm over the surface of actin and this motion permits force 
generation and shortening. After crossbridge formation, i.e. the attachment of the 
myosin head of the thick filament to the actin molecules of the thin filament, the myosin 
head changes confirmation „pivoting‟ towards the M-line, with concomitant ATP 
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hydrolysis to ADP that generates force causing the thin filament to slide over the thick 
filament and the sarcomere to shorten, altogether resulting in contraction. Binding of 
adenosine triphosphate (ATP) to the myosin head causes detachment of cross-bridges 
and (re)exposure of active sites making possible interaction with another cross-bridge 
(Fig 1.2B). This highly dynamic phenomenon termed the „sliding filament theory‟ 
moves the filaments approximately 10 nm with an average velocity of 0.98 µm/s  
(Koeppen and Stanton, 2008). Factors such as SR Ca
2+
 release, sensitivity of the 
myofilaments to Ca
2+
, number of crossbridges formed, duration of the action potential 
and ATP stores appear to decisively affect cardiomyocyte contraction. Following 
contraction, relaxation and is achieved by the removal of Ca
2+
 (that activates 
myofilaments) from the cytosol by cellular Ca
2+
transport systems. This phase 
corresponds to repolarisation or phase 3 of the action potential, wherein decay of the 
calcium transient occurs due to the reuptake of Ca
2+ 
into the SR by SERCA and the 
extrusion of Ca
2+ 
from the myocyte, primarily by the Na
+
/Ca
2+
 exchanger (Fig 1.2 C, 1.2 
D). This phase is characterised by the closure of sarcolemmal Ca
2+ 
channels and 
increased K
+
 conductance through the (slow and rapid) delayed rectifier K+ currents 
corresponding to a negative change in membrane potential. When membrane potential is 
restored to -80 to -85 mV, conductance is limited to the inward rectifier K+ channels 
that together set the resting membrane potential (phase 4) (Walker and Spinale 
1999;Vander et al 2007). 
1.1.3 Mechanical events of the cardiac cycle 
The cardiac cycle consists of alternate periods of systole (contraction and emptying) and 
diastole (relaxation and filling) in the atria and ventricles. Contraction results from the 
spread of the action potential across the heart whereas relaxation follows the subsequent 
repolarisation of the myocardium. In the text below, as one full cardiac cycle that begins 
and ends with ventricular diastole is described (Fig 1.3). The terms systole and diastole 
are used to indicate events in the ventricle and only activity in the left side of the heart is 
described. These are identical to those on the right side, with the exception of lower 
pressures in the right side of the heart (Sherwood, 2008). 
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Fig 1.3: Mechanical events of the cardiac cycle. Currently accepted time frames of 
systole and diastole (A).  The physiological phases of cardiac cycle that include 
isovolumic contraction, ejection, isovolumic relaxation rapid and slow filling, and atrial 
contraction are shown. Measurements of intravascular pressure in the aorta, LV, left 
atrium (LA), and LV volume that underlie the phases of the cardiac cycle, together with 
their impact on the mitral and aortic valves and the corresponding ventricular 
electrocardiogram (ECG). Aortic flow occurs between the 2 intervals that define 
ejection. AO: Aortic valve opens; AC: Aortic valve closes; MO: Mitral valve opens. 
(Images adapted from www.merckmanual.org) 
 
(B) 
(A) 
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As given in Fig 1.3, beginning at mid ventricular diastole, where the atrium is also in 
diastole, there is a continuous inflow of blood from the venous system into the atrium 
and hence a pressure differential. During this phase, the AV valve is open and passive 
ventricular filling results in a rising ventricular volume. This stage corresponds to the 
TP interval on the ECG. The next phase, late ventricular diastole, the SA node reaches 
threshold and fires and is detectable on the ECG as the P wave as the impulse spreads 
throughout the atria. This atrial depolarisation results in atrial contraction, squeezing 
blood into the ventricle. Although ventricular pressure rises simultaneously with rise in 
atrial pressure from this additional volume of blood added to the ventricle, the AV valve 
remains open throughout atrial contraction as pressure in the atria slightly exceeds that 
in the ventricle. During the next stage, where ventricular diastole ends, atrial contraction 
and ventricular filling are completed and the volume of blood, also known as end 
diastolic volume (EDV) averages at about 135 ml (Sherwood, 2008). During the next 
phase that sees the onset of ventricular excitation and ventricular systole, the impulse 
after atrial excitation travels to the AV node and the His-Purkinje system to depolarise 
the ventricle, represented on the ECG as the QRS comples. The modest delay between 
the QRS complex and the actual onset of ventricular systole is the time required for the 
EC coupling process. Atrial repolarisation and ventricular depolarisation occur 
simultaneously, so the atria are in diastole throughout ventricular systole. With the onset 
of ventricular contraction, ventricular pressure exceeds atrial pressure and the backward 
pressure gradient forces the AV valve closed. During the next phase, Isovolumetric 
ventricular contraction, the AV valves and the aortic valves are closed, and hence blood 
does not enter or leave the ventricle and ventricular pressure continues to rise as the 
volume remains constant. When the ventricular pressure exceeds aortic pressure, the 
aortic valve opens and ejection of blood begins. The aortic pressure curve continues to 
rise as blood is pumped into the aorta faster than that being drained into smaller vessels. 
The T wave on the ECG signifies the end of ventricular systole and as the ventricles 
start to relax, on repolarisation, ventricular pressure falls below aortic pressure resulting 
in the closure of the aortic valve. At this point, synonymous with isovolumetric 
ventricular relaxation, the AV valve is not yet open, as ventricular pressure still exceeds 
atrial pressure. When ventricular pressure falls below atrial pressure, the AV valves 
open and ventricular filling occurs again. Subsequently, the phase continues as 
described into late ventricular diastole, where the SA node fires again and the cardiac 
cycle continues. 
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1.2 Heart Failure 
Congestive HF (CHF) or simply HF has been defined as „a complex clinical syndrome 
that can result from any structural or functional cardiac disorder that impairs the ability 
of the ventricle to fill with or eject blood‟ (Dokken, 2008). Classification into systolic 
and diastolic
 
dysfunction has further emphasized the functional distinction between
 
abnormalities in contraction and relaxation. Systolic heart failure arises from a 
compromise in the contractility of the heart and is defined as a left ventricular ejection 
fraction (LVEF) of <45%. Diastolic dysfunction is a consequence of impaired 
relaxation and abnormal ventricular filling (Gutierrez and Blanchard, 2004).  Moreover, 
recent years have seen the recognition and confirmation of the clinical syndrome of HF 
with preserved LV ejection fraction, often accompanied by diastolic dysfunction and a 
prognosis similar to „classical‟ systolic HF (Owan et al., 2006) 
HF susceptibility is greatly increased in patients with diabetes mellitus (DM), metabolic 
syndrome, hypertension, ischemic events, history of cardiomyopathy and on use of 
cardiotoxins (e.g. cocaine, alcohol) (Francis, 2001). The condition is supremely 
debilitating and is known to reduce self reported quality of life more than most other 
chronic medical conditions (Gill et al., 2009) including arthritis or chronic lung disease 
(Hobbs et al., 2002). Sudden cardiac death is responsible for at least half of deaths 
although many succumb to progressive pump failure and congestion (Swedberg et al., 
2005). Most patients have signs and symptoms of fluid overload and pulmonary 
congestion including ascites, edema, dyspnea, orthopnea, and paroxysmal nocturnal 
dyspnea. Outside congestive symptoms, patients often present with signs of low cardiac 
output, including fatigue, effort intolerance, cachexia, and renal hypoperfusion (Hobbs 
and Boyle, 2010).  Deaths from end-organ failure due to insufficient systemic organ 
perfusion are not uncommon, particularly to the kidneys. Occurrence of renal 
dysfunction, cachexia, valvular regurgitation, ventricular arrhythmias, lower LVEF, 
high catecholamine and BNP levels, low serum sodium level, hypocholesterolemia, and 
marked LV dilation are all considered indicators of poor prognosis (Hobbs and Boyle, 
2010). Patients with combined systolic and diastolic LV dysfunction also have a worse 
prognosis than patients with either in isolation (Hansen et al., 2001).
 
 Presently, HF prevalence is on the rise as populations age, western diets predominate, 
cardiac disease from infectious aetiologies are overcome and the rate of acute mortality 
from ischemic events subside owing to dramatic improvements in sanitation, preventive 
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and interventional medicine (Jessup and Brozena, 2004; Benjamin and Schneider, 2005; 
Gill et al., 2009). Combining recent data on incidence and survival, the British Heart 
Foundation estimates that at least 4% of all deaths in the UK are due to HF 
(www.heartstats.org). The incidence and prevalence of HF increases steeply with age, 
the average age of first diagnosis being 76 years (Hobbs et al., 2002). Surveys in the 
UK and elsewhere show that 10-20% of the very elderly have HF. In 2008, of the 8650 
registered deaths in England and Wales attributed to HF, 97% were in the 65 and over 
age group (Wells and Gordon, 2008). Needless to say, HF is also a major burden on 
healthcare expenditure. In this regard, a 2009 estimate was that HF directly accounted 
for 1.9% of total NHS spending in the UK with 69% being on hospitalisations and 
indirectly via long term nursing care costs and secondary admissions for a further 
equivalent of 2% of NHS expenditure (Gill et al., 2009).  In 2008-9 there were 58,849 
admissions for HF in England alone, resulting in 740,697 bed days and 106,808 finished 
consultant episodes (www.heartstats.org). Mortality rates associated with HF are 
astronomical, at around 80% in men within 6 years of diagnosis, a prognosis worse than 
most forms of cancer, with almost 40% of those diagnosed dying within a year 
(National horizon scanning centre clinical guidelines, 2010).  
1.2.1   Pathophysiology of the failing heart 
Myocyte contractile dysfunction 
The traditional construct has viewed HF as a functional disorder, precipitated by 
impaired LV pump performance in response to increased hemodynamic burden of the 
heart and associated defects in myocyte contractility (Houser and Marguiles, 2003).
 
 HF 
is associated with a multitude of cellular and molecular defects that culminate in 
electrophysiological dysfunction, depressed myocyte contractility, fatal arrhythmias and 
pump failure (Kumar and Clark, 2009). Numerous studies have suggested that failing 
human cardiac myocytes undergo several changes that might be expected to lead to a 
progressive loss of contractile function, including decreased α-myosin heavy chain 
(MHC) gene expression with a concomitant increase in βMHC expression, progressive 
loss of myofilaments in cardiac myocytes and alterations in cytoskeletal proteins 
(Schaper et al., 1991; Nuebauer et al., 1995; Lowes et al., 1997; Gupta et al., 2000). In 
addition to these changes and the desensitization of adrenergic regulation, substantial 
evidence indicates that depressed myocyte contractility results from EC coupling 
alterations.  These include slowed Ca
2+
 reuptake as a result of reduced SERCA2a 
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expression and upregulated NCX exchanger in compensation, increased RyR2 
phosphorylation and ensuing increase in SR Ca
2+
 leak (Gupta et al., 2000). Moroever, 
an increased Na
+
 influx and intracellular Na
+
 accumulation, that increases internal Ca
2+
 
and SR Ca
2+
 load has also been previously documented (Pieske and Houser, 2003). 
Recent studies have indicated that a loss of t-tubules may occur in HF, leading to the 
anatomic and functional dissociation between electrical activation of the sarcolemma 
and release of SR Ca
2+
 (Wasserstrom et al., 2009). It is postulated that this process 
results in the isolation of increasing numbers of Ca
2+
 release units from the the L-type 
Ca
2+
 channel, and activation by Ca
2+
 diffusion from neighboring Ca
2+
 release units 
rather than by Ca
2+
 channels (Song et al., 2006). The ensuing delay in activation of the 
RyRs may cause a poorly coordinated release of Ca
2+
 along the cell length, leaving a 
highly fractionated cellular wavefront during Ca
2+
 release altogether contributing to 
reduced rates of calcium cycling and diminished cellular contractile performance in 
CHF (Wasserstrom et al., 2009).  
The idea that myocyte contractility is depressed in the failing
 
heart is supported by 
many, but not all,
 
(Gupta et al., 2000) studies.
 
Current or previously used HF treatments 
that increase contractility, primarily by increasing cAMP, have generally increased 
mortality (Houser and Marguiles, 2003). Similarly, a recent study has reported that that 
maintaining myocyte contractility after  myocardial ischemia (MI), by increasing Ca
2+ 
influx, depresses rather than improves cardiac pump function
 
by reducing myocyte 
number (Zhang et al., 2010). It is generally agreed upon that contractile properties can 
be similar in normal and
 
failing muscles under basal conditions but rate-related 
contractile
 
reserve is absent or significantly reduced in failing human
 
myocardium. 
Several studies have described that at least in the end-stage
 
failing human heart, basal 
contractility is well preserved but
 
"contractility reserve" i.e. the ability to increase 
contractility
 
with heart rate or sympathetic stimulation is severely depressed.
 
Such 
alterations may underlie the poor pumping function, reduced exercise capacity
 
and 
tachycardia intolerance of the failing human heart (Scrutinio et al., 2000; Gudjonnson et 
al., 2002; Houser and Marguiles, 2003) 
Reduced pump performance of the failing heart may not exclusively be the result
 
of 
fundamental defects in myocyte contractile properties. Other important factors include 
geometric remodelling and ECM alterations, cell death (apoptosis), altered vascular 
structure
 
and reactivity, abnormal energy utilization and neurohormonal
 
disturbances 
that can also contribute to the progression of
 
HF (Swynghedauw, 1999)  at least under 
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certain conditions and may do so independent of defective
 
myocyte contractility (Fedak 
et al., 2005).
 
 Most importantly, contrasting the traditional view that contractile failure 
leads to overt HF, today the HF pathophysiology paradigm has shifted towards the 
notion that the
 
systolic and diastolic dysfunction are consequences of a structural 
increase in ventricular
 
chamber volume (Swynghedauw et al., 2010). This is related to 
changes in ventricular geometry that places the heart at a considerable mechanical 
disadvantage, independent of any functional changes at the cellular level. Several 
studies detailing the natural history of HF have shown that progressive LV remodelling 
is directly related to future deterioration in LV performance and a less favorable clinical 
course in HF patients (Cohn et al., 1995; Douglas et al., 1989; Vasan et al., 1997; 
Mann, 1999). Conversely, preventing the progression of HF by slowing or reversing
 
the 
remodelling process is today an important target of therapy. The chronic effects of 
therapies
 
on surrogate measures of remodelling including changes in ejection fraction, 
LV end-diastolic
 
and end-systolic volumes have been assessed in large randomised 
studies and serve as a guide to the remodelling process. Given the potential central 
importance of LV remodelling in the progression of HF, the following section outlines 
putative cellular and molecular mechanisms underlying this process. 
Cardiac Structural Remodelling  
Structural and functional integrity of the heart is orchestrated by a fine balance between 
several neurohormonal and hemodynamic influences. Disruptions in this „fine tuning‟ 
(e.g. in duress or injury) activate a complex, progressive process of diverse adaptive 
responses at transcriptional, molecular, cellular and functional levels that allow the heart 
to adjust to new working conditions and can be collectively termed „remodelling‟.  For 
the intents and purposes of this work, cardiac remodelling may be broadly defined as 
alterations in cardiac structure resulting from altered hemodynamic load and/or cardiac 
injury. While remodelling may be physiological or pathological and by extension 
adaptive or maladaptive, in the present context the above definition excludes all aspects 
gestational or developmental as well as favourable remodelling that follows intensive 
exercise and is restricted to acquired structural rearrangement in the left myocardium.  
Cardiac remodelling is a common denominator in the aetiology of several primary 
cardiovascular diseases notably DM, coronary atherosclerosis, hypertension, 
cardiomyopathy, and myocarditis (Swynghedauw, 1999). As shown in Fig 1.4, HF may 
be viewed as a progressive disorder that is initiated in response to an index event (that 
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may be acute i.e. MI, chronic i.e. DM or hereditary) that results in a loss/damage of 
functioning myocytes or alternatively produces a decline in the ability of the heart to 
function as a pump. Irrespective of the inciting event, several neurohormonal and 
inflammatory pathways are activated, including the renin–angiotensin–aldosterone 
system (RAAS), the adrenergic system, inflammatory cytokine systems and a host of 
other autocrine and paracrine events as compensatory mechanisms to maintain stroke 
volume at a reduced ejection fraction (Packer, 1992; Fedak et al., 2005). Thus far, a 
multitude of proteins including norepinephrine, angiotensin II, endothelin, aldosterone, 
TGFβ1, tumor necrosis factorα (TNFα) have been implicated in to disease progression 
of the failing heart (Maytin and Colucci, 2002; Fedak et al., 2005; Swynghedauw et al., 
2010). These processes are initially compensatory and beneficial, and in most instances, 
patients remain asymptomatic or minimally symptomatic following the initial decline in 
pumping capacity of the heart, or will develop symptoms only after the dysfunction has 
been present for some time (Maytin and Colucci, 2002).  As such, the index event 
produces remodelling of the LV frequently along one of two patterns: hypertrophy or 
dilation. Myocardial hypertrophy associated remodelling results in increased LV mass 
without any effects on LV volume in a process termed „concentric remodelling‟ that is 
associated with preserved function as the ventricle is capable of generating greater force 
and higher pressure. The onset of LV dilation is characterised by „eccentric 
remodelling‟ and substantial increases in intraventricular volume with comparable 
increases in LV mass that represents a compensatory response to augment cardiac 
output in the face of  diminished contractile function. Eventually, functional demands 
override physiological compensatory mechanisms. It follows that the hypertrophic 
reserve of the myocardium is met; LV dilation progresses without appreciable increases 
in LV mass and in accordance with the Law of Laplace induces excessive wall stresses 
known to be typically antecedent to overt HF (Swynghedauw, 1999) (Fig 1.4).   Self-
sustaining neurohormonal and cytokine input becomes deleterious in the long term and 
the overexpression of the portfolio of bioactive molecules are known to contribute to 
disease progression independently of hemodynamic status by exerting direct cardiotoxic 
effects. Targeting neurohormonal input is therefore the basis of current HF treatment. 
Altogether, the triggers that stimulate the development of HF and varied and diverse 
and sustained LV remodelling is associated with a poor prognosis, gradual myocardial 
deterioration and a critical step towards transition to decompensatio cordis. However, it 
is important to appreciate that cardiac remodelling is a biological adaptive processes 
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triggered by environmental stress, and the onset of HF represents the limits of said 
adaptation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 1.4: Heart failure pathogenesis. Currently accepted schema of HF development and 
progression states that HF begins in response to an index event that produces an initial 
decline in pumping capacity of the heart following which a variety of compensatory 
mechanisms are activated to restore homeostatic CV function, including the adrenergic 
nervous system, the renin angiotensin system, and the cytokine system.  Although 
beneficial in the short term, sustained activation of these systems can lead to worsening 
LV remodelling and cardiac decompensation that underscores the transition to 
symptomatic HF. (Image courtesy Mann et al., 2009) 
 
1.2.2   Molecular signature of cardiac structural remodelling 
 
Cardiac remodelling occurs in response to cues generated by mechano-sensors 
(Connexins, integrins) that couple cellular signalling pathways to altered or mechanical 
stress/ injury. Where the nature and extent of signals that are transitorily activated are 
far from fully understood, it is accepted that the myocardial response to injury or altered 
mechanical load involves profound alterations in gene expression including the 
activation of those that are normally involved in embryogenesis, also known as the 
foetal gene program (Swynghedauw, 1999). In the context of MI-induced cardiac 
remodelling alone, genome-wide analyses have revealed significant coordinated 
changes in over 1400 genes early and 125 genes late in the infarct zone, and nearly 600 
genes early and 100 genes late in the non-infarct zone (LaFramboise et al., 2005). 
 Foetal gene reprogramming, characteristic of pathological remodelling frequently 
involves an upregulation
 
of fetal isoforms of genes whose products regulate cardiac 
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contractility
 
and Ca
2+
handling and paralleled by a down-regulation
 
of their adult 
isoforms (i.e., up-regulation of ß-MHC
 
vs. down-regulation of -MHC) and often 
includes decreased SERCA2a and increased NCX expression (Hilfiker-Kleiner et al., 
2006). Another important feature of the foetal gene phenotype markedly expressed in 
the remodelled myocardium is that of the natriuretic peptides ANP and BNP, often 
detectable in the circulation where they are used as an indirect marker for myocardial 
injury/overload (Lukowicz et al., 2005). These transcriptional changes culminate in 
several molecular and cellular alterations that characterise myocardial remodelling. For 
the purposes of this work, they are broadly categorised into those that occur in the 
myocyte and changes that occur in the volume and composition of the ECM.  
Within the myocyte, in addition to the functional changes described in the previous 
section, the remodelling process is invariably associated with sarcomeric reorganisation; 
Dilation of the heart is associated with myocyte re-lengthening, mediated by the 
generation of new sarcomeres in series and an enhancement of the length-to width ratio 
whereas a hypertrophic phenotype is the result parallel addition of new sarcomeres. At 
the molecular levels, hypertrophy appears to
 
be characterized by increased expression of 
adult isoforms of
 
sarcomeric genes (i.e., αMHC, cardiac αSKA) and is often 
concomitant with increased natriuretic peptide synthesis (Hilfiker-Kleiner et al., 2006). 
Furthermore, biomechanical stretch signalling, altered redox states and pathological 
stimuli including HG and TGFβ1 may induce the activation of the phosphatidylinositol 
3-kinase (PI3-K)/protein
 
kinase B (Akt)-p70S6K,
 
and/or activation of extracellular 
signal-regulated kinases
 
(ERK) which co-ordinate the hypertrophic response (Selvetella 
et al., 2004, Wu and Derynck, 2009). 
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Fig 1.6: Cardiac Hypertrophy. Left and Right Ventricles (LV and RV) in cross section. 
a, normal; b, concentric hypertrophy; and c, eccentric hypertrophy. Image adapted from 
Albert et al., 2004. 
Much experimental evidence suggests that the gradual loss of myocytes through 
necrotic and apoptotic cell death contributes to progressive and LV remodelling and 
cardiac dysfunction in the failing heart (Sabbah 2000; Wenker et al., 2003; Foo et al., 
2005). Particularly in relation to apoptosis, this point of view has received increasing 
support with the recognition that DNA damage characteristic of apoptotic cell death 
occurs in myocytes from failing hearts (Sabbah, 2000). Apoptotic events are 
characterised by the activation of caspase-8 and subsequently procaspase-3, an event 
initiated by the activation of
 
cell surface death receptors (e.g., Fas/FasL). On activation, 
caspase-3 activates downstream proapoptotic effector proteins
 
such as Bax and Bad and 
subsequently the release of cytochrome
 
c and other apoptogens from mitochondria 
(Hilfiker-Kleiner et al., 2006). Additionally, caspases may also cleave myocardial
 
contractile proteins and promote systolic dysfunction.
 
Therefore, treatment with caspase
 
inhibitors after myocardial infarction has been shown to preserve
 
myocardial contractile 
proteins, reduce systolic dysfunction,
 
and attenuate adverse ventricular remodelling and 
reduce infarct size after MI (Chandrashekar et al., 2004).  Despite the undeniable 
intrinsic appeal of programmed cell death as a potentially important mechanism for 
disease progression in the failing heart, a definitive role for cell death has not been 
established on account of several considerations including: 1. As catecholamines can 
provoke apoptosis, there is the possible overestimation of myocyte apoptosis frequency 
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assessed in explanted hearts obtained from patients awaiting cardiac transplantation, 
many of whom receive inotropic support (Narula et al., 1996; Olivetti et al., 1997).               
2. Data concerning myocyte cell death in mild to moderate HF is not forthcoming, 
casting doubt over whether apoptosis contributes to failure or whether it is a 
phenomenon that is observed only in end-stage HF. 3. There is considerable disparity in 
the published literature over estimates of apoptotic processes, ranging from 
0.003%/year to to clinically unrealistic estimates of '5% to 35% (estimated myocyte 
loss> 100%/year) (Mann, 1999). These inconsistincies in findings may be attributable to 
varying inclusion criteria amongst studies. For e.g. a study examining the zone of 
infarction may report significantly greater apoptotic myocytes opposed to another 
examining non infracted hearts and/or a milder pathology. Thus, it is difficult to 
definitively ascertain whether myocyte cell loss is an important contributor to HF 
pathogenesis, occurs early and continually in HF or, instead, only in end-stage hearts.  
Outside changes in the myocyte, structural remodelling in the myocardium is associated 
with alterations in the structure and function of the ECM. Indeed, ECM deposition is a 
widely recognized alteration in the failing heart and the notion that progressive fibrosis 
underlies LV dilatation and HF progression has been engendered by several 
experimental and clinical studies (Cohn, 1995; Mann, 1999; Maytin and Colucci, 2002; 
Fedak et al., 2005, Miner and Miller, 2006; Bowers et al., 2010). In pathological 
conditions, the ECM can be temporarily remodeled, reversibly remodeled or fully adapt 
to the changes in biomechanical load. However, prolonged overload results in 
detrimental collagen deposition that can render the heart electrically and structurally 
heterogenous, result in excessive diastolic stiffness  (Van Heerebeek et al., 2008) and/or 
induce LV dilatation altogether resulting in overt HF. Particular emphasis is given to the 
collagenolytic MMPs and their inhibitors, the TIMPs in underlying LV dilatation. The 
balance of proteolytic and antiproteolytic activity appears to be an important 
determinant of the rate of ventricular enlargement. The general view is that disruption of 
this balance results in progressive MMP activation leading to degradation of the ECM, 
myocyte slippage, thinning of the ventricular wall, and ventricular dilation that occurs 
in end stage HF (Swynghedauw, 1999; Maytin and Colucci, 2006; Yan et al., 2009). In 
support of this stance, pharmacologic MMP inhibition in a pacing-induced animal 
model of HF improved LV dimensions and performance when administered early in the 
remodelling process (Spinale et al., 1999). Chronic pharmacologic inhibition of MMP 
activity in rats with HF of hypertensive origin resulted in an attenuation of ventricular 
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dilation and dysfunction that was sustained throughout the 4 months of therapy 
(Peterson et al., 1999). Similarly, targeted deletion of MMPs has been shown to limit 
maladaptive remodelling in experimental models (Matsusaka et al., 2006) altogether 
indicating the potential therapeutic relevance of MMP inhibition which may be 
exploited in the near future. Studies employing transgenic mice clearly show the
 
role of 
MMPs and TIMPs in mediating the preservation of normal cardiac geometry
 
and 
function, and are consistent
 
with less deleterious cardiac remodelling in animal models 
treated
 
with pharmacological MMP inhibitors (Graham and Trafford, 2007). 
1.2.3 TGFβ1 in Cardiac Remodelling and Failure 
In recent years, a central role for TGFβ1 in the remodelling myocardium has come to 
light, given consistent myocardial upregulation in experimental models of MI and HF, 
and frequently in patients with dilated or hypertrophic cardiomyopathy (Dobaczewski et 
al., 2010). TGFβ1 is the most prevalent isoform of the TGFβs, a family of pleiotropic 
cytokines which are implicated in a wide variety of cell functions, including regulation 
of inflammation, ECM depostition, cell proliferation, differentiation and growth. The 
activating stimuli for TGFβ1 are varied, including reactive oxygen species, integrin- 
mediated interactions and also MMP‟s 2 and 9, a phenomenon that couples matrix 
degradation with activation of a molecule that primarily mediates matrix integrity and 
stability (Annes et al., 2003). Beyond homeostatic roles, TGFβ1 mediates phenotype 
and function of several cell types crucial in tissue injury and repair processes including 
fibroblasts. In addition to enhancing ECM synthesis from fibroblasts, it exerts potent 
matrix-preserving actions by suppressing the activity of the MMPs and by inducing 
synthesis of TIMPs (Schiller et al., 2004). TGFβ1 is a key upstream effector of CTGF, a 
fibrogenic mediator that acts in concert with TGFβ to promote persistent fibrosis (Leask 
and Abraham, 2004). The hypertrophic effects of TGFβ1 stimulation on cardiomyocytes 
may be by TGFβ1-mediated synthesis of fetal contractile proteins (Parker et al., 1990). 
Alternatively and of particular importance, a recent invitro study elegantly demonstrated 
the ability of HG to induce hypertrophy in fibroblasts and epithelial cells (Wu et al., 
2009) and implicated a central role for TGFβ1 signalling in this process (Fig 1.5).  It 
was demonstrated that blocking the kinase activity of the TβRI receptor or loss of its 
expression prevented the hypertrophic effects of HG. The authors proposed that 
exposure of cells to HG induced a rapid increase in cell surface levels of the TGFβ 
receptors, TβRI and TβRII, and a rapid activation of TGFβ ligand by MMP2 and 
MMP9. The consequent autocrine TGFβ signalling in response to glucose led to  
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activation of pro-hypertrophic Akt-TOR pathway. As such, blocking MMP2/MMP9 (by 
transfection of cells with siRNA specific for MMP2 or MMP9) or TGF-β-induced TOR 
activation (by administering rapamycin) inhibited high glucose-induced cell 
hypertrophy. However, whether this mechanism holds true in vivo and in the context of 
the cardiomyocyte has not been established. 
Although there is substantial evidence indicating that TGFβ1 mRNA and protein 
induction is upregulated in the remodelling myocardium, direct evidence of increased 
activity is still lacking (Dobaczewski et al., 2010) and in vivo effects of TGFβ1 in 
promoting the myocardial fibrotic and hypertrophic response are supported by 
overexpression experiments in transgenic mice (Rosenkranz 2002, Dobaczewski et al., 
2010). Targeting regulatory mechanisms of ECM homeostasis that precede transition to 
HF remains a vital goal in HF management. As TGFβ1 levels often reflect the 
development of cardiac remodelling (Villar et al., 2009) the TGFβ1 system is a 
promising therapeutic target for myocardial infarction and for cardiomyopathic 
conditions such as diabetic cardiomyopathy that are associated with fibrosis and 
hypertrophy. Also late, but not early, TGFβ blockade has been demonstrated to 
attenuate remodelling in experimental MI and TGFβ inhibition through administration 
of inhibitory peptides (Hermida et al., 2009), or neutralizing antibodies (Kuwahara et 
al., 2002), has prevented the development of cardiac fibrosis in experimental pressure 
overload. 
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Fig 1.5: Functional interactions of HG with TGFβ signalling that underlie in vitro 
cellular hypertrophy in epithelial cells. HG-induced cell hypertrophy required functional 
TβRI signalling and rapid induction of TGFβ signalling including Smad (Smad, “sma”( 
Caenorhabditis elegans protein) + “Mad” mothers against decapentaplegic) activation 
and MMP-dependent mediation of latent TGFβ, altogether   leading to activation of the 
Akt-TOR pathway and increased cell size. Image courtesy Wu and Derynck, 2009. 
 
In précis, structural remodelling pathognomonic of HF is characterised by alterations in 
cardiomyocyte phenotype with re-expression of a fetal gene program, defective EC 
coupling, disturbed intracellular Ca
2+
 handling, and ECM aberrations. These findings 
have been reproduced in vitro and in experimental model systems and are produced in 
response to  several stimuli known to be associated with pathologic remodelling, 
including mechanical strain, catecholamines, angiotensin, endothelin, peptide growth 
factors like TGFβ1, inflammatory cytokines, and oxidative stress.  
Knowledge and understanding of the mechanisms underlying HF has developed steadily 
over the last century. Once considered an edematous disorder, 40 years ago a 
hemodynamic derangement and today a principally neurohormonal event, the central 
dogma of HF onset and progression has evolved considerably. However, a unifying 
mechanism underlying HF pathogenesis is still elusive and there is still considerable 
uncertainty of the exact nature of the disease, defaulting to
 
the analysis of its parts from 
various perspectives. In this regard, where numerous drug and nondrug strategies have 
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been developed
 
over the last 20 years, based on the prevailing mechanistic
 
understanding at the time, many efforts to correct fluid retention, stimulate the inotropic 
state of the heart, and modulate neurohormonal systems have not predictably improved 
the condition of HF patients (Lionetti and Recchia, 2010). The complexities and 
intricacies of the field and the challenges encountered in translational study are outside 
the scope of this thesis but were effectively emphasised in a 2002 editorial stating 
„Nearly 1,000 new drugs and devices have been developed for the treatment of HF 
during the past 20 years, but only 9 have received regulatory approval and are being 
used in the clinical setting‟ (Packer, 2002). Unfortunately, almost a decade later, the 
editorial comment is still highly topical.   
What cannot be contested is the impact of DM towards HF pathogenesis. CHF and DM 
commonly coexist and each condition appears to increase the likelihood of developing 
the other. Their synergistic influence in the same patient markedly increases the risk of 
morbidity and mortality and complicates therapeutic intervention (McDonald et al., 
2008; Van Melle et al., 2010). In the next section, epidemiological overlap and 
fascinating intersection between these 2 common conditions is addressed. However, for 
the purposes of the present work, text is limited to the contribution of DM towards HF 
pathogenesis 
1.3  Diabetes Mellitus 
The importance of studying DM is illustrated by the fact that it is a disease of 
epidemiological impact, being one of five leading causes of death in most developed 
countries (Bandyopadhyay, 2006). The estimated prevalence rate for DM in 2010 was 
285 million, projected to affect 438 million people by 2030 (Diabetes UK, 2010). The 
epidemic of DM is accompanied by the scourge of CVD. With morbidity and mortality 
rates reaching epic proportions, the disease today represents one of the greatest medical 
and socio-economic challenges for this century. 
 Clinical Presentation of Diabetes Mellitus 
DM is a progressive, debilitating disease characterised by HG and glucose intolerance 
due to insulin deficiency, impaired effectiveness of insulin action or both (Kumar and 
Clark, 2009). Current diagnosis of the disease is based on glucose levels (WHO, 2006); 
random venous plasma glucose levels above 11.1mmol/L on two occasions and/or 
fasting plasma glucose ≥7 mmol/l (126 mg/dL) is required for a diagnosis of DM. A 
two-hour blood glucose ≥ 11.1mmol/L (200 mg/dL) on administration of an OGTT (2 
hour venous plasma glucose after ingestion of 75 g oral glucose load) compared to 
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normal glucose tolerance value of <7.8 mmol/L is used to further confirm DM. Other 
signs and symptoms include polydypsia, polyphagia and unexplained weight loss. 
On the basis of aetiology, natural history and clinical presentation of the disorder, the 
disease is classified into type 1 (T1DM) and type 2 DM (T2DM). T1DM, previously 
known as juvenile-onset DM ranks as one of the most common childhood diseases in 
developed nations and comprises <10% of all cases of DM. The causative factors of 
T1DM continue to be under some speculation and a genetic vulnerability has been 
suggested (Horst et al., 1997). The prevailing concept is that T1DM, also known as 
„Insulin Dependent Diabetes Mellitus‟ results from a cellular-mediated autoimmune 
destruction of pancreatic islet β cells that is strongly associated with the major 
histocompatibility complex resulting in loss of insulin production that is restored, up to 
a point by imunosuppression (Parving et al.,1999). Despite several advances in the 
field, T1DM is currently refractory to prevention, barring toxic immunosuppression 
(Mordes et al., 2008). T2DM, previously known as Non Insulin Dependent Diabetes 
Mellitus, accounts for 90-95 % of diabetic individuals (Zimmet and Alberti, 2006). The 
disorder is characterised by HG due to an impairment of insulin-mediated glucose 
uptake, i.e. insulin resistance (IR) or a defective secretion of insulin by pancreatic β 
cells. As age advances, insulin secretion tends to decline. In this respect it is noteworthy 
that most diagnoses of T2DM are made after the age of 40 years although the age of 
onset maybe several years earlier (Kannel and McGee, 1979). Factors initiating T2DM 
are multi-factorial, cumulative and are usually related to obesity, and decreased physical 
activity altogether accelerated by genetic predisposition.  These alterations increase 
insulin resistance and in concert with progressive β cell failure, resulting in rising 
glycemia in the nondiabetic range. In recent years, it has become apparent that being 
non-diabetic does necessarily imply normoglycemia. An interim condition termed 
„prediabetes‟ that presages the onset of T2DM has been identified wherein glucose 
levels are elevated but do not meet the current criteria that define diabetes (Bergman, 
2009). The term prediabetes is used interchangeably with impaired fasting glucose 
(IFG) and/or impaired
 
glucose tolerance (IGT), both of which are associated with IR, 
IFG being primarily due to hepatic insulin resistance and IGT related to IR in muscle 
(Nathan et al., 2007). IFG is currently defined as an elevated fasting plasma glucose of 
100-125 mg/dl (5.6-7.0 mmol/l) and IGT as a 2-hour glucose value between 140-199 
mg/dl (7.8-11.1 mmol/l) on OGTT. Although the transition from these early metabolic 
abnormalities to overt diabetes may take many years,  current estimates indicate that up 
to 70%  of individuals with these prediabetic states eventually develop DM and as many 
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as 83% of individuals with IGT may develop the disease over a lifetime unless changes 
occur in diet and level of activity (Nathan et al., 2007). It is noteworthy that the absolute 
glucose concentration that clearly distinguished normal from abnormal glucose 
tolerance has not been established and the current literature advocates the 
acknowledgement of a „continuum of risk‟ opposed to a specific value (Nathan et al., 
2007; Cefalu and Watson, 2008; Bergman et al., 2009). Independent studies have 
reported strong associations between normal FPG levels and the incidence of diabetes, 
suggesting that diabetes risk increases with fasting glucose levels even within the 
normal range (Shaw et al., 2000; Nichols et al., 2008). Taking this into account, the 
speculation has arisen that mild diabetes may not differ substantially from IGT and by 
extension that that IFG differs from “normal” glucose tolerance at least at the upper 
limits of the fasting range (Bergman et al., 2009). Finally, the term „dysglycemia‟ has 
been coined to describe a state of plasma glucose at which adverse outcomes are likely 
to occur (Schainberg et al., 2010). 
 
The Burden of Cardiovascular Disease in Diabetes Mellitus 
Cardiovascular disease (CVD) refers to dysfunction of the heart and/or the blood 
vessels, or the blood itself (Marso and Stern, 2003) and includes the clinical 
manifestations of microvascular and macrovascular disease, coronary heart disease 
(CHD), stroke, and peripheral vascular disease. CVD is a major cause of death and 
disability in people with DM, accounting for 44% of fatalities in people with T1DM and 
52% in people with T2DM (Diabetes UK, 2010). CVD accounts for up to 80 % 
premature mortality associated with DM and in the UK, diabetes is second only to 
smoking as the leading cause of CVD (British Medical Association, 2004). DM has 
been established as a major independent risk factor for CVD in current risk assessment 
algorithms such as the Framingham risk score, the New Zealand risk calculator and the 
British Guidelines (Cameron and Cruikshank, 2007). Diabetic patients frequently show 
signs of accelerated atherosclerosis, undergo acute coronary syndromes, MI with 
peripheral artery disease and stroke (Spinetti et al., 2008). Compared with a non 
diabetic individual, a person with T2DM has a 2-4 fold increased risk of dying from MI 
or stroke and a 10-15 fold increased risk of a lower extremity amputation (Peter et al., 
2008).  Diabetic patients also have an adverse course following MI, with high rates of 
post infarct failure and death (Goodfellow, 1997).  
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1.3.1 Influence of Diabetes Mellitus on Heart Failure Risk and Outcomes 
While CHD is the most common cardiac manifestation in patients with DM, several 
epidemiological studies have provided clear evidence of the negative influence of 
diabetes on the prevalence, severity and prognosis of HF (Zimmet and Alberti, 2006). 
The 2005 „Guideline Update for the Diagnosis and Management of Chronic Heart 
Failure in the Adult‟ of the American College of Cardiology/American Heart 
Association designated patients with DM as having stage „A‟ HF in recognition of the 
disease as an important precursor for HF and an independent risk factor for death in HF 
patients (Hunt et al., 2005). 
The first demonstration of an increased risk of HF in patients with DM was reported by 
Kannel and colleagues in 1979, based on data obtained from 20 years follow-up of the 
Framingham cohort, wherein a 2.4-fold increase in the incidence of HF in diabetic men 
and a 5.1-fold increase in diabetic women was reported, independent of age, 
hypertension, dyslipidaemia, obesity and CHD (Kannel et al., 1974). Since then other 
large population-based studies have yielded similar results. These include the 
Cardiovascular Health Study (CHS) (Gottdeiner et al., 2000), the Strong Heart Study 
(SHS) (Devereux et al., 2000) and the Multi-Ethnic Study of Atherosclerosis (MESA) 
(Bertoni et al., 2006) that have observed correlations between DM and increased 
incident HF and also markers of HF risk including LV mass, volume and systolic 
dysfunction. Cross sectional studies have reiterated these findings, frequently reporting 
an unusually high prevalence of HF in diabetic patients. A report by Nichols et al.,  
(2001) noted 12% of Type 2 diabetic patients with HF at entry, with an annual 
incidence of 3.3%. In a similar study of 2737 elderly patients over 43 months, the 
incidence of HF was vastly higher in diabetic (39%) compared with non-diabetic (23%) 
patients (Aronow et al., 1999). As expected, subgroup analyses of randomised studies 
have shown that, that diabetic patients are over-represented in large HF trial 
populations;  26% of patients in the Prevention arm of  the Studies of Left Ventricular 
Dysfunction (SOLVD) clinical trial were diabetic (The SOLVD Investigators, 1991). 
Similarly, 19% of ATLAS (Assessment of Treatment with Lisinopril and Survival) 
study patients were diagnosed with DM (Komadja et al., 1994). Finally, in the V-HeFT-
II, trial (Vasodilator-Heart Failure Trial) (Cohn et al., 1986), RESOLVD (Randomized 
Evaluation of Strategies for Left Ventricular Dysfunction) (McKelvie et al., 1999) and 
Epidémiologie de l'Insuffisance Cardiaque Avancée en Lorraine  (EPICAL) (Zannad et 
al., 1999) trials diabetic patients represented 20%, 27% and 26% of the population 
CHAPTER 1                                                           GENERAL INTRODUCTION 
30 
 
respectively. Overall, recent estimates indicate that the prevalence of HF in diabetic 
patients is 12%, rising to 22% in those over the age of 64 years, significantly higher 
than the 4-6% prevalence in age-matched control populations (Asghar et al., 2009). In 
2003, up to a third of all HF hospital admittances were diabetic and conversely, DM has 
a prevalence of 30% in patients with HFand the disease may be up to four times as 
prevalent in patients with newly diagnosed HF (Bauters et al., 2003). Finally, diabetic 
patients are also more likely than non-diabetic patients to develop HF following MI, 
despite comparable infarct sizes (Mak et al., 1997)  
 
Diabetic Cardiomyopathy in Heart failure Pathogenesis 
The association of DM with increased HF risk can be broadly grouped into two main 
categories, namely CHD and DCM. Although the common final pathway for both CHD 
and DCM is HF, the latter is the focus of this thesis. A heightened cardiovascular 
mortality rate in diabetics is accountable in part, to an accelerated atherosclerosis and 
microvascular dysfunction coupled with augmented thrombogenicity, procoagulability 
and activation of systemic inflammation culminating in atherothrombotic CHD, diabetic 
microangiopathy, small artery endothelial dysfunction and increased arterial stiffness. 
However, HF in DM patients may also have a non-thrombotic/ischemic aetiology with 
the disease resulting in a distinct metabolic cardiomyopathy. The concept of DCM was 
first introduced by Rubler et al., (1972), and has subsequently been widely used by 
epidemiologists and clinicians. Its pathogenesis is underscored by a combination of 
structural (hypertrophic and fibrotic) remodelling of the myocardium and diastolic 
dysfunction that precedes systolic failure and overt CHF (Grossman and Messerli, 1996; 
Bracken et al., 2003).  
Evidence substantiating the existence of DCM arises from numerous clinical trials and 
epidemiological studies implicating structural changes within the myocardium that 
impair function as a consequence of the disease and its (dys)metabolic milieu, 
independent of other cardiac co-morbidities (Galderisi et al.,1991; Ishihara et al., 2001; 
Marwick, 2006; Fox et al., 2007; Sack, 2009). Increased LV diastolic stiffness is often 
the earliest manifestation of DM-induced LV dysfunction and frequently becomes the 
main functional
 
deficit of the diabetic heart. Hence HF often presents with normal 
LVEF (Van Heerebeek et al., 2008) but reduced diastolic complicance is known to 
modify
 
ischaemic LV dysfunction, as is evident from the reduced LV remodelling
 
and 
increased incidence of HF after acute myocardial infarction in patients with DM (Stone 
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et al., 1989; Solomon et al., 2002). Several studies in diabetic populations have reported 
echocardiographic changes consistent with diastolic dysfunction and LV hypertrophy 
that precedes the onset of systolic dysfunction. Increased LV wall thickness, LV mass 
index, impairment of early diastolic filling, prolongation of isovolumetric relaxation, 
increased atrial filling and increased numbers of supraventricular premature
 
beats, an 
age-related decline in ejection fraction, and an age-related
 
increase in diastolic diameter 
are frequently reported in diabetic patients and portend
 
an increased risk for the 
subsequent development of HF,
 
particularly in the presence of coexisting hypertension 
(Liu et al., 2001; Bell, 2003; Schannwell et al. 2002; Fang et al., 2004; Boudina and 
Abel, 2007; Dokken, 2008).
 
 Echocardiography measurements have revealed that these 
complications can occur in „uncomplicated‟ T1DM without clinically apparent 
macrovascular or microvascular complications and that 30% of patients with well 
controlled T2DM may have diastolic dysfunction (Boudina and Abel, 2007). In the 
same vein, data collected utilizing Flow and Doppler methods suggest traditional 
techniques may have underestimated this figure, further indicating a 40% to 60% 
prevalence of diastolic dysfunction in community
 
surveys and in smaller studies of 
individuals with type 1 and
 
type 2 diabetes without overt CHD (Poirier et al., 2001; 
Redfield et al., 2003; DiBonito et al., 2005; Galderisi et al., 2006). These findings have 
been confirmed in the laboratory where experimental DCM models demonstrate 
structural remodelling and abnormalities in diastolic LV function, with or without 
systolic LV dysfunction. Most studies have been performed
 
in isolated perfused hearts 
and reveal depressed cardiac function (Sidell et al., 2002; Mazumdar et al., 2004; 
Boudina et al., 2005; Buchanan et al., 2005). In vivo work in rodent models has 
provided evidence for systolic and
 
diastolic dysfunction by echocardiography (Zhou et 
al., 2000; Semeniuk et al., 2002). At the cellular level, these abnormalities have been 
associated with myocyte hypertrophy, fibrosis proliferation and contractile dysfunction 
of isolated myocytes (Fang et al., 2004; Marwick, 2006; Asghar et al., 2009). 
While the existence of DCM as a distinct clinical entity might be conceptually agreed 
upon and many structural and functional manifestations characterised, its origins are 
incompletely understood.  Several putative mechanisms have been proposed including 
microangiopathy and
 
cardiac autonomic neuropathy, the metabolic derangements of 
HG, IR/hyperinsulinemia and their adverse sequelae including depletion of glucose 
transporter 4, increased free fatty acids, advanced glycation end products and reactive 
oxygen species, dysfunctional Ca
2+
 homeostasis, that synergistically predispose to the 
detriment of cardiac structure and function (Dhalla et al., 1998; Kajstura et al., 2001; 
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Brownlee et al., 2005; Boudina and Abel, 2010). Evidence indicating the involvement 
and relative contribution of these abnormalities in the development of DCM is still 
largely equivocal. Where further description of each underlying cause is outside the 
remit of this report, emphasis in this work is placed on the singular role of HG in the 
myocardial complications of DM. 
1.3.2 Relation between Hyperglycemia and Heart Failure 
HG- the sine qua non for a diagnosis of DM, the target for antidiabetic therapy and 
(together with glycated haemoglobin {HbA1c}) the prinicipal marker of glucose control 
(Schainberg et al., 2010), is an important factor that increases the risk for the 
development of CV events in general and HF in particular in patients with DM (Bauters 
et al., 2003; Anselmino et al., 2010). The significance of HG in HF pathogenesis is 
perhaps better appreciated against a background of clinical trial data.  In this context, 
the level of HbA1c, as a measure of cumulative glycemic burden, is an important 
marker of increased risk. In an epidemiological analysis of the United Kingdom 
Prospective Diabetes Study (UKPDS), for each 1% rise in HbA1c, a 14% rise was 
shown in the risk for MI, a 12% rise in the risk for stroke, and a 16% rise in the risk for 
HF (Stratton et al., 2000). In the Strong heart study, T2DM was associated with LV 
enlargement and decreased myocardial function, where the extent and frequency of 
diastolic dysfunction was directly proportional to A1c level (Devereux et al. 2000). In a 
Danish study of MI survivors with DM and HF, each 1% increase in HbA1c above 5% 
over a 2.5-year follow-up period resulted in a 24% increase in mortality (Gustafsson et 
al., 2007). Preliminary data from an ongoing study in Scotland demonstrated that 1% 
increase in HbA1c was independently linked to a 19% increase in incident HF after 
controlling for mean arterial pressure and use of anti-diabetic drugs such as 
thiazolidinediones (Wong et al., 2010). A number of mechanisms have been postulated 
by which HG can contribute to the development and progression of DCM and HF. 
Diastolic dysfunction in DCM is thought to be the result of HG-induced structural 
remodelling characterised by myocellular hypertrophy and apoptotic cell death, 
alterations in myocardial Ca
2+
 handling and ECM modifications, leading to increased 
ventricular stiffness and impaired relaxation (Bell, 2003; Asghar et al., 2009; Boudina 
and Abel, 2010). Experimental studies indicate that cardiac efficiency is decreased in 
diabetes because of increased fatty acid utilization, which leads to an increased 
production of ROS. The increase in HG-mediated oxidative stress in diabetic hearts has 
been found to alter mitochondrial function, decrease NO levels, worsen endothelial 
function, and induce myocardial injury through stimulation of inflammatory mediators 
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resulting in cardiomyocyte contractile dysfunction and altered Ca
2+
 homeostasis (Dhalla 
et al., 1998; Kajstura et al., 2001; Brownlee et al., 2005; Boudina and Abel, 2010).  
Compelling epidemiological and experimental evidence notwithstanding, the role of HG 
per se in HF pathogenesis is still controversial and several factors potentially contribute 
to the contention: A significant proportion of what is known about the underlying 
aetiology of DCM is based on scattered data obtained from several animal models and 
considerable inconsistency exists in the demonstration of cardinal manifestations of the 
disease including myocyte contractile dysfunction and structural remodelling (Asghar et 
al., 2009). In the interpretation of experimental results, differences in animal models
 
examined are another major consideration. Moreover, because DM develops at varying 
tempos in these models, it is important
 
to bear in mind that studies performed in animals 
before the
 
onset of DM may reflect changes that are secondary to other risk factors
 
 (e.g. 
underlying obesity), and studies performed
 
after the onset of DM may reflect the added 
effects of
 
HG of various durations. Thus despite numerous studies of experimental 
diabetes, there are varying degrees of disparity in the exposition of the „hallmark‟ 
characteristics of DCM (addressed further in Chapter 3).   
DM is a multifaceted disease that often clusters with the metabolic syndrome 
(especially obesity and hypertension). Hence it is a challenge to de-tangle the 
importance of contributory insults to the myocardium and distinct delineation of the 
syndrome from other cardiac risk factors is not always feasible in clinical studies (Sack, 
2009). The extensive overlap between DM, hypertension, and ischemic heart disease 
also makes it difficult to tease out the degree of myocardial dysfunction that is caused 
by the metabolic syndrome, per se. Caution is advised in the interpretation of clinical 
trial/epidemiological study data as conclusions sometimes tend to be drawn from small, 
heterogeneous populations using indices with known limitations. These include non-
adjustment for accepted confounding factors such as diastolic dysfunction or LVEF and 
short follow up times (Held et al., 2007; Van Melle et al., 2010). Moreover, despite 
strong associations between
 
increasing dysglycemia and CV risk it has not been clearly 
demonstrated that lowering of blood glucose improves
 
in HF prognosis/ delays HF onset 
patients with T2DM (Goldfine and Beckman, 2008). Where glycemic control is 
expected to eliminate morbidity and mortality in DM, recent trials have demonstrated 
that very tight
 
control of glucose in patients with diabetes (with or without
 
episodes of 
hypoglycemia) may not improve mortality, and may,
 
in fact, increase it  (DCCT 
research group, 1993; Nathan et al., 2005; Gerstein et al., 2008).  Results for some 
outcomes, such as all-cause and cardiovascular mortality have varied significantly 
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across trials. For instance, the UKPDS metformin trial reported that tight glycemic 
control reduced mortality risks (UKPDS study group, 1999). In stark contrast, the 
ACCORD (Action to Control Cardiovascular Risk in Diabetes) trial reported that 
stringent glycemic control increased these risks (ACCORD study group, 2008). Possible 
explanations for the increased mortality risk with tight control in the ACCORD trial 
included the adverse effects from hypoglycaemia or the anti-diabetic insulin sensitizer 
rosiglitazone and chance. (!) (Montori and Fernández-Balsells,  2009).  
 
1.3.3   Animal models of Diabetes Mellitus 
A significant part of the current understanding of the pathophysiology and pathogenesis 
of cardiac disease in DM can be attributed to experimentation in the rodent model 
system. The rodent model shares many phenotypic similarities to human disease and 
meaningful correlates can be drawn in metabolism and physiology. With regard to the 
influence of DM on cardiac structure and function, rat models have been effectively 
used to study structural phenotypes, physiology of altered energy flux and storage, 
insulin secretion and action and numerous other metabolic parameters (McNeill, 1999; 
Kahn, 2005). Considering the limitations of invasive testing in human tissues and 
ethical and logistical constraints herewith, rat models provide invaluable opportunities 
to study detailed molecular mechanisms underlying the pathophysiology of diabetes in 
controlled conditions accounting for microbiological, chemical, genetic and 
environmental factors. Other advantages include relatively short generation intervals, 
adaptability to invasive testing and other economic considerations. Rat models 
mimicking physiological and pathological states unique to each diabetes subtype have 
been developed to investigate inherent etiopathologic heterogeneities. Spontaneous 
models of type 1 DM include BB (bio breeding) rat and the Long Evans Tokushima 
lean rat, whereas the Otsuka Long-Evans Tokushima Fatty (OLETF) rat and Israeli sand 
rat are examples of monogenic models of obesity and diabetes. The rat models utilized 
in this study are described below. 
 
The Streptozotocin-induced type 1 diabetic rat model 
Chemically induced type-1 diabetes is by far the most common model of animal DM 
and frequently involves administration of agents that produce the desired pathology by 
producing toxic effects on the beta cells of the pancreas. Alloxan and Streptozotocin 
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(STZ) are widely used diabetogenic agents owing to their specific action on β cells 
resulting in lesions that quite accurately resemble β cell destruction characteristic of 
T1DM and the sustenance of a relatively permanent diseased state to enable 
investigation of chronic effects of DM (Lenzen, 2008). Compared to alloxan (cyclic 
urea analog), STZ is reported to have a greater specificity to β cells, a longer half life 
and is associated with lower mortality rates (Lenzen, 2008), making it the agent of 
choice for chemical induction of experimental diabetes in this study. The antimicrobial 
STZ [2-deoxy-2(3-methyl-3-nitrosourea)1-D-glucopyranose], is a product of 
Streptomyces achromogens and has been used as a chemotherapeutic alkylating agent.  
Declared diabetogenic in 1963, by Rakieten et al., (1963) STZ results in a metabolic 
milieu characterised by insulinopenia termed „STZ-diabetes‟  resulting from targeted β  
cell necrosis via processes of methylation, free radical generation and NO production. 
Post administration, the GLUT-2 transporter transports STZ into pancreatic cells 
wherein it generates highly reactive carbonium ions(CH
3+
) that alkylate and fragment 
DNA bases along a defined sequence of events. DNA damage results in the activation 
and overstimulation of the pro-survival, cell repair nuclear enzyme poly(ADP-ribose) 
polymerase and concomitant reduction in β cell NAD+ and ATP stores. This alteration 
in redox states and histological changes in the affected cells ultimately result in β cell 
necrosis. Other supplementary hypotheses in the diabetogenic potential of STZ include 
its ability to act as an intracellular nitric oxide (NO) donor, generating 3',5'-cyclic 
guanosine monophosphate (cGMP) and NO that participate in DNA damage by 
inhibiting aconitase (Turk et al., 1993). Finally, the participation of STZ in xanthine 
metabolism has been associated with increases in ROS that may further accelerate cell 
death and inhibition of insulin synthesis (Nukatsuka et al., 1990). In aggregate, these 
mechanisms result in deficits in insulin biosynthesis, glucose-induced insulin secretion 
and glucose transport and metabolism culminating in diabetes that resembles human 
hyperglycemic nonketotic DM (Weir et al., 1981).  
 
The GK rat  
The GK rat is a non-obese, spontaneously T2DM model obtained by the selective 
breeding of mildly glucose-intolerant Wistar rats, repeated over several generations 
(Goto et al., 1975).  The pathogenesis of diabetes in the GK rat includes reduced 
pancreatic β cell mass (upto 50%) and pancreatic insulin stores, an impaired insulin 
secretion in response to glucose both in vivo and in isolated pancreata, IR in adipose 
tissue, muscle and liver, moderate but stable fasting HG and late complications 
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manifesting as nephropathy and neuropathy (Ostenson et al. 1993; Yashushi et al., 
2007; Howarth et al., 2007). T2DM in the GK rat is speculated to be polygenic, and six 
independent genetic loci have been identified to be involved in the disease (Gaugier et 
al., 2006). GK rats have a stable, inheritable form of T2DM and do not develop marked 
obesity, hypertension or hyperlipidemia (Portha et al., 1991; Zhou et al. 1995; Begum 
and Ragolia, 1998; Yashushi et al., 2007; Darmellah et al., 2007).  
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1.3.4 Aims and Scope of Developmental Experiments 
To summarise the concepts presented in this section, independent of CHD, diabetic 
patients appear to have an increased risk of developing HF. Although this phenomenon 
is strongly correlated with increasing HG, the convoluted nature of the disease, 
ambiguous clinical data and inconsistencies in experimental results emphasise a need to 
re-examine cardiac effects of HG and its potential contribution to DCM in order to 
formulate independent observations and draw concrete conclusions. This was the 
rationale for „developmental‟ experiments presented in this thesis. The main mechanical 
defects of DCM (encompassing reduced contractility, prolonged relaxation, and 
decreased compliance) are associated with impaired contractile function at the level of 
the cardiomyocyte and/or LV remodelling changes (Fang et al., 2004; Asghar et al., 
2009).  
The following hypotheses were tested in the developmental phase of this study using the 
the STZ-induced rat model of DM. 
1. A milieu dominated by HG can produce impairments in myocyte contractility and 
altered [Ca
2+
]i  handling. 
 2. LV Structural remodelling occurs as a result of uncontrolled HG, characterised 
principally by myocyte hypertrophy, ECM proliferation and apoptotic cell death. 
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2.1 Experimental design: Developmental experiments assessing myocyte 
contractility and remodelling changes were conducted in STZ-induced T1 diabetic rats 
and age-matched Wistar controls. Subsequently, in one set of experiments, cellular and 
molecular reorganisation of the myocardium in prediabetes was studied in young adult 
GK rats at 8 weeks of age. Next, the effect of chronic overt (mild) T2DM on the same 
variables was evaluated in aged animals at 18 months of age. For each experiment, there 
was a diabetic/prediabetic group and a normoglycemic Wistar control group matched 
for age. Focus was on the LV as it is recognised as the primary target of apoptotic and 
remodelling changes, especially in the ageing heart (Kwak et al., 2006). 
2.2 Experimental models: The project received the relevant ethical clearance from 
the Ethics Commitee at the University of Central Lancashire. All procedures confirmed 
to the „UK Animals (Scientific Procedures) Act 1986‟. Animals were housed in groups 
under institutional regulations at standard vivarium conditions, granted free access to 
water and commercial chow (unless specifically indicated) and exposed to a 12 hr 
light/12 hr dark cycle. Rats were monitored throughout the experimental period for any 
signs of distress. 
2.2.1 Streptozotocin induction: For experiments described in Chapter 3, 10 Male 
Wistar rats (initial body weight 100-150 gm) were given a single intraperitoneal 
injection of 60 mg/kg body weight Streptozotocin (Sigma, S-0130) dissolved in 0.1 M 
citrate buffer solution (0.1 M citric acid, 0.1M sodium citrate in distilled water, pH 4.5). 
An equivalent volume of citrate buffer solution was administered to 10 healthy age-
matched Wistar controls. 2-4 days following STZ-administration and prior to 
experimentation at 6-7 weeks, blood glucose was assessed using a glucose meter (One 
Touch II glucose meter, Lifescan inc) to confirm DM after an overnight fast.  
2.2.2 GK model of prediabetes and T2DM: Young adult male GK rats and age-
matched Wistar controls with initial body weights of 150-180 gm were obtained from a 
commercial colony (Taconic, USA). Aged GK rats were 18 months old and weighed 
approximately 413 gm. No spontaneous deaths were recorded in the colony at this age. 
Prediabetes in the young group (n=8) and overt DM in the aged GK rats (n=8) was 
confirmed by measuring fasting blood glucose as described for the STZ-rats. 
Additionally, an OGTT was administered in GK rats and age-matched controls (n=8 for 
both old and young groups) to assess glucose tolerance. In brief, after an overnight fast, 
animals were injected intraperitoneally with 6 g glucose /kg bodyweight. Blood glucose 
was measured using a glucosemeter (One Touch II glucose meter, Lifescan inc) at time 
zero, 30, 60 and 120 min after glucose injection.  
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2.3 Sample collection: Animals were weighed throughout the study period and before 
termination of the experiment at six-seven weeks for the STZ-treated rat group, eight 
weeks for young (prediabetic) GK rat group and at eighteen months for the aged GK rat 
group and respective age-matched male Wistar controls for all cohorts.  Animals were 
humanely killed by cervical dislocation and hearts rapidly removed by midsternal 
incision. Blood was collected from bifurcation at the aorta  in tubes containing 25 mM 
Ethylenediaminetetraacetic acid (EDTA) and rapidly put on ice following centrifugation 
at 3,000 rpm for 5 min. Plasma was removed, transferred to a new tube, and spun again 
at 12,000 rpm for 5 min to remove residual red blood cells and platelets. Samples were 
stored at -70⁰C until use. After the excision of the heart, the great vessels were trimmed 
off and blood was removed by opening atrial and ventricular chambers, and heart 
weight was recorded.  Subsequently, the atria were dissected along the atrio-ventricular 
groove and the coronary arteries cut perpendicular to their course for assessment of 
atherosclerotic lesions. The LV was isolated and the weight (inclusive of the septum) 
was determined. In a subset of hearts from both the GK groups (n=4), wall thickness 
was estimated by cross-sectioning midway between the apex and the coronary groove 
by averageing 10 equally spaced measurements from sections of the LV representing 
the portion halfway between the base and the apex of the heart. These determinations 
were restricted to the LV free wall. In all groups of animals, the LV free wall was then 
dissected radially to obtain tissue fragments extending from the endocardial to the 
epicardial surface. These samples were then immersed in a drop of freezing medium 
(OCT, BDH), frozen in liquid N
2
 for RNA/protein assays and stored at -70⁰C or 
processed for light/electron/confocal microscopy as follows:  
2.4 Histology: Tissue samples were fixed in 10% formalin, dehydrated with ethanol 
and embedded in paraffin using previously described methods (Bilim et al., 2008). 
Paraffin embedded LV samples were sectioned at 4 µm, deparaffinised in Histoclear 
(Sigma Aldrich), de-hydrated in a graded alcohol series (50, 70, 80, 95 and 100% 
Ethanol), re-hydrated and stained with the hematoxylin and eosin stain (H&E) for 
general examination and with Masson‟s trichrome stain for the determination of ECM 
deposition according to established methods (Luna et al., 1968; Shishido et al., 2003). 
In the GK rat groups, sections were also stained with Picrosirius red that highlights 
myocardial collagen.  H&E, Masson‟s trichrome and Picrosirius-red stained sections 
were visualized by light microscopy using an objective with a calibrated magnification 
of 400X. Sampling fields were captured digitally into a computer database via a high 
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resolution colour camera (Carl Zeiss) coupled to an objective lens attached to the 
microscope (Zeiss, Germany). Images were analyzed with a freely available computer-
assisted
 
colour image analysis system (NIH ImageJ 1.37 V (Bethesda, MD, USA). The 
program was calibrated using a calibration slide (GRATICULES LTD) traceable to 
national standards (National Physical Laboratory, Teddington, Middlesex, UK). Visual 
fields encompassed 2816 X 1880 square pixels with a resolution of 15.88 pixels/micron 
(area = 0.02099 mm
2
). For all quantitative assessments a minimum of 4 separate regions 
of the LV/animal encompassing the entire thickness of the wall were examined in order 
to ensure that results would be representative of the entire tissue.  
Extent of ECM proliferation in the LV was morphometrically assessed using methods 
described by Farah et al., (2009).  This procedure involved the application of colour 
segmentation to digitized images of sections stained with Massons‟ trichrome that 
specifically stained the ECM green or with Picrosirius red that stained collagen fibres 
red. Using Image J programmed to highlight shades of a specified colour (green or red) 
on stained sections based on operator‟s threshold settings, collagen area fraction 
(percent fibrosis) was calculated as the ratio of the area of fibrotic tissue to total 
myocardial tissue area. The measured total tissue
 
area within each field was further 
corrected for white non-tissue spaces by a similar method of demarcation to provide a 
corrected area of true myocardial tissue. 35-40 systematically selected fields 
(encompassing approximately 0.7-0.8 mm
2
) per experimental group were included in 
the analysis.  
2.4.1  Immunohistochemistry:  To investigate the contribution of  mild diabetes 
towards activation of the apoptotic pathway, activity of caspase-3, the prime effector of 
cardiomyocyte apoptosis, was estimated using a commercially available caspase-3 
detection kit (Apoptosis Marker: Signal Stain Cleaved Caspase-3 (Asp175) IHC 
detection kit, Cell Signalling Technology) and manufacturers‟ instructions. Caspases 
have been previously described as „cysteine-dependent aspartate specific proteases 
functioning as endonucleases integral in the final execution of nuclei and cell death‟ 
(Kwak et al., 2006). A critical step in the execution of the apoptotic program eliciting 
DNA fragmentation is cleavage of caspase-3 into 19 and 17 kDa fragments.  
Briefly, formalin fixed paraffin embedded (FFPE) sections were deparaffinized in 
Histoclear (Sigma Aldrich, H2779) and rehydrated in graded alcohol series whereas 
frozen sections were allowed to equilibrate for 5 minutes at room temperature before 
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being post-fixed with 10% neutral buffered formalin. Endogenous peroxidase
 
was 
inhibited using 0.3% H2O2 in methanol. Epitope retrieval in the FFPE sections was 
accomplished by heating the sections in 10mM
 
citrate buffer (0.1 M Citric Acid, 0.1 M 
NaCitrate, dihydrate 10 mM, pH 6) for 20 minutes using a conventional microwave 
oven. Following antigen retrieval, FFPE sections were allowed to cool for 20 min 
before
 
the reaction was stopped in running distilled water. Prior to
 
the application of the 
primary antibody, nonimmune goat serum was applied as a protein block. Sections were 
incubated overnight at 4⁰C with prediluted polyclonal rabbit anti-active caspase 3 
antibody, washed in 2 changes of PBS for 10 minutes each (that specifically recognizes 
the large fragment (17/19 kD) of activated, but not full length caspase-3) then incubated 
for 30 min in biotinylated (prediluted) goat anti-rabbit IgG. Sections were then washed 
in PBS and incubated with horseradish peroxidase (HRP)-streptavidin for 30 min. The 
antibody complex was visualized using H2O2 as a substrate and diaminobenzidine
 
as 
chromogen. The development
 
of the immunohistochemical staining was monitored by 
microscopy. Finally, slides were rinsed in running tap
 
water, counterstained with 
Mayers‟ Hematoxylin (Sigma Aldrich, MHS16) for 1 minute, dehydrated through a 
series of ethanols to Histoclear, and
 
coverslipped with Permount (Fisher Scientific, 
Norcross, GA). A semiquantitative estimation of apoptotic cells as an average of 35-40 
LV fields/group defined as cleaved-caspase-3 positive cells/area (mm
2
) was carried out 
by Image J using photomicrographs imaged at X400 and utilization of a plugin known 
as DeadEasy Caspase that is based on a mathematical algorithm for object recognition 
and custom designed for the quanitifcation of cleaved caspase-3 mediated apoptosis 
(Forero et al., 2009). 
2.4.2 Immunofluorescent labelling and confocal laser scanning microscopy 
Paraffin sections were processed for immunofluorescence microscopy. Briefly, sections 
were deparaffinised in Histoclear (Sigma Aldrich) and dehydrated through a series of 
alcohols before antigen retrieval as described above. Sections were then blocked in 
1.5% normal goat serum (NGS), incubated overnight in either Fluorescein 
isothiocyanate (FITC)-conjugated Lectin (Sigma Aldrich) at a concentration of 1µg/µl 
or αSKA (Abcam, 1:50). For αSKA labelling, tissues were further incubated with FITC-
conjugated anti-mouse IgG (Sigma Aldrich) at a dilution of 1:200 for 2 hours at room 
temperature. Post labelling, sections were washed with PBS three times and mounted in 
Fluoromount (Sigma Aldrich). Slides were examined using a laser scanning confocal 
microscope (LSM 510, Carl Zeiss, UK) equipped for detection of FITC (excitation 
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bandpass 450–490 nm, emission low-pass 515 nm) and subjective material captured as 
512 x 512 pixel images (magnification X400) collected  at constant settings wherever 
applicable.  Image J was used to measure either cell size or fluorescent intensity/unit 
area. Specificity of staining patterns was established by replacement of primary 
antibody/ Fluorescent probe with 1.5% normal goat serum in PBS and background 
florescence thus determined.  
Cell size measurement by Lectin labelling: Lectin labelling clearly defined individual 
cardiomyocytes. To compare size, the short axis diameter of individual myocytes was 
measured thrice on transverse sections by drawing a point to point perpendicular line 
with Image J and averageing obtained values. 
Fluorescent intensity measurement for anti-αSKA labelling: 
Sections to be compared were immunolabelled under identical experimental conditions 
on the same day. Digital images for each experimental group were at the same settings 
for gain and threshold. All random scans of myocardial tissue from control and diabetic 
groups were recorded at the same photo multiplier tube setting of 450–500, pinhole 
aperture setting of 50 µm, and at the same laser
 
voltage setting of 20 mW. Confocal 
settings were: laser power 10%, iris 2.0 and gain around 950 (variable between 
experiments but constant for each experimental group). Fluorescent signal 
quantification of anti-αSKA labelled sections was achieved by transforming confocal 
micrographs in gray luminance values ranging from 0 (corresponding
 
to black) to 255 
(corresponding to white) and splitting into RGB channels on Image J. The green 
channel was used to calculate fluorescence intensity, evaluated as the sum of pixel 
intensity values. The total fluorescence intensity within each field was inferred and the 
value obtained was subtracted from the background, i.e.  Signal detected using the 
negative control stained in tandem. This corrected value for pixel intensity in the image 
was then expressed as labelling intensity/unit area of field (512x512 pixels).  Values 
were averaged for each section and given as mean+SEM value for control and GK 
groups. 
2.4.3 Electron Microscopy: Freshly isolated LV samples from 2 month old Wistar and 
GK rats were cut to 2 mm x 2 mm size, transferred into Karnovsky‟s fixative (16% 
paraformaldehyde, 50% EM grade glutaraldehyde, 0.1 M sodium phosphate buffer) at 
pH 7.2 in 7 ml glass vials and allowed to rotate on a rota mixer for 4-5 hours at room 
temperature. Samples were washed in 0.1M phosphate buffer 3 times for 15 minutes 
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each and stored at 4⁰C until further processing. Postfixation procedures included adding 
1 ml of 1% osmium tetroxide buffered in 0.1 M sodium cacodylate and allowed to mix 
for one hour at room temperature on a rotamixer, following washing in distilled water 
and dehydration in graded ethanol series as follows: 15 minutes each in 30%, 50%, 
70%, 80%, 90%, ethanol, and 2 changes in absolute ethanol and propylene oxide. 
Tissues were then embedded using flat molds, in resin of the following composition: 
Agar 100 epoxy resin, 24 ml; Dodecenylsuccinic anhydride, 16ml, Methylnadic 
anhydride, 10 ml and Tri(Dimethylaminomethyl phenol, 1.2 ml; Polymerization was 
done at 60°C for 24 hours. Semithin sections, (1 ~tm thick) were cut with glass knives 
from randomly chosen blocks and stained with Toluidine blue for examination by light 
microscopy. Five blocks with both transverse and longitudinally directed myocytes 
were chosen from each experimental group. Tissues which were abnormal by light 
microscopic examination were excluded from ultrastructural studies. Semithin sections 
stained with methylene blue were examined in the light microscope and appropriate 
areas were chosen for preparing ultrathin sections. Thin sections were cut with diamond 
knife (DuPont) on LKB III ultratome from the same 5 blocks and picked up on mesh 
copper grids. The sections were stained with saturated uranyl acetate solution in 50 
percent ethanol for 15 minutes and lead citrate solution for two minutes. Ultrathin 
sections were examined under a JEM 1010 electron microscope at an accelerating 
voltage of 60 kV. Electron micrographs were printed on 8 x 10 inch photographic paper 
at various magnifications. 
 
 
2.5 Functional studies in the STZ-induced type 1 diabetic rat 
Solutions and Reagents 
1. The cell isolation solution (Physiological salt solution) was composed of the 
following (in mM): 130.0, NaCl (VWR, 102415-R); 5.4, KCl (VWR, 1019842); 1.4, 
MgCl2 (VWR, 220933-M), 0.4 NaH2PO4 (VWR, 102494-C); 5, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid  (HEPES) (Sigma, C-0780); 10, glucose; 20, taurine 
(Sigma,T-0625) and 10 creatine (Sigma,T-0780)  set to pH 7.3 (Orion pH meter, 920-A) 
with 4M NaOH (VWR,10252).  
2. Normal Tyrode solution (Cell perfusion solution) was made up of (in mM): 140, 
NaCl; 5, KCl; 1, MgCl2.6H2O (VWR, 101494-V); 10, glucose; 5, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; 1, CaCl2 set to pH 7.4 with 4 M NaOH. 
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2.5.1 Measurement of Left Ventricular Action Potential 
Five STZ-treated rats and age-matched Wistar controls were humanely killed by 
decapitation and the hearts rapidly excised, perfused in a retrograde fashion at constant 
flow (8 ml/gm/heart/min) in Langendorff mode with Normal Tyrode solution 
continuously bubbled with oxygen and at 37⁰C (physiological temperature). When the 
isolated heart preparation stabilized to contract regularly at 300 beats per minute 
(BPM), extracellular ventricular action potentials were recorded using a purpose built 
suction electrode in accordance with methods that have been previously described 
(Howarth et al., 2007). Recordings were collected at 400 Hz, amplified (ML136 
Bioamp, ADInstruments, Castle Hill, New South Wales, Australia) and visualised by 
interfacing with a PC via Powerlab (PL410, ADinstruments). Data analysis was carried 
out using ADInstruments software version 4.21 (ADInstruments). Action potential 
duration (APD) was analyzed using IDL software (IDL research Systems, Boulder, 
CO). APD50 was measured as the time taken for 50 % repolarization 
2.5.2 Isolation of Ventricular Myocytes: 
Ventricular myocytes were isolated from 5 STZ-treated and 6 control rats by methods 
that have been previously described for studies of contractility and [Ca
2+
]i transients 
(Howarth et al., 2007). Briefly, after the completion of action potential recordings 
described above, hearts were perfused with a Ca
2+ 
free isolation solution that contained 
Ethylene glycol tetraacetic acid (0.01 mM), following which the heart was perfused 
with a physiological salt solution containing 0.05 mmol/L Ca
2+
, 0.75 mg/mL 
collagenase (type 1; Worthington Biochemical Corp., Lakewood, NJ, USA) and 0.075 
mg/ml protease (type X1V; Sigma, Taufkirchen, Germany). The last solution was re-
circulated to expose the heart to the enzymes for duration of 6 min. After, perfusion 
with the enzyme, the heart was removed from the perfusion apparatus; the ventricles 
were excised, minced and gently agitated at 300 oscillations/min in a 5ml collagenase 
solution supplemented with 1% Bovine Serum Albumin (BSA). Cells were filtered at 
through gauze (300 µm aperture, Cadish precision meshes, Finchley, London) and 
suspended in isolation solution. The filtrate was centrifuged at 400 rpm for 1 minute, 
supernatant removed and cell pellet resuspended in physiological salt solution 
containing 0.75 mM Ca
2+
. The process was repeated 4 times and isolated myocytes 
from the 2
nd
 and 3
rd
 repetition(s) were stored at 4⁰C until use at a period not exceeding 
1-2 hours.   
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2.5.3 Measurement of contraction in isolated ventricular myocytes 
Freshly isolated ventricular myocytes were allowed to settle on the glass bottom of a 
Perspex chamber mounted on the stage of an inverted microscope (Axiovert35, Zeiss, 
Germany) with a 40X objective lens and were superfused at 3-5 ml/min with a HEPES-
based Tyrodes solution maintained at 35-37⁰C using a power driven magnetic micro 
pump (Cole parmer instruments, London) and a heating system coupled to a 
temperature controller (Medical systems corp., USA). Myocytes were field stimulated at 
1Hz (S88 stimulator, Grass-Telefactor, USA) using 2 platinum electrodes positioned at 
either side of the chamber. Shortening was measured as an index of contractility using a 
video edge detection system. (VED-114, Crystal Biotech, Northborough, MA, USA) 
and data was acquired and analysed using SignalAverager (version 6.16, Cambridge 
Electronic Design, Cambridge, UK). The degree of shortening (expressed as a 
percentage of resting cell length) and the time to peak shortening and time from peak 
shortening to half-relaxation were recorded. 
2.5.4 Measurement of intracellular calcium transients in isolated ventricular 
myocytes 
    [Ca
2+
]i transients were measured by previously described methods (Howarth et al., 
2007). To briefly summarize, cardiomyocytes were loaded with a fluorescent indicator 
fura-2-AM (Molecular probes, Leider, The Netherlands) by adding  6.25 ul of a 1.0 mM 
stock of fura-2-AM dissolved in dimethyl sulfoxide  to  a 2.5 ml solution containing 
freshly isolated myocytes resulting in a final fura-2-AM solution of 2.5 µM/L. The cells 
were then gently agitated for 10 min at RT, following which they were centrifuged at 
400 rpm for 1 minute, resuspended in normal tyrodes solution and incubated for 30 min. 
Following loading of the fluorescent indicator, [Ca
2+
]i transients were measured by 
exposing the myocytes to light at 340 nm and 380 nm in an alternate fashion using a 
monochromator (Cairn Research, Faversham, UK) that switched between the 2 
wavelengths every 2 ms. A photomultiplier tube recorded fluorescence emission at 510 
nm and the ratio of emission at the 2 excitation wavelengths (340/380 ratio) was 
determined as an index of [Ca
2+
]i. The amplitude of the Ca
2+
transient was recorded 
along with a time course of [Ca
2+
]i analysis, including time to peak and the time from 
peak to half-relaxation of the [Ca
2+
]i transient. Decay of the transient was measured as 
time form the peak amplitude of the transient to half its decay. Finally, the rate of decay 
was obtained by plotting a gradient on the decay of the [Ca
2+
]i transient.  Data were 
collected and analysed using Signal Averager. 
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2.6   Transforming growth factor β1 Immunoassay 
 Protein extraction 
 LV samples from 3 Wistar controls and 3 GK rats (at 2 and 18 months) were weighed 
and homogenised in the following buffer (ELISA kit manufacturers recommendation): 
0.5% Triton X-100, 2 µg/ml Aprotinin (Sigma Aldrich, A6013) in PBS (concentration 
in mmol/L- NaCl: 137, KCl: 2.7, Na2HPo4 10, KH2PO4: 1.76, pH 7.4). Homogenate was 
sonicated and centrifuged at 14,000 g for 1 minute at 4⁰C. The supernatant was 
aliquotted into tubes on ice and was further assayed for protein concentration or stored 
at -80⁰C 
Modified Lowry protein assay 
Protein concentration in LV tissue homogenate was assayed by the modified Lowry 
method described previously (Lowry et al., 1951). The linearity range for protein 
detection is given as 1-1,500 µg/ml. Briefly, protein in samples or BSA standards was 
reacted with 1% cupric sulfate and 2% Sodium potassium tartate in an alkaline solution 
of 1N NaOH and 2% Na2CO3, which resulted in formation of a tetradentate copper-
protein complex. This complex further reduced a 2N Folin-Ciocalteu Reagent added to 
samples/ standards to produce a blue colored, water-soluble product. Absorbance of the 
latter was measured at 750 nm with a microplate reader (Micro Quant, Biotech 
Instruments). Five standards, 0, 1, 2,5, 10 and 20  were diluted from a 20 µg/µl stock 
solution to produce a standard curve.   
Detection of Total and active Transforming growth factor β1 by Enzyme-Linked 
ImmunoSorbent Assay (ELISA):  
 Endogenous TGFβ1 in plasma and LV homogenates (extracted as described above) 
from control and GK animals was assayed using TGFβ1 Emax Immunoassay system 
(Promega, Madison, WI) and manufacturer‟s protocol. The TGFβ1 Emax 
ImmunoAssay System is an ELISA designed to detect biologically active and/or total 
TGFβ1 in an antibody sandwich format and typically demonstrates ≤ 3% cross 
reactivity with other TGFβ1 isoforms (e.g. TGFβ2/3).  
Following this protocol, flat bottomed 96-well plates were coated with TGFβ1 
monoclonal antibody in freshly prepared carbonate coating buffer (0.025M sodium 
bicarbonate, 0.025M sodium carbonate, pH 9.7) at a dilution of 1:1000 and incubated 
overnight at 4°C. Nonspecific binding was blocked by adding diluted TGFβ Block 5X 
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Buffer (manufacturer supplied) and incubation at 37°C for 35 minutes, following which 
plates were washed once with Tris buffered saline-tween Wash buffer (20mM Tris-HCl 
(pH 7.6) 150 mM NaCl 0.05% (v/v) Tween 20). All subsequent washes were conducted 
with the same buffer. Standards were prepared in duplicate by diluting the 
manufacturer‟s supplied 1 µg/ml TGFβ1 standard to produce a standard curve from 0-
1000pg/ml (0, 15.6, 31, 62, 125, 250, 500, 1000 pg/ml) as given in Figure 2.1.  
 
 
Fig 2.1: Standard calibration curve for TGFβ1 
 
To assay total and active TGFβ1, plasma samples or centrifuged supernatant from LV 
sample homogenate were divided into 2 equal fractions. One fraction was acid-treated 
to activate total TGFβ1 per manufacturer‟s instructions. Briefly, either plasma or LV 
homogenate diluted 1:5 in Dulbecco‟s PBS were acidified to pH 2.6 by adding 1N HCl/ 
50µl of sample. Following incubation for 15 minutes at room temperature, samples 
were neutralized to pH 7.6 by adding 1N NaOH/50 µl sample. This method is based on 
the premise that acid treatment releases the active TGFβ1 molecule from the latent 
complex present in the sample fractions. As such, the fraction of the samples without 
acid treatment represented endogenous levels of biologically active TGFβ1 whereas 
acid-treated fractions represented the total TGFβ1 in the sample. Susbsequently, a 
volume of 100 µl of acid treated and/or naturally processed samples were added to 
coated well plates and incubated for 90 minutes at room temperature. Optimal sample 
concentrations were established by testing a dilution series. As such, plasma samples 
were diluted 1:16 and LV homogenate was diluted 1:2 in the provided Sample Buffer. 
After washing 5 times, the amount of specifically bound polyclonal antibody was 
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detected by adding 100 µl of provided polyclonal anti-TGFβ1 (at a dilution of 1:1000) 
to each well and incubation for 2 hours at room temperature. TGFβ HRP Conjugate was 
added at a dilution of 1:100 to each well and incubated for 2 hours. The unbound 
conjugate was removed by washing five times, and samples were incubated with 100 µl 
of provided chromogenic substrate (TMB One Solution) for 15 minutes at room 
temperature to produce a blue colour in the wells. Acidification of samples by adding 
100 µl of 1N HCl changed colour to yellow. The color change was measured at 450 nm 
using a microplate reader (Anthos Hill, Biochrome Ltd, UK).  The amount of active 
TGFβ1 in the samples was proportional to the color generated in the oxidation-
reduction reaction. Total and active levels of TGFβ1 in LV samples and Plasma were 
analysed in duplicate. The results in pg/ml were obtained by extrapolation from 
standard curve expressed as ratio of Active:Total TGFβ1 for plasma samples and pg/mg 
of total protein for LV homogenate samples.  
 
2.7  Western Blotting  
The contribution of mild HG in Prediabetes and overt mild T2DM towards levels and 
activation of Akt and downstream signalling to p70S6K (that mediates the hypertrophic 
response) was investigated by western blotting. Western blotting, also known as 
immunoblotting is a technique that involves separation of proteins using SDS-PAGE 
followed by protein immobilisation of polyvinylidene fluoride (PVDF) or nitrocellulose 
membranes (Burnette, 1981). 
Protein extraction: Frozen LV samples from 2 and 18 month old GK and age-matched 
control rats were washed in ice-cold PBS, minced with a sterile blade and sonicated 
after homogenisation on ice in a buffer containing  250 mM KCl, 20 mM Imidazole, 2.5 
mM Dithiothreitol, 0.3 M Sucrose, Phosphatase 1,  pH 7.2. Lysates were then 
centrifuged at 14000 g for one minute following which the supernatant was collected, 
aliquotted and stored at -70°C or used for determination of protein content by the 
Modified Lowry assay described in section 2.6. 
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE) and 
electroblotting: Dithiothreitol in gel dissociation medium (62.5 mMTris-base, 6% 
SDS, 20% glycerol, and 0.002% bromophenol blue  at a concentration of 10mg/ml was 
added to lysate containing 50 µg/µl extracted LV protein to give a final volume of 30 µl 
and the mixture was centrifuged for 10 seconds at 130 g. Next, samples were placed in a 
boiling water bath for 15 minutes and following brief centrifugation for 10 seconds at 
130 g were loaded onto commercially available 4-15% Tris-HCl gels (Bio-Rad 
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Laboratories, Hercules, CA, USA) run at 150V for 140 min in a running buffer 
comprising 250 mM Glycine, 25mM Tris-base, 0.1% (w/v) SDS in dH2O at pH 8.3. 
Prestained molecular weight markers (Prestained SDS-PAGE Standards, broad range', 
Bio-Rad Laboratories, Hercules, CA, USA). Electrophoretic transfer of proteins onto 
methanol-activated „Immobilon‟ polyvinylidene fluoride (PVDF) membranes 
(Millipore) was achieved using a semi-dry transfer apparatus (Bio-Rad Laboratories, 
Hercules, CA, USA) and buffer containing 10 mM 3-[cyclohexylamino]-1-propane 
sulfonic acid, 10% methanol, 0.1% (w/v) SDS in dH2O, pH 9 adjusted with NaOH. 
Electroblotting was carried out at 0.3 A (constant amperage) for 2 hours at 4⁰C. 
Electrophoretic transfer was indicated by the complete transfer of prestained molecular 
weight markers, following which gels were stained with gentle agitation in Commassie 
blue and finally destained in a solution of 7.5% glacial acetic acid and 10% absolute 
ethanol in distilled water for 2 hours with constant agitation. Stained gels were plaved 
on a white surface and photographed under white lights to document the consistency of 
protein loading (Fig 2.2). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.2: Typical Tris-HCl gel after electrophoretic transfer. Gel was destained and 
photographed after staining with Commassie blue to highlight protein loading 
 
Antibodies and densitometry: PDVF membranes were probed with antibodies given 
in Table 2.1 as follows: 1. Primary antibody and anti-β actin as a loading control 
(1:1000 in 0.5% BSA in PBS) overnight at 4⁰C.  2. Secondary antibody, (1:2000 in 
0.5% BSA in PBS) for one hour at room temperature. 3. 2ml Enhanced 
Chemiluminescence (ECL) reagent mix from ECL™ Western Blot Detection Reagents 
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(GE Healthcare) (1:1 mix of Amersham reagents 1 and 2) and exposure to film (Blue 
ultra autorad film 8x10, Double emilsion blue, ISC BioExpress) for 30 seconds. 
Multiple exposures ensured the desired intensity was achieved. Sizes of the 
immunodetected proteins were verified by standard molecular weight markers and β 
actin that served as a loading control .The ECL method is based on the emission of light 
during the Horeseradish peroxidise (HRP)- and hydrogen peroxide-catalyzed oxidation 
of luminol. The emitted light is then captured on film. After each step membranes were 
rinsed in several changes of washing buffer (TBS + 1%Tween 20, pH 7.4) at 10 minutes 
each. 
Table 2.1: List of antibodies used in the study indicating catalogue number and dilution  
  
  Antibody Source and catalogue 
number  
Dilution 
1 Mouse monoclonal 
anti Alpha skeletal 
actin 
Abcam 
(ab74245) 
1:50 
2 Goat FITC-
conjugated anti 
mouse IgG 
Sigma Aldrich 
(M0659) 
1:200 
3 Mouse monoclonal 
anti-Akt 
Cell Signalling (2967) 1:1000 
4 Rabbit  polyclonal 
anti phosphorylated 
Akt  
(Ser 2771) 
Cell Signalling 
(9271) 
1:1000 
5 Rabbit polyclonal  
anti p70S6K 
Cell Signalling 
(9202) 
1:1000 
6 Rabbit polyclonal 
anti phosphorylated 
p70S6K (Thr 389) 
Cell Signalling 
(9205) 
1:1000 
7 Goat polyclonal anti 
beta actin (Actin 1-
19)-HRP 
Santa Cruz 
Biotechnology 
(sc 1616) 
1:2000 
8 bovine anti mouse 
IgG-HRP 
Santa Cruz 
Biotechnology 
(sc2371) 
1:2000 
9  
 
donkey anti rabbit 
IgG-HRP 
Santa Cruz 
Biotechnology 
(sc2305) 
 
1:2000 
10 donkey anti goat 
IgG-HRP 
Santa Cruz 
Biotechnology (sc2304) 
 
1:2000 
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Exposed film was scanned (Fig 2.3) and proteins imaged by densitometry using the „Gel 
Analysis‟ method on Image J which provides reproducible estimates of protein 
concentration in terms of  relative band intensity, by quantifying optical density (pixels) 
of selected areas and semi-automated correction for background noise. Data were 
computed and quantified in densitometry units (area x pixel density).  This value was 
then normalized to band intensity of loading control (β actin). Finally, normalized 
values are presented in graphs as ratio of phosphorylated target protein: total target 
protein. Membranes were stripped (with buffer made containing 15 gm glycine, 1 gm 
SDS, 10 ml Tween 2 in lL of distilled water, pH 2.2) and reprobed by steps 1, 2 and 3 
outlined above. Experiments for each protein measured were conducted in triplicate.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 2.3: Representative scan of exposed film showing PVDF membrane and proteins 
detected by ECL. The film is of a western blot with bands showing phosphorylated 
p70S6K protein and β-actin serving as a loading control for quantification purposes in 
Wistar control LV at 2 weeks. The molecular weight markers are visible on the left and 
were highlighted with a felt tip marker 
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2.8 mRNA quantification by Quantitative Reverse transcriptase Polymerase chain 
reaction 
Reverse transcription (RT) followed by quantitative polymerase chain reaction (qPCR) 
is a sensitive method for mRNA quantification. In comparison to more traditional 
approaches such as Northern blot, dot blot and in situ hybridisation, RTqPCR assays are 
most commonly used methods for characterizing or confirming patterns of gene 
expression and comparing mRNA levels in sample populations. In this study, „real time‟ 
RTqPCR assays were used for the quantification of mRNA expression of several target 
genes using the two-step SYBR green I RT-PCR protocols. RTqPCR follows the 
general principle of PCR, a key differentiating factor being that the amplified DNA is 
detected as the reaction progresses in real time compared to standard PCR, where the 
product of the reaction is detected at its end.The experimental design, primer sequences, 
experimental conditions and techniques detailed below have been previously carefully 
validated (Tellez et al., 2006; Yanni et al., 2010). Very briefly, the process involved the 
extraction of RNA from frozen samples, reverse transcription of RNA into 
complementary DNA (cDNA) using reverse transcriptase and the random hexamer 
priming method and use of the resulting cDNA as a template for subsequent PCR 
amplification using primers (given inTable 2.2) specific for genes of interest followed 
by automated detection and quantification of amplification products.  
 
mRNA isolation and generation of cDNA 
 
For isolation and purification of mRNA, frozen LV samples were cut into 20 μm 
sections on a cryostat. Total RNA was isolated from sections using Qiagen muscle RNA 
extraction procedure and manufacturer‟s instructions (Qiagen, Hilden, Germany). In 
summary, this process involved the addition of β-mercaptoethanol to provided „RLT‟ 
buffer followed by homogenisation of samples on ice and addition of proteinase K to 
digest proteins in tissue. Next, the samples were centrifuged at 13000 rpm for 5 minutes 
and supernatant dissolved in β-mercaptoethanol-„RLT‟ mix and vortexed. This step is a 
modification of the orinigal protocol and by increasing salt concentration in the 
homogenate, led to more reliable yields. After addition of 100% ethanol and vortexing, 
the samples were applied to the Qiagen-provided columns in aliquots, centrifuged for 15 
seconds at 13000 rpm for after each aliquot and flow through decanted. DNAse was 
then diluted in the provided buffer and added to the columns and left to digest for one 
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hour at room temperature. After 3 rounds of centrifugation and addition of „RW‟ buffer, 
the column was dried and eluted by addition of Millipore H2O and spinning down. A 
second elution resulted in a final volume of roughly 90µl that was left to precipitate 
overnight at -20C. After spinning for 30 minutes at 13000 rpm in the cold, resulting 
RNA was ethanol precipitated and pellets dissolved in 6-10µl, Diethylpyrocarbonate-
treated (RNAse free) water. The RNA concentration was then measured with a 
Nanodrop ND-1000 spectrophotometer (Nanodrop Techologies, USA). 
The isolated RNA (and resulting cDNA) samples from different rats were kept separate, 
i.e. the samples were not pooled. 125 ng of total RNA from each sample was reverse 
transcribed with Superscript III reverse transcriptase (Invitrogen) in a 20 μl reaction 
according to the manufacturer‟s instructions, using random hexamer priming. In précis, 
to each 8 µl of RNA, 2 µl  a solution  made up of Hexamers/ deoxyribonucleotide 
triphosphate in buffer containing manufacturer provided RT buffer, 25 mM MgCl2    
0.1M DTT and Superscript III reverse transcriptase and heated to 65°C for 10 min. The 
tubes were then transferred onto ice immediately for 3 minutes and subsequently, 10 µl 
of the RT/buffer master was added ice, following incubation at 25 °C for 10 min in the 
PCR machine, for first priming, 50 °C for 50 min, for further synthesis and 85 °C for 15 
min, to stop the reaction. Aliquots of the resulting cDNA were diluted 10-fold in water 
for direct use in qPCR. 
Quantitative PCR: RTqPCR was performed using an ABI Prism 7900 HT Sequence 
Detection System (Applied Biosystems, Foster, USA). The size of qPCR products and 
specificity of primers were previously tested in our laboratory by running samples on 2 
% agarose gels containing ethidium bromide and visualised by ultraviolet light. 
Commercially available primers gave amplicons of similar size. The reaction mixture 
was comprised of 1 μl of cDNA, 900 nM forward primer, 900 nM reverse primer or 1x 
Qiagen assay, 1x SYBR Green Master Mix (Applied Biosystems) and DNAse-free 
water and the final volume was 10 μl. All samples were run in triplicate. The reaction 
conditions were: denaturation step of 95°C for 10 min, 40 cycles of amplification and 
quantification steps of 95°C for 30 s, 60°C for 30 s and 72°C for 1 min. The melt curve 
conditions were: 95°C for 15 s, 60°C for 15 s and 95°C for 15 s. The technical validity 
of the PCR assay setup was assessed by examining RNA amplification data. Fig 2.4 
illustrates representative data obtained with the primers. By running a melting curve 
after the PCR reaction, the desired amplicon was differentiated from other non-specific 
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products. Dissociation curves were examined to rule out formation of contaminants or 
Primer-dimers (Fig 2.4 B). 
Table 2.2: List of primers used in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Connexin 43 primers were custom designed with Primer 3
®
 software provided by the 
Whitehead Institute for Biomedical Research, Cambridge, MA, USA and were of the 
following sequence 
Forward primer: 5′-GGAATGCAAGAGAGGTTGAAAG-3′  
Reverse primer: 5′-GGCATTTGGAGAAACTGGTAGA-3′ 
 
 
 
 
 
Target transcript Species Qiagen catalogue 
number 
CTGF Rat QT00182021 
BNP Rat QT00183225 
Elastin Rat QT01575924 
Fibronectin 1 Rat QT00179333 
Integrin alpha 1  Rat QT00193172 
Integrin alpha 5 Rat QT00431053 
Integrin beta 1 (fibronectin receptor beta)  Rat QT00187656 
Matrix metallopeptidase 2  Rat QT00996254 
Matrix metallopeptidase 9  Rat QT00178290 
ANP Rat QT00366170 
Procollagen, type III, alpha 1 Rat QT01083537 
Transforming growth factor β1  Rat QT00190953 
Vimentin  Rat QT00178724 
GAPDH Rat QT00199633 
NCX Rat QT01592451 
SERCA2a Rat QT01082508 
CaV1.2 Rat QT01571822 
CaV1.3 Rat QT00194306 
RyR2 (ryanodine receptor) Rat QT02348003 
Pln_1 (phospholamban) Rat QT01290058 
Collagen type 1 Rat QT01621417 
Tumour necrosis factor alpha Rat QT00178717 
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Fig 2.4: Representative RTqPCR validation methodology. GAPDH rtqPCR 
amplification (A) and dissociation (melting) curve (B), exemplify the protocol used to 
validate each primer set (Rat GAPDH in figure) and experimental conditions.  
A 
B 
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Gene Expression Analyses 
The cycle threshold (Ct) is the number of cycles required for fluorescent signal to 
exceed background levels, and is inversely proportional to the amount of target nucleic 
acid in the sample.  In the present study, gene expression was analysed using SDS 2.1.1 
software (Applied Biosystems) by a double standardisation method known as the 
modified 2
-ΔΔCt
 method that adjusts for PCR efficiency differences (Skern et al., 2005).  
This mathematical model calculates changes in gene expression as a comparison of the 
Ct values of the samples of interest with a control or calibrator. The Ct values of both 
the calibrator and the samples of interest are then normalized to an appropriate 
endogenous housekeeping gene. GAPDH was chosen as the housekeeping gene in the 
present study as its amplification efficiency has been previously determined in our 
laboratory to be be approximately equal to that of other PCR targets of this study (This 
is a requirement for 2
-ΔΔCt
 calculation validity). To analyse gene expression, for each 
run, ratios relative to the calibrator (reference standard sample) were determined based 
on the respective delta Cts and an average efficiency value was obtained. These ratios 
were then averaged over all three runs and related to the average content of GAPDH 
cDNA in each sample to correct for variations in input RNA. The expression levels 
were represented graphically as corrected value of mRNA abundance relative to average 
GAPDH content.  
 
2.9 Statistical Analysis 
Differences in fasting blood glucose and blood glucose on GTT administration, 
quantified histology data, RTqPCR-determined relative abundance, TGFβ1 protein 
levels by ELISA and band intensities from Western Blot between control and diabetic 
(or prediabetic) groups were compared by unpaired Student‟s t- test using SPSS for 
Windows v17.0 (SPSS Inc., Chicago, IL, USA). Data in graphs are represented as 
mean+SEM of 3 or more independent experiments or as indicated. A value of p<0.05 
was considered statistically significant. Two-way ANOVAs were conducted to 
determine differences for ageing and dsyglycemia effects and are described in Chapter 
7. The level of significance was set at p< 0.05
 
 
  
 
 
 
 
 
CHAPTER 3 
 
 
DEVELOPMENTAL EXPERIMENTS 
 
 
 
ASSESSMENT OF CARDIOMYOCYTE CONTRACTILE 
FUNCTION AND STRUCTURAL REMODELLING IN 
THE LEFT VENTRICLE OF THE STREPTOZOTOCIN-
INDUCED TYPE 1 DIABETIC RAT 
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3.1 Abstract: HF in DM is a major cause of premature morbidity and mortality but the 
underlying mechanisms are elusive and treatment remains empirical. This chapter 
represents a set of preliminary experiments in the investigation of the role of HG in 
diabetic heart disease with primary reference to assessments of cardiomyocyte 
contractile function and histopathological changes in the LV of STZ-treated type 1 
diabetic male Wistar rats compared to age-matched male Wistar controls. Six-seven 
weeks following STZ-administration (60 mg/kg body weight) ventricular action 
potentials were measured in the isolated, spontaneously beating Langendorff perfused 
rat heart. Contraction and [Ca
2+
]i were measured in electrically stimulated ventricular 
myocytes by a Video edge detection system. In another set of experiments, a portion of 
the LV underwent processing for histological studies employing the Haematoxylin and 
Eosin stain, labelling with FITC-conjugated Lectin and the Masson‟s trichrome stain for 
determination of myocyte size and quantitative assessment of fibrosis respectively. 
Immunohistochemical studies were conducted to assess the contribution of diabetes 
towards activation of apoptotic pathways mediated by by caspase-3.  STZ-treated rats 
presented with significantly higher blood glucose values relative to controls (p<0.01).  
Measurements of ventricular action potential indicated that resting heart rate and 
duration of the action potential was slightly reduced in the STZ-treated rats compared to 
controls. When electrically stimulated at 1 Hz, contractility was depressed in myocytes 
from diabetic rats and also exhibited prolonged time(s) for contraction and relaxation 
(p<0.05). Alterations in [Ca
2+
]i homeostasis manifested as prolonged time to peak and 
prolonged rate of decay of the Ca
2+
 transient in diabetic myocytes relative to controls. 
LV morphology was also severely altered by DM. Morphometric analysis indicated 
significant increments in fibrous tissue proliferation, and smaller myocyte transverse 
diameter. In relation to the latter, the heart was atrophied in type-1 DM as STZ-treated 
animals presented with lower heart weights and  heart weight to body weight ratios 
relative to controls (p<0.01). In STZ-treated LV, the pathology frequently manifested as 
focal scarring, myofibrillar loss, vacuolisation and large clusters of cells showing 
histological signs of apoptosis. Activity of cleaved caspase-3 was also significantly 
increased in the STZ-treated group (p<0.05). The results of the study indicate that STZ-
induced type-1 DM results in the development of a cardiac disease characterised by LV 
histopathological changes and functional abnormalities manifesting as altered Ca
2+
 
homeostasis and contractility in the cardiomyocyte. These
 
findings are consistent with a 
dominant influence of HG and underlying alterations in insulin action. 
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3.2  Assessment of Cardiomyocyte Contractile Function and Intracellular Calcium 
Transients in the Streptozotocin-Induced Type 1 Diabetic Rat Heart 
3.2.1 Introduction 
Clinical and experimental evidence indicates that the myopathic changes in DM are 
associated with impairments in contractile force generation, reduced wall compliance, 
abnormal filling
 
and delayed relaxation of cardiac muscle (Dhalla et al. 1985;
 
Ren & 
Davidoff, 1997; Choi et al. 2002; Boudina and Abel, 2007). Experimentally, these 
defects have been assessed in several species with variations in method, treatment times 
and as a consequence, variable results. With STZ-induced diabetic animal models, 
functional deficit has previously been assessed in the intact animal, the isolated perfused 
heart, papillary muscle preparations and isolated cardiac myocytes. The use of 
cardiomyocytes is particularly useful as it allows the investigation of contraction and 
[Ca
2+
]i transient kinetics without the confounding effects of hormones and metabolites 
that are common in in vivo studies and changes in perfusion rates that invariably occur 
in intact hearts. The STZ-induced type 1 diabetic rat has been widely used as a model of 
DCM. Cardiac rhythm disturbance is reported to be a cardinal feature of DCM in the 
STZ-treated rat (Zhang et al., 2008). By extension, alterations in the amplitude
 
and time 
course of contraction and
 
relaxation have been frequently reported in myocytes from 
STZ-treated
 
rats (Yu et al. 1994; Okayama et al. 1994; Ren & Davidoff, 1997;
 
Howarth 
et al. 2001; Choi et al. 2002).  
Nevertheless, substantial discrepancy exists in the published literature regarding 
parameters of contractile dysfunction in chemically induced type 1 DM, wherein 
isolated cardiomyocytes from STZ-induced diabetic hearts have been reported to have 
depressed (Yu et al. 1994; Okayama et al. 1994; Ren & Davidoff, 1997; Choi et al. 
2002) elevated (Howarth et al. 2001) and conversely unaltered (Tamada et al., 1998; 
Ishitani et al., 2001) contractile kinetics. Blighted mechanical performance in the 
diabetic heart has been previously attributed, at least in part to underlying defects in 
[Ca
2+
]i homeostasis (Pierce and Russell, 1997; Choi, 2002; Bracken et al., 2003; Zhang 
et al., 2008). However, there is limited consensus in results from studies of [Ca
2+
]i 
homeostasis performed on isolated cardiomyocytes as resting Ca
2+
 has been shown to be 
decreased (Norby et al., 2002; Ozdemir et al., 2005; Yaras et al., 2005), increased 
(Howarth et al., 2005; Howarth and Qureshi, 2006), or unchanged (Howarth et al., 
2002; Howarth et al., 2004). Similarly, conflicting observations of  the amplitude of the 
Ca
2+
 transient also abound, being reported as decreased (Yaras et al., 2003; Kotsanas et 
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al., 2000; Bracken et al., 2004), increased (Howarth et al., 2005), or unchanged (Singh 
et al., 2006). It is possible that the inconsistency in experimental findings for these 
parameters is due to differences in duration of the disease in conjunction with 
experimental conditions (e.g., different stimulation frequencies, voltage, times and 
temperatures) (Zhang et al., 2008). Thus, experiments were conducted to independently 
identify the contribution of HG towards experiments contractile characteristics and 
calcium homeostasis in ventricular myocytes from STZ-induced type 1 diabetic rats and 
age-matched controls 6-7 weeks post STZ-induction. 
3.2.2 Methods 
As given in Chapter 2 
3.2.3 Results 
1. Evaluation of experimental model 
General Characteristics of STZ-treated rats and age-matched Wistar controls are 
represented in Table 3.1. Following 6-7 weeks of treatment, it was observed that the 
STZ-induced diabetic rats weighed significantly less than age-matched controls 
(p<0.05). Heart weights (HW) were also significantly lower (p<0.01) along with a 
reduction in the HW/BW ratio (P<0.05). At sacrifice, plasma glucose levels were 
approximately 2.41-fold higher in diabetic animals than non diabetic counterparts, in 
accord with previously published glucometry values at similar time points (Singh et al., 
2006; Cosyns et al., 2007).  
Table 3.1: Glucometry and Gravimetry data obtained at 15 weeks post STZ-
administration. Data are given as mean±SEM, *p<0.05, **p<0.01 
Animals Fasting Blood 
Glucose 
(mg/dL) 
BW (g) HW (g) HW/BW ratio 
(g/100g body 
weight) 
Controls 
(n= 5) 
89±3.56 301±16.31 0.94±0.05 0.31±0.02 
STZ-
treated 
(n=6) 
305±7.48** 232±11.07* 0.55±0.03** 0.24±0.11* 
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1. Left ventricular action potential 
  Figure 3.1 A represents typical records of left ventricular action potentials in control 
and STZ-treated hearts. Summarised data for mean heart rate and time from threshold of 
action potential to 50% repolarisation (APD50) are given in 3.1 B and C respectively. 
The results indicated that STZ-treated rats have slightly lower heart rates compared to 
controls (190±5.83 vs. 173±1.33 bpm) as well as increased action potential duration 
(32.83±1.90 vs. 37.91±2.53 ms) However, the differences did not reach statistical 
significance in either case (p>0.05). 
 
 
 
       
 
 
    (B)                                                                         (C)                                                                                      
 
 
 
 
 
 
Fig 3.1: Ventricular action potentials. Typical recordings of left ventricular action 
potentials (A), Spontaneous heart rate [beats/minute, (bpm)] from control and STZ-
treated rats (B) and time from threshold of action potential to 50% repolarisation 
(APD50). Data are representative of 5 independent preparations and given as 
mean+SEM; n=5 for each group 
 
 
(A) 
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    3.   Ventricular Myocyte Contractility: 
Fig 3.2 A represents a typical trace showing cell contraction. Fast time-base recordings 
of contraction in ventricular myocytes stimulated 1Hz are depicted in 3.2 B.  Table 3.2 
describes amplitude and time course of shortening in myocytes from control and STZ-
treated rats. No significant differences were found in resting cell length (RCL) between 
the 2 groups, but peak amplitude of shortening (expressed as a % of RCL) was 
significantly reduced by STZ treatment (p<0.01). In comparison with their control 
counterparts, diabetic rats also displayed a slower time course of shortening i.e. 
increased time to peak shortening and time to 50% relaxation (p < 0.05). 
A 
 
 
 
 
 
B 
 
 
 
 
 
Fig 3.2: Ventricular cardiomyocyte contractility. Representative traces of shortening in 
Control and STZ-treated ventricular myocytes (A).  Representative fast time-base 
recording of unloaded shortening in control and STZ-treated ventricular myocytes  (B). 
Traces are typical of 29-33 myocytes isolated from hearts of 5-6 rats. 
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Table  3.2:  Contractility in ventricular cardiomyocytes. Mean data showing effect of 1 
mM Ca
2+
 on the amplitude, time to peak shortening and time to half relaxation  in 
electrically stimulated (1 Hz, 50 V, 1 ms pulse width) and superfused (35–37°C) 
ventricular myocytes of age-matched control and diabetic rat hearts (n=5-6). Figures in 
brackets represent number of cells *p< 0.05, **p<0.01, unpaired students-t test. 
 
 
 
 
 
 
 
 
5. Calcium homeostasis in ventricular myocytes 
Representative fast time-base recordings of Ca
2+ 
transients in ventricular myocytes from 
control and STZ-treated rats are given in Fig 3.3. Data describing amplitude and time 
course of Ca
2+
transients in cells from STZ-treated and control rats are summarized in 
Table 3.3. The results showed that STZ-treatment did not result in a statistically 
significant difference in peak or resting [Ca
2+
]i between groups.  However, the kinetics 
of the Ca
2+
 transient were slower for diabetic rats (increased time to peak [Ca
2+
]i and 
time constant of Ca
2+
 transient decay; p< 0.05). 
 
Fig 3.3:  Representative fast time-base recording of Ca
2+
 transients in control and STZ-
treated ventricular myocytes.  RU: ratio units. Traces are typical of 29-33 myocytes 
isolated from hearts of 5-6 rats. 
MEASURED 
PARAMETERS 
          CONTROL     STZ-TREATED 
Resting cell length (µm) 103.57±2.85 (33) 97.55±3.29 
Peak amplitude shortening                      
(% resting cell length) 
5.82±0.34 (33) 3.86±0.23 (33)** 
Time to peak shortening 
(ms) 
112.47±5.01 (16) 129.39±5.99 (19)* 
Time to half relaxation 
(ms) 
40.71±2.09 (16) 48.47±2.90 (19)* 
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Table 3.3: [Ca
2+
]i transient kinetics. Data showing effect of 1 mM Ca
2+
 on the 
amplitude, time to peak, and time to half relaxation of Ca
2+
 transients in electrically 
stimulated (1 Hz, 50 V, 1 ms pulse width) and superfused (35–37°C) ventricular 
myocytes of age-matched control and diabetic rat hearts (n=5-6). Values are mean ± 
SEM and figures in brackets represent number of cells *p< 0.05, **p<0.01, unpaired 
students-t test    
Measured Parameters Control STZ-Treated 
Resting Fura-2 
(Fluorescent ratio units) 
1.63±0.25 (23) 1.56±0.18 (21) 
Ca
2+
 transient amplitude 
(Fluorescent ratio units) 
0.37±0.04 (23) 0.33±0.03 (21) 
Time to peak calcium 
transient (ms) 
77.16±3.5 (23) 89.53±2.54 (21)* 
Rate of Ca
2+
 decay 
(ratio units/s) 
0.75±0.02 (23) 0.57±0.02 (21)** 
 
3.2.4   Discussion 
Various clinical and experimental studies have demonstrated alterations in the rate and 
force of cardiac contraction in diabetes that are likely to be key events mediating the 
adverse effects of diabetes on cardiac performance (Schaffer et al.,1989; Ren and 
Davidoff 1997; Ren and Bode, 2000). The present study has demonstrated intrinsic 
defects in contractile function in ventricular myocytes of STZ-treated diabetic rats 
independent of any overt hormonal/vascular effects which is congruent with clinical 
findings of the existence
 
of a diabetes-specific cardiomyopathy independent of 
atherosclerosis, vascular, or
 
valvular diseases in human T1DM (Rubler et al., 1972; 
Kannel et al., 1974; Galderisi et al., 1991; Choi et al., 2002).  
The principal findings of this study are summarised as follows: Firstly, 6-7 weeks post 
STZ-administration, rats presented with significantly greater blood glucose levels and 
showed significantly less body and heart weight gain compared to age-matched 
controls.  Second, No statistically significant differences were found in resting heart rate 
in STZ-induced diabetic rats, although contractility was depressed and time course(s) of 
contraction and relaxation at physiological conditions were prolonged in in myocytes 
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from diabetic rats. Third,  These impairments in mechanical function may be due in part 
to alterations in [Ca
2+
]i homeostasis that manifested as prolonged time to peak and 
prolonged rate of decay of the Ca
2+
 transient in diabetic myocytes relative to controls.  
Overt mechanical abnormalities in diabetes characterised by  altered duration and rate of 
ventricular
 
contraction and relaxation have been observed in intact working hearts
 
(Davidoff et al., 1990), isolated papillary muscle (Fein et al., 1980; Ren et al., 1998) 
and isolated ventricular
 
myocytes (Ren and Davidoff, 1997) with the severity of 
dysfunction generally increasing with duration of the disease. In this
 
study, the finding 
that STZ-induced diabetes resulted in depressed contractility i.e. lower peak amplitude 
and altered time-course of shortening in STZ-treated ventricular myocytes is in 
agreement with previous studies, albeit under different conditions (Choi et al., 2002; 
Noda et al., 1993; Ren and Davidoff, 1997). At the molecular level, such alterations in 
chronotropic and inotropic paramteres have been hypothesised to be an offshoot of 
deranged expression and/or function of several sarcolemmal membrane receptors and 
other key proteins involved in regulating/maintaining intracellular ionic homeostasis 
(Bidasee et al., 2004). Specifically, alterations in [Ca
2+
]i , the  major regulator of cardiac
 
contractility are appreciated as key mechanisms underlying diabetic cardiac dysfunction 
(Zhang et al., 2008) although, as noted previously, experimental findings are 
inconsistent. Disturbed
 
Ca
2+
 homeostasis in DM may alter cardiac function by 
mechanisms including a reduced activity of the ATPases, decreased ability of the SR to
 
take up calcium, and reduced activities of other exchangers
 
such as Na
+
/Ca
2+
 exchanger 
and SERCA (Boudina and Abel, 2007).  Although the present study did not examine the 
critical systems that regulate
 
[Ca
2+
]i, it is feasible that altered [Ca
2+
]i kinetics observed 
in myocytes from STZ-induced diabetic rats may be indicative of
 
disturbed
 
electrically 
stimulated [Ca
2+
]i release
 
and extrusion. In this study, myocytes from STZ-treated rats 
had unchanged resting [Ca
2+
]i level, and Ca
2+
 transient amplitude, despite showing 
reduced contractility relative to controls. These results are consistent with some 
previous studies (Howarth et al., 2002; 2004; Zhang, 2008) performed on isolated 
cardiomyocytes at identical conditions (35–37°C and 1 Hz). In contrast, results from 
other studies showed a reduced Ca
2+
 transient amplitude or peak [Ca
2+
]i (Lagadic-
Grossman et al., 1996; Kotsanas et al., 2000; Yaras et al., 2005), but it should be noted 
that the experiments in question were performed at lower temperatures (21–25°C) and 
different stimulation frequencies (0.2–0.5 Hz).  
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The lower contractility in diabetic myocytes may be further attributable to a reduced
 
myofilament Ca
2+
 responsiveness/sensitivity, which has been reported in diabetic
 
heart 
(Pierce and Dhalla, 1985; Metzger et al., 1999; Ren and Bode, 2000). This mechanism 
is speculated to be related to decreased
 
cardiac myosin Ca
2+
-ATPase activity, which is 
noted as a feature of both chemically induced
 
and genetic diabetes (Ren and Bode, 
2000). Previous studies in STZ-treated rats have documented impaired activity of 
SERCA and/or other Ca
2+
-regulating proteins such as Na
+
/Ca
2+
 exchanger (Russ et al., 
1991; Chattou et al., 1999; Ren and Bode, 2000). It is likely that these impairments may 
underscore
 
the defects in [Ca
2+
]i clearing and subsequently result in the prolonged time 
course of cardiac contraction and relaxation observed in the STZ-induced diabetic 
myocytes relative to controls. While it is impossible to definitively establish the 
relationship between reduced rate of the decay in the Ca
2+
 transient and slowed 
mechanical relaxation, the findings of this study are supplemented by previous work 
suggesting that mechanical relaxation is intrinsically slower in diabetic animals and is 
exacerbated by the reduced rate of decrease of [Ca
2+
]i (Zhang et al., 2008). Moreover, 
myocytes from STZ-treated rats presented with a slightly prolonged APD, which could 
possibly result in the slower kinetics of the Ca
2+
 transient as it is well known that the 
rate of return of [Ca
2+
]i to resting levels is decreased by sustained depolarization, an 
effect that is partly due to inhibition of Ca
2+
 extrusion by the sodium calcium exchanger 
(NCX) (Zhang et al., 2008). In explanation of the changes observed in the time course 
of contraction, duration of shortening and relaxation in this study, parallels can be 
drawn with previous work in chemically-induced diabetic models that has attributed the 
lower rate of shortening with diabetes-induced shifts in contractile
 
protein isoforms, 
notably the redistribution of myosin isozymes
 
from the fast type (V1) to the slow type 
(V3) (Baum et al., 1989; Dillmann, 1989; Metzger, 1999; Ren and Bode, 2000). Lastly, 
a reduction in mitochondrial respiration and
 
pyruvate dehydrogenase activity in the 
diabetic heart may result in a depressed rate of ATP production that could further 
compromise cardiac contractile mechanics in DM (Yu et al., 1997; Ren and Bode, 
2000).  
In conclusion, this study has demonstrated that experimental DM results in altered 
mechanical function and cellular Ca
2+
 homeostasis in the isolated ventricular myocyte. 
Where altered Ca
2+ 
transport has been thoroughly investigated at cellular, molecular and 
genetic levels, less is known about the contribution of ventricular remodelling and 
alterations in contractile proteins in DCM towards functional deficit. The findings 
discussed in this chapter suggest that cardiac dysfunction in STZ-induced diabetes is 
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likely to be attributable
 
to changes at the single-cell level, i.e. altered EC-coupling 
mechanics. However, distinct from subcellular alterations, ventricular remodelling in 
DM may also significantly contribute to overt functional deficit (Zhang et al., 2008). 
Although some features of cardiac remodelling in DM may be in dispute, a large body 
of evidence associates hyperplasia of myocardial ECM and myocytes with 
abnormalities in systolic and prominently, diastolic function that are also reiterated in 
clinical and experimental heart failure.  In the context of the latter, cardiac remodelling 
is known to be a critical factor in the transition from compensated to decompensated 
states. However, the same features divide opinion in experimental DM and reported 
findings of the nature, severity and extent of cardiac remodelling in DM are 
considerably divergent. As such, features of ventricular remodelling are assessed in the 
next section to determine the scope of cardiac changes (myocyte and non-myocyte 
remodelling) in experimental diabetes that may predispose to a decline in cardiac pump 
function. 
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3.3 Association of Diabetes with Histopathological Changes in the Left Ventricle: 
3.3.1   Introduction 
Myocardial structural remodelling been the focus of several studies investigating 
diabetic cardiomyopathy (DCM) in rodent, murine, canine, and primate models of the 
disease (Asghar et al., 2009) that report a cascade of myocardial changes including 
fibrosis (Syrovy and Hodny, 1992), alterations in myocyte size and microcirculatory 
abnormalities such
 
as the thickening of the endothelial basal lamina (Hamby et al., 
1974; Wang et al., 2006).  These changes are believed to result from metabolic 
abnormalities and subcellular defects resulting as a reactionary response of the 
myocardium to HG (Fein, 1996; Depre et al., 2000; Cai et al., 2000). The latter in also 
known to evoke abnormal gene expression and cardiac cell death by both apoptosis and 
necrosis (Cai et al., 2000) as the disease progresses untreated.  
However, there are substantial discrepancies in inferences drawn regarding the onset, 
severity and nature of pathological alteration in experimental studies (Asghar et al., 
2009); These run the gamut from absence of detectable changes (Regan et al., 1981) to 
severe myocytolysis and contracture band formation (Jackson et al., 1985), with some 
studies demonstrating significant changes within the first week of disease induction 
(Reinila and Akerblom, 1984).Contrastingly, in other studies structural manifestations 
of the disease were only apparent after 6 and 12 weeks (Thompson, 1988). Where 
common findings in biopsies of the diabetic heart  are interstitial fibrosis and myocyte 
hypertrophy, in some cases further examination revealed a regional heterogeneity with 
areas showing no increase in ECM deposition (Wang et al., 2006). With regard to 
cardiomyocyte size, contrasting studies in the same model of the disease (e.g. STZ-
induced diabetic rats) demonstrate both hypertrophy (Xia et al., 2007) and atrophy 
(Nemoto et al., 2006, Bilim 2008).  
As mentioned previously, it is important to appreciate the valid interpretation of 
experimental evidence on structural remodelling in DCM is confounded by factors such 
as the diabetogen, differences in the severity and duration of DM, the simultaneous 
presence of experimental hypertension or the subjective nature of the experimental 
design focussing upon one component of the tissue (Thompson, 1988). As such, the 
present study was undertaken in order to assess and confirm the development of LV 
histopathological changes induced by HG in the rat heart, 6-7 weeks post-STZ 
administration.  
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3.3.2    Methods 
As given in Chapter 3 
3.3.3    Results 
1. Histopathology of the LV myocardium  
Visual analysis of the stained sections by light microscopy revealed general 
disorganization of myocardial architecture characterized by thinner fibres, disarray of 
myofibres and scarcity of myofibrils in the STZ-diabetic group compared to Wistar 
controls (Fig 3.4).  
 
 
Fig 3.4:   Histopathology of the LV. Representative light micrographs showing H & E 
stain. In control LV muscle fibres are well organized (A). In contrast, diabetic LV 
frequently demonstrated architectural distortion along with a disordered and irregular 
pattern of myofibrillar arrangement and thinner fibres (B). Occasionally, diabetic LV 
also presented with spongy and vacuolated cytoplasm reminiscent of impending 
apoptotic cell death (ref, B, arrows). Photomicrographs are typical of 55-60 
fields/experimental group consisting of 5 animals per group. The bar in the right 
photomicrograph indicates 20 µm and 10 µm on the left . 
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2. Myocyte Diameter 
The effects of STZ-induced diabetes on myocyte diameter in the LV are represented in 
Figure 3.5. Image analysis of FITC-conjugated lectin stained sections revealed a change 
in cardiomyocyte width in the diabetic group (C).  Compared to age-matched controls 
(A), myocyte diameter was significantly smaller in the STZ-treated rats (B) (9.93±0.26 
vs. 9.11±0.25 µm, p<0.05). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Myocyte diameter. Representative light micrographs showing FITC-
conjugated Lectin staining. Myocytes in the STZ-treated group (B) appeared smaller 
 
A 
B
  A 
A 
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than age-matched controls (A). Original magnification X 200; Photomicrographs are 
typical of 25-35 fields/experimental group consisting of 5-9 animals per group. The bar 
in the lower right photomicrograph indicates 10 µm, and accounts for all micrographs. 
Cardiomyocyte transverse diameter (µm) measured by image analysis (C). *p<0.05, vs. 
respective control, unpaired t test, n=48-51 myocytes.                                                    
3. Myocardial fibrosis 
 When compared to respective controls, STZ-induced rats demonstrated increased ECM 
deposition in both interstitial and perivascular regions, as evidenced by Masson‟s 
trichrome staining (Fig 3.5). Quantitatively, area of interstitial fibrosis was significantly 
greater in STZ-treated rats compared to age-matched controls occupying 5.05±0.44% 
vs. 3.51±0.44% (p<0.05) of the myocardial area analysed, representing an approximate 
43.8% increase (Fig 2.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig  3.6:   Investigation of collagenous matrix deposition. Representative light 
photomicrographs of Masson‟s Trichrome stained myocardial sections. Sections from 
A B
  A 
C 
 
C 
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STZ-treated (B) rats developed greater extents of  fibrosis deposition (green staining) in 
interstitial and perivascular regions relative to respective controls (A). Original 
Magnification X400, Photomicrographs are typical of 37-41 fields/experimental group 
consisting of 5-9 animals per group. Scale bar indicates 20 µm. Interstitial ECM 
deposition in left ventricular myocardium (C) * p<0.05 vs. control. Unpaired t test. 
4. Apoptosis: Diabetes has been associated with cardiac myocyte loss through 
apoptotic mechanisms (Adeghate, 2004). Also, in STZ-treated diabetic LV, H&E 
stained sections occasionally demonstrated signs of end stage apoptosis, manifesting as 
condensation of nuclei and cell shrinkage (Fig 2.7).  Therefore, the contribution of 
diabetes in the activation of caspase-3, a key effector of the apoptotic process, was 
assessed. Immunohistochemical staining for cleaved (active) caspase-3 showed a 
significant increase in immunoreactivity in the hearts of STZ-treated diabetic rats 
compared to age-matched controls (Fig 2.7 D) (1.86±1.30 in control LV vs. 8.56±7.92 
positive cells/mm
2
 in STZ-treated LV, p<0.05 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.7:   Myocyte apoptosis. STZ-treated LV, H&E stain (A). In the STZ-treated rats 
clusters of cells showed signs of end stage apoptosis (A , circle) characterized by 
condensation of nuclei and cell shrinkage. Active Caspase 3-positive myocytes (brown 
staining) in the left ventricle of control (B) and STZ-treated rats (C).  Original 
magnification X 400, Photomicrographs are typical of 10-15 fields/experimental group 
consisting of 5-6 animals per group. The bar in the left photomicrograph indicates 20 
 
   
 
 
B   
A 
D 
A 
 
C B 
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µm, and accounts for all micrographs. Sections are counterstained with Haematoxylin 
(blue). Semi-quantitative analysis of cleaved caspase-3 labeling (D). Results indicated 
iwncreased active caspase-3 labelling in STZ LV compared to age-matched wistar 
controls. (n= 5-9, results expressed as mean+S.E.M, *p<0.05 vs. control, unpaired t test) 
2.3.4 Discussion  
The chemically-induced diabetic rat is a well documented model for the study of 
diabetic complications arising from HG and in this study STZ-treatment produced a 
constellation of characteristics that mimics (severe) clinical type-1 diabetes. The 
experimental design and duration resulted in a stable population of insulin-deficient 
animals for the intervals studied. 
 A notable finding was that STZ-induction resulted in significant cardiac atrophy 
characterised by loss of heart weight, reductions in heart weight to body weight ratios, 
and reduced cardiomyocyte diameter, in accordance with previous studies (Kawaguchi 
et al., 1999; Nemoto et al., 2006; Bilim et al., 2008). The mechanisms underlying 
cardiac atrophy in this model have not been identified although a role of nutrient 
deficiency as been suggested (Savabi et al., 1992; Nemoto et al., 2006). As heart size is 
reported to be sensitive to nutritional status, calorie deprivation in the diabetic rats as an 
offshoot of metabolic disturbance in diabetes and energy production shift from glucose 
utilization towards β-oxidation of free fatty acids may have brought about the observed 
phenotype (Rodrigues et al., 1998; Nemoto et al., 2006). However, previous studies 
examining the differences between atrophic remodelling in STZ-diabetic and food-
restricted, malnourished rats demonstrated divergent features of LV remodelling as well 
as nutritional status between the two (Savabi et al., 1992; Nemoto et al., 2006). 
Alternatively, cardiac atrophy may be attributed to severe insulinopenia in STZ-treated 
rats. Among various signalling pathways, the role of insulin, a potent anabolic hormone 
and its key downstream effector Akt is particularly implicated in the regulation of body 
and organ size in several species ranging from c.elegans and drosophila to mammals 
and in multiple organs including the heart (Abel, 2005). Indeed a previous report has 
correlated myocardial atrophy with decreased Akt phosphorylation in STZ-treated rats, 
an effect that may be modulated by signalling to mTOR and p70S6K downstream of 
Akt (Bilim et al, 2008). The kinase mTOR is noted as a key positive regulator of protein 
synthesis and cell growth transducing signals from growth factors, nutrients and energy 
status. Once activated mTOR influences translation machinery and protein synthesis by 
TORC1-dependent phosphorylation of ribosomal S6 Kinases (Bertrand et al., 2008), 
Activated p70S6K phosphorylates ribosomal S6 protein that regulates translation
 
of the 
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5'TOP mRNAs that encode several translation factors and
 
ribosomal proteins (Alessi et 
al., 1998). As such upregulation/ activation of Akt, mTOR and p70S6K have been 
associated with mesangial cell and glomerular hypertrophy in STZ-induced diabetes 
(Sakaguchi et al., 2006; Yang et al., 2007). 
Another important component of the pathological alterations observed in this study was 
the diffuse ECM deposition in STZ treated LV interstitium. This finding is in agreement 
with previous reports wherein long standing diabetes was observed to exaggerate LV 
remodelling whilst increasing perivascular and interstitial fibrosis (Thompson, 1988; 
Kita et al., 1991; Riva et al., 1998). Despite some conflicting observations, collagen 
deposition and ECM alterations in experimental models of diabetes, are accepted as 
structural hallmarks of diabetic heart as well as other target organs of diabetic 
complications (Ban and Twigg, 2008; Brownlee et al., 1988; Brownlee, 2001). 
Production of fibrosis is an adaptive response of the heart to pathophysiological stimuli 
and various mechanisms have been suggested via which chronic HG and its 
downstream biochemical pathways contribute towards posttranslational modification of 
the ECM, thereby increasing turnover and predisposing towards pathological 
remodelling. The increased matrix turnover in the diabetic milieu is also hypothesized 
to be a result of increased TGFβ1 activity, altered activity of collagen degrading MMPs, 
or upregulation of collagen mRNA expression (Tschope et al., 2004). Remodelling of 
the extracellular matrix is also regulated by profibrotic acting peptides (e.g., angiotensin 
II, aldosterone, endothelin) concentrations of which have been previously discussed as 
altered in diabetes (Tcshope et al., 2004; Ban and Twigg, 2008).  Regardless of the 
underlying mechanisms, morphological and biochemical consequences of ECM 
proliferation are known to be directly related to loss of function in the myocardium and
 
this non-myocyte remodelling process is known a significant
 
role in the decline of 
cardiac pump function in DM (DeTombe, 1997) by adverse effects on ventricular 
compliance.  
Cell death, as a consequence of myocardial abnormalities, can evoke a series of 
pathological changes in the myocardium including a loss of contractile tissue, 
compensatory hypertrophy of myocardial cells, and reparative fibrosis and has been 
considered one of the
 
major contributing factors for various cardiomyopathies and HF 
(Sharma et al., 2007).
 
 In particular, the loss of myocardial cells through the highly
 
regulated process of apoptosis occurring during cardiac
 
remodelling in a failing heart is 
suspected to play a critical role in the
 
transition from compensated hypertrophy to heart 
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failure by causing a reduction in the relative myofibrillar
 
mass, resulting in cardiac 
dysfunction (Dhalla et al., 1996; Cook et al., 1999; De Moissac et al., 2000). Diabetes 
induced cell death has been observed in multiple organs in vivo in both clinical and 
experimental settings and in endothelial cells in vitro (Cai and Kang, 2002).  Moreover, 
Rota et al. have (2006) described the influence
 
of HG and secondary metabolic 
disturbances
 
in the induction of apoptosis, as a potential cause of HF in experimental 
DM. Similarly, several reports have shown that inhibition of myocardial cell death by 
antioxidants or inhibitors of apoptosis-specific signalling pathways leading  to a 
significant prevention of DCM (Cai and Kang, 2003). In the present study, 
immunohistochemical quantification of cleaved caspase-3 indicated there was a 
significant increase in caspase-3 labeling indices in STZ-rats compared to age-matched 
controls. These observations are in agreement with a previous study that has reported 
apoptotic cell death in STZ-treated rats and cultured myocytes in response to 
hyperglycemia at levels analogous to the present study (Cai and Kang, 2003). In the 
same study,  insulin supplementation, further confirmed that the observed effects were a 
result of HG and not a direct effect of the β cell toxin STZ, as has been argued 
previously (Cai and Kang, 2003). Insulin is a predominant protective component of the 
GIK metabolic
 
cocktail (Diaz et al., 1998) administered to attenuate
 
myocardial 
reperfusion injury, including apoptosis and exerts significant
 
cardioprotection in patients 
with AMI who are receiving reperfusion (Jonassen et al., 2000).  Furthermore, in 
cultured neonatal rat cardiac
 
myocytes, administration of insulin alone at reoxygenation 
reduced apoptotic myocardial cells exposed to hypoxia/reoxygenation (Gao et al., 
2002). Several signalling pathways have been implicated in the anti-apoptotic effect of
 
insulin, notably signalling via the PI3-K/Akt axis. On the basis of these findings, it can 
be speculated that loss of the protective, cell-survival effects of insulin and its 
downstream effectors in diabetes may contribute to the cardiomyocyte apoptosis 
observed in this study. It is notable that the incidence of apoptotic myocytes in all 
groups was very low. In this sense, previous work in transgenic mice that express a 
conditionally active caspase exclusively in the myocardium has demonstrated that 
chronically elevated but very low levels of myocyte apoptosis play a vital role in HF by 
predisposing towards dilated cardiomyopathy (Wencker et al., 2003). Moreover, at the 
risk of making further interspecies comparisons, low frequency of cardiac myocyte 
apoptosis in failing human hearts has been implied in the pathogenesis of HF (Olivetti 
et al., 1997; Saraste et al., 1999; Guerra et al, 1999).  
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In conclusion, this study was conducted in order to assess structural remodelling 
changes in the LV as a result of uncontrolled DM. The results have indicated that HG 
can produce marked alterations in myocardial architecture and the expression of a 
cardiomyopathic phenotype characterised by fibrosis proliferation, apoptotic cell death 
and atrophy of cardiomyocytes. Together, with altered contractility in ventricular 
cardiomyocytes, these alterations likely represent the cellular correlates of the 
prolonged relaxation and decreased compliance that characterises LV diastolic 
dysfunction in diabetes. (Galderisi et al. 1991,
  
Ren et al. 1997, Ren & Bode 2000). 
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3.4   The Story So Far 
At first blush, preliminary experiments indicate that LV dysfunction in DM may be due 
in part at least, to HG-induced alterations in ventricular structural remodelling and 
myocyte contractility both of which may contribute to diastolic dysfunction and are 
frequent features of the failing heart. However, certain caveats merit consideration in 
the interpretation of this, or any study utilizing chemically-induced models of Type 1 
DM. These include results being potentially confounded by the fact that STZ is a 
general toxin which can cause other abnormalities in addition to diabetes mellitus (e.g. 
hypothyroidism) which may contribute to the phenotype (National heart lung and blood 
institute working group, 1998). STZ has also been reported to directly induce defects in 
myocyte contractility via an oxidative stress and p38-MAP kinase-dependent 
mechanism (Wold and Ren, 2004). Moreover, the relevance of this experimental model, 
to human DM leaves much to be desired, especially in relation to T2DM that 
epidemiologically represents the bulk of cardiac complications. In this respect, the 
phenotype  described in the developmental study resembles very poorly controlled 
T1DM and one extreme of the metabolic profile that is very rarely encountered in 
clinical practise given current standards of care. Where T2DM is frequently diagnosed 
after the first CV event (Schainberg et al., 2010), and complications most prominent in 
the ageing diabetic, short study periods typical of experimental protocols utilizing the 
STZ-induced T1DM rat model are neither realistic nor
 
desirable. Indeed, age is regarded 
as a major risk factor underlying CHF incidence in DM. Advances in the therapeutic 
management of DM and CHF and general improvement in living conditions has 
accentuated the phenomenon; In the 65 years and older age group, of the incidental 
cases of CHF, 22% of men and 24% of women were diabetic between 1990 and 1994 
compared to 15% and 18%, respectively, 20 years earlier) (Verny, 2007). Another key 
issue in experimentation with the STZ-rat model is that it presents impediments in the 
study of the modifications in glucose metabolism that precede clinical DM. At present, 
the clinical research environment is becoming increasingly reflective of the fact the 
myocardial complications of DM may begin in response to elevated HG that is below 
the range defined for a diagnosis of T2DM and the significance of the prediabetic phase 
herein. This situation is briefly discussed in the following section. 
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3.4.1 Cardiac Complications in Prediabetes: Overview of the status quo 
Several studies, summarised in Table 3.4, have reinforced the concept that incidence of 
CV events including HF risk can be correlated with the degree of glucose elevation and 
not by the presence or absence of DM per se. Additionally, the Australian Diabetes, 
Obesity, and Lifestyle Study (AusDiab), the largest national diabetes population 
prevalence survey employing an OGTT in more than 11,000 adults over 25 years of age 
in Australia found that 65% of all cardiovascular disease deaths occurred in people who 
not only had known DM and newly diagnosed DM, but also IFG or IGT at baseline. 
The study further indicated that a significant proportion of CVD deaths occur in people 
with abnormal glucose metabolism (Barr et al., 2007). The authors have postulated that 
“strategies to prevent premature mortality and particularly CVD death need to be 
targeted not only to people with diabetes but also to people with milder forms of 
abnormal glucose metabolism” (Barr et al., 2007). Supporting the AusDiab study, an 
earlier metaregression analysis of published data by Coutinho et al., from 20 studies of 
95,783 individuals followed for 12.4 years has shown the progressive relationship 
between glucose levels and cardiovascular risk extends below the diabetic threshold and 
“that dysglycemia is a cardiovascular risk factor” (Coutinho et al., 1999). As such, it 
appears that glucose intolerance and IFG that presage the development of T2DM are not 
only indications of risk for progression to DM, but also to have independent 
pathophysiologic significance that includes mortality, macrovascular complications 
including MI or stroke. Specifically with respect to cardiac disease, glucose intolerance 
and IR have been associated with LV hypertrophy (Bianchi et al., 2008), concentric 
remodelling and diastolic dysfunction (Fujita et al., 2007; Schneider et al., 2010). Thus, 
from an epidemiological stance, there is a basis to suggest that dysglycemia may reflect 
a risk for HF even in the absence of overt DM.  
Epidemiology aside, the factors underlying the association between dysglycemic states 
and CVD, especially HF, have not been extensively studied. Most importantly, the 
benefit of primary prevention of HF pathogenesis associated with glucose lowering in 
prediabetes based on current definitions has not been established as of this writing. 
Clinical studies are also rarely without inherent limitations, often failing to describe the 
potential role of intercurrent events such as acute coronary syndromes or even changes 
in blood pressure accounting for subsequent hospitalization for HF. Moreover, 
dysglycemia is often described as associated with a diffuse and aggressive form of 
coronary artery disease, which could potentially lead to myocardial injury and failure. A 
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diversity of potential mechanisms of adverse cardiac consequences with glucose 
intolerance have been reported, the general opinion being that the mechanisms by which 
diastolic dysfunction may occur in patients with IGT appear to be similar to those 
operating in DM (Fujita et al., 2007). Thus, where the direct effects of HG have been 
implicated, at present there are more questions than answers regarding pathogenesis and 
pathophysiology. The natural history of DM heart function by Doppler 
echocardiography is limited, because most patients do not have a prediabetic study, and 
receive treatments in the full-blown stage of DM or after having diabetes complications 
(Bergman 2010). Because glucose intolerance may affect over 9 million adults in the 
UK (Diabetes UK, 2010), has been reffered to as „The Silent Pandemic‟ in the popular 
media (The Press and Journal, 2009) and may increase the lifetime risk of HF 
substantially, associations between these common and potentially co-morbid conditions 
are of interest and clinical relevance. 
Table 3.4: Studies correlating dysglycemia and HF. MESA: Multi-ethnic study of 
atherosclerosis. Table adapted from Schainberg et al., 2010 
Study Design Subjects Results 
UKPDS 35 
(Stratton et 
al ., 2000) 
Prospective 
observational study 
n=4,585 patients 
(white, asian, 
Indian, afro-
caribbean 
Incidence of clinical 
complications significantly 
associated with glycemia. No 
risk threshold for any point. 
16% rise in HF risk with 1% 
A1c rise 
EPIC 
Norfolk 
(Khaw et al., 
2004) 
Epidemiological study 
6 year follow-up 
n=10,000 (45-79 
years) 
21% increase in CV events for 
each 1% rise in A1c>5%. 
Increase in CHD event by 40% 
and 25% in mortality for each 
1% A1c> 7% 
OPTIMAAL 
study group 
(Gustaffson 
et al., 2007) 
Clinical trial comparing 
ACE inhibitors Losartan 
and captopril 
n= 2,841 
(baseline 
HbA1c) Dm 
patients that 
survived MI 
complicated by 
HF 
Each 1% increase in A1c>5% 
over 2.5 year follow up 
increased mortality by 24% 
FUNGATA 
study 
(Tominaga 
et al., 1999) 
Cohort population 7 year follow up IGT was a risk factor but IFG 
was not 
MESA Population-based 
sample 
n= 6,814 men 
and women 
from ethnic 
groups (white, 
Hispanic, 
African 
American and 
Chinese) 
Differences in LV mass index, 
volumes and function detected 
amongst IFG and DM vs. 
normoglycemia. Ethnicity 
modified the association 
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Held and 
colleagues 
(2007) 
ONTARGET and 
TRANSCEND cohorts 
(both randomized 
controlled trials) 
ONTARGET; 
n=25620 
TRANSCEND 
n=5,926. people 
with a high risk 
of CVD 
with/without 
DM. 2.4 year 
follow up 
FPG was a significant 
independent risk factor for 
incident CHF and combined 
endpoint of CHF/CV death that 
persisted after adjustment of 
DM status 
Ingelsson et 
al., (2005) 
Prospective population-
based cohort 
n=1,187 
swedish men≥ 
70 years 
Abnormal 2-h postload glucose 
response was an independent 
CHF predictor 
Nielsen and 
Lange 
(2005) 
Data extracted from the 
Veterans Affairs 
electronic medical 
record systems 
n=20,810 
nondiabetic 
males 
(predominantly) 
Increasing glucose below DM 
range independently associated 
with greater HF incidence 
Reykjavik 
study 
(Thrains- 
dottir et al., 
(2005) 
Population-based cohort n=19,381 Strong association between 
dysglycemia, prevalent CHF and 
incident morbidity and mortality 
during 21.3 yr follow up after 
traditional risk factor adjustment 
As such, there is an urgent need to for appropriate animal models that provide the least 
ambiguous answers to allow a better understanding of the processes that lead to diabetic 
cardiac dysfunction. The OLETF rat is an animal model of congenital DM by selective 
mating. Using the OLETF model, the serial changes in LV filling dynamics 
histopathology and metabolic disorders, such as HG, myocardial collagen accumulation 
during the process of DM progression beginning in prediabetes have been evaluated. In 
the OLETF rat, an increased deposition of collagen in the myocardium and a reduced 
peak velocity and prolonged deceleration time of early transmitral flow was observed 
during the pre-stage of T2DM (Mizushige et al., 2000).  Nonetheless, the role of HG 
alone in underlying the reported complications is not clear as in addition to 
complications induced by HG, the OLETF rat has the added impact of complications 
due to dyslipidemia and hence is perhaps better suited to studies of the metabolic 
syndrome opposed to uncomplicated DM.. Furthermore, there is a gender bias with 
T2DM observed in most (86%), but not all, male rats of this strain, which may further 
obscure interpretation (Kawano et al. 1991, 1992; Yamamoto et al. 1999).  
Where the pathophysiological relevance of the STZ and OLETF rat to delineating 
cardiac effects of a milieu dominated by HG is in question, the quest may be more 
fruitful when pursued in the Goto-Kakizaki (GK) rat. 
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3.4.2 Physiological relevance of the Goto-Kakizaki Rat model  
The GK rat is a non-obese, spontaneously T2DM model obtained by the selective 
breeding of mildly glucose-intolerant Wistar rats, repeated over several generations 
(Goto et al., 1975).  The pathogenesis of diabetes in the GK rat includes reduced 
pancreatic β cell mass (upto 50%) and pancreatic insulin stores, an impaired insulin 
secretion in response to glucose both in vivo and in isolated pancreata, IR in adipose 
tissue, muscle and liver, moderate but stable fasting HG and late complications 
manifesting as nephropathy and neuropathy (Ostenson et al. 1993; Yashushi et al., 
2007; Howarth et al., 2007). T2DM in the GK rat is speculated to be polygenic, and six 
independent genetic loci have been identified to be involved in the disease (Gaugier et 
al., 2006). From the colony utilized in the present study, all animals were known to 
exhibit DM and IGT after 10 weeks of age. Thus during the first 8-9 weeks, the animals 
may be considered prediabetic and thus present a valuable opportunity to study initial 
pathophysiological changes in the myocardium that precede the onset of DM. 
Furthermore, GK rats have a stable, inheritable form of T2DM and do not develop 
marked obesity, hypertension or hyperlipidemia (Portha et al., 1991; Zhou et al. 1995; 
Begum and Ragolia, 1998; Yashushi et al., 2007; Darmellah et al., 2007). This makes it 
a particularly useful model to studying cardiac effects of DM alone, excluding the 
confounding effects of obesity and/or hypertension per se that tends to cluster with 
T2DM in clinical settings. Cardiac complications of prediabetes in the GK rat have not 
yet been established but few studies have addressed functional changes in overt T2DM. 
These are signposted in the subsequent sections. 
3.4.3 Aims and Scope of the Study  
Although HF treatment has markedly improved, reversal of pathological changes and 
full restoration of function remains difficult. Consequently, identification of 
predisposing conditions and prevention of early cardiac injury is very desirable. Past 
studies, analyses of datasets from populations and theoretical mechanisms are consistent 
with the proposition that increasing glucose has a continuous association with risk for 
HF, even at concentrations below the cut-offs for a diagnosis of DM, but the underlying 
pathogenesis is unclear. Because IGT is a common and potentially treatable condition, 
information concerning how increasing glucose may contribute to other risk factors for 
HF is of particular clinical consequence.  
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As described in the first chapter of this thesis, failure of the heart, during either systolic 
and/or diastolic phases of the cardiac cycle, has its origins rooted in an adverse 
structural, biochemical, and molecular remodelling of myocardium that involves its 
cellular constituents and the ECM. In this work, focus is on the pathogenic role of 
dysglycemia beginning in prediabetes and progressing to overt mild T2DM, in 
contributing to adverse remodelling of the myocardium and the identification of 
potential molecular and transcriptional mechanisms that underlie this association. An 
intrinsic myocyte contractile dysfunction may supplement the remodelling process in 
contributing to the failure of the heart as a pulsatile muscular pump, underscored by 
changes in bioenergetics, myosin isoforms, cytoskeletal proteins, and ion transport 
systems. However, assessment of myocyte contractile function was not further pursued 
in the GK rat as earlier studies (in our laboratory) were unable to demonstrate any 
significant abnormalities in the contractile function of myocytes isolated from the GK 
LV for up to 18 months of untreated DM (Howarth et al., 2007).  
In the present work data regarding the development and progression of remodelling 
changes can be roughly divided into (1) that concerning the phenotype and (2) that 
concerning the mechanisms that govern the establishment of the phenotype. 
Specifically, the following issues have been addressed: 
1. It has become clear that cardiac remodelling is attended by cardiac hypertrophy 
and interstitial fibrosis, leading to the loss of normal cardiac function and that dynamic 
structural remodelling is a milestone in HF progression. Using the GK rat as a model of 
prediabetes, (at 8 weeks of age), this study tests the hypothesis that dysglycemia of 
prediabetes may contribute to HF pathogenesis by stimulating myocyte hypertrophy and 
fibrosis proliferation in the LV. How mild HG per se impacts LV structure in the long 
term was also examined by studying remodelling changes at the other end of the 
dysglycemia continuum, i.e. in overt chronic (mild) T2DM in the GK rat. Moreover as 
ageing is an independent risk factor for HF, the study design enabled assessment of the 
combined effects of ageing and mild HG on the myocardium. Conventionally,
 
a limit 
for advanced age in humans is set at 65 years and in the literature, a corresponding
 
cut-
off point for rats is set at age above 18 months (Ferrari et al., 2003). This has been 
adopted in the present study in the choice of age groups.  
2. In investigating the putative mechanisms that could underlie structural 
remodelling in the dysglycemic LV, this study has investigated the involvement of 
TGFβ1, cytokine activation being a pivotal mediator in cardiac remodelling in response 
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to myocardial overload or injury. Several lines of evidence point to the role of HG-
induced TGFβ1 as a powerful initiator of tissue repair, sustained production of which 
underlies the development of myocardial fibrosis. Moreover, increased TGFβ1 
expression has also been identified in the myocardium during cardiac hypertrophy and 
HF. Confirming the activation of TGFβ1 in dysglycemic states may highlight a role in 
HF pathogenesis and inversely, present therapeutic opportunities.  
3. HF has come to be recognised as a disorder of cell signalling and several protein 
kinases and phosphatases are now seen as having especially cogent roles in HF 
pathogenesis. Of the labyrinthine maze of signal transduction events initiated by HG 
that lead up to HF, this work investigates alterations in Akt activity and its downstream 
signalling via the mTOR/p70S6K axis.  The  Akt-MTOR-p70S6k axis is a key mediator 
of the hypertrophic response and recent studies have suggested an HG-dependent 
TGFβ1 mediated activation of this pathway in vitro 
4. As most signal transduction mechanisms that are involved in HF pathogenesis 
converge on the cell nucleus and long-term effects on virtually every aspect of cardiac 
function are exerted through the enforcement of altered gene expression, thus making it 
a logical target for therapeutic intervention. Therefore, a major objective of this study 
was to examine the occurrence of transcriptional reprogramming of key genes that 
execute hypertrophic/fibrotic gene programmes during pathological remodelling of the 
heart in response to dysglycemic states 
Altogether, this study has utilized a broad transcriptomic and proteomic approach to 
provide an overview of the profound modifications that affect the heart at both ends of 
the dysglycemia continuum. An improved understanding of how HG can account for the 
causes of adverse myocardial remodelling carries with it the potential of identifying new 
biomarkers predictive of risk, onset and progression, and response to intervention(s) 
aimed at preventing and/or regressing the remodelling of myocardium in dysglycemic 
states. 
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THE PREDIABETIC GOTO-KAKIZAKI RAT 
 
 
 
 
 
 
 
 
 
CHAPTER 4                                                   LV REMODELLING IN PREDIABETES 
 
85 
 
 
Left Ventricle Structural Remodelling in the Prediabetic Goto-Kakizaki Rat 
4.1 Abstract 
Background: This study tested the hypothesis that experimental prediabetes can elicit 
structural remodelling in the LV.  
Methods: LV isolations from 8-week old male GK rats and age-matched male Wistar 
controls were used to assess remodelling changes and underlying TGFβ1 activity, pro-
hypertrophic Akt-p70S6K signalling and gene expression profile of the extracellular 
ECM using histological, immunohistochemical, immunoblotting and quantitative gene 
expression analyses.  
Results: Prediabetes in GK rats was confirmed by impaired glucose tolerance and 
modestly elevated fasting blood glucose. LV remodelling in the GK rat presented with 
marked hypertrophy of cardiomyocytes and increased ECM deposition that altogether 
translated into increased heart size in the absence of ultrastructural changes or fibre 
disarray. Molecular derangements underlying this phenotype included recapitulation of 
foetal gene phenotype markers BNP and α-SKA, activation of the Akt-p70S6K pathway 
and altered gene expression profile of key components (Collagen 1α, fibronectin) and 
modulators  (MMP2 and 9 and CTGF) of the ECM. These changes were correlated with 
parallel findings of increased TGFβ1 transcription and activation in the LV and elevated 
active TGFβ1 in plasma of GK rats compared to controls (t test, p<0.05 vs. age-matched 
Wistar control for all parameters).  
Conclusions: This is the first report describing LV structural remodelling in 
experimental prediabetes. Results suggest that ventricular decompensation 
pathognomonic of advanced diabetic cardiomyopathy may have possible origins in pro-
fibrotic and pro-hypertrophic mechanisms triggered before the onset of T2DM. TGFβ1 
activity may represent a key intermediary in this process. 
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4.2 Introduction 
The high prevalence of HF seen in individuals with T2DM is partly accounted for by a 
diabetes-specific cardiomyopathy (Boudina and Abel, 2010).  HG is the primary 
diagnostic feature of DM, the target for anti-diabetic therapy and together with HbA1C 
the principal marker of glucose control (Schainberg et al., 2010). It follows that several 
lines of epidemiological evidence have accumulated to suggest an independent effect of 
HG on HF, in the absence of confounding co-morbidities/risk factors. Indeed, previous 
work and theoretical mechanisms are consistent with the proposition that increasing 
glucose has a continuous association with risk for HF and adverse cardiovascular 
outcomes even at concentrations below the range defined for a diagnosis of diabetes; i.e. 
in the dysglycemia of IGT (also impaired fasting glucose), used interchangeably with 
the term ‘prediabetes’ (Nielsen and Lange, 2005; Bergman, 2010; Schainberg et al., 
2010).  
The association between HG and HF may be mediated, in part by an effect of HG on 
LV structure. Structural remodelling of the LV characterised principally by myocyte 
hypertrophy and fibrosis proliferation is recognised as the pathological sine qua non of 
the failing heart. It is noteworthy that in recent years, HF has been redefined as the 
sustained progression of LV myocardial remodelling that precedes the impairment of 
chamber performance and overt clinical manifestation (Fedak et al., 2005). One 
mechanism whereby HG can elicit unfavourable structural remodelling is via activation 
of the pro-fibrotic cytokine TGFβ1. This concept is reinforced by previous clinical and 
experimental work highlighting the functional linkage of HG-stimulated increase of 
protein synthesis, in particular of ECM proteins with increased TGFβ1 signalling, 
mainly in the kidney (Ziyadeh, 2004) but also in the heart (Ramos-Mondragon et al., 
2008), suggestive of systemic effects. Less established is the causal relationship of 
TGFβ1 in provoking myocyte hypertrophy. As described in Chapter 1, recent in vitro 
work has demonstrated the capacity of HG to induce hypertrophic growth by TGFβ1-
mediated activation of the Akt-mTOR-p70S6K signalling, a canonical pathway in cell 
size regulation (Wu and Derynck, 2009). However, in vivo validation of this mechanism 
in a setting of moderate HG and in the context of the cardiomyocyte is pending.   
Compelling epidemiological evidence notwithstanding, the role of HG in HF 
pathogenesis is unclear. The relationship of HG to HF is complicated by converse 
observations that improved glycemic control does not improve cardiac function and 
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hence prevent HF (Neilsen and Lange, 2005) and also that HF can in turn, induce 
insulin resistance and DM (Schainberg et al., 2010). Genetic heterogeneity of sample 
populations, intercurrent events such as acute coronary syndromes, sex-pooled analyses 
and environmental risk factors are amongst other caveats confounding interpretation of 
clinical studies. Experimental support is limited, with most work focussing on  
chemically induced Type 1 models of the disease that ultimately represent an extreme of 
the metabolic profile (rarely encountered in clinical practice) or Type 2 models 
burdened with the twin load of DM and other element(s) of the metabolic syndrome. 
Prediabetes was estimated to affect over 7 million in the UK population in 2009 
(Diabetes UK, 2009) and considering prevalence is ever-burgeoning, the importance of 
assessing the myocardial consequences of mild-moderate HG in animal models that 
represent a pure diabetic aetiology cannot be overstated.  
 In light of the foregoing, the well characterized GK rat model (Goto et al., 1975) was 
utilized to address whether LV structural remodelling begins in a state of IGT that 
precedes the onset of T2DM. Briefly, characteristics of the disease in the GK rat include 
a reduced β cell mass, hepatic and peripheral insulin resistance altogether culminating in 
mild basal HG, marked glucose intolerance that deteriorates over time to frank T2DM 
(Yasushi et al., 2007). As the disease progresses untreated, the GK rat also manifests 
main features of metabolic, hormonal and vascular disorders described for T2DM 
(Howarth et al., 2007). In this chapter, data are presented to substantiate the hypothesis 
that the HG of prediabetes is sufficient stimulus to induce LV remodelling characterised 
by myocyte hypertrophy and ECM proliferation concomitant with increased circulating 
active TGFβ1, alterations in TGFβ1-sensitive signalling events and the gene expression 
profile of the ECM. 
 
4.3 Methods 
 As given in Chapter 3 
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4.4 Results 
1. Characterisation of prediabetes in the Goto-Kakizaki rat 
At 8 weeks of age, fasting blood glucose in GK rats was within the normal range (<125 
mg/dL) but consistently higher than age-matched control animals (76.2±5.73 vs. 
107±6.21 mg/dl, p<0.01) (Fig4.1 A). Glucose clearance capacity in diabetic and control 
animals was assessed using the glucose tolerance test (GTT) (Fig 4.1 B). Maximal 
response to glucose challenge was significantly higher in untreated diabetic animals 
versus control. Additionally, blood glucose levels following GTT were higher at all 
time points measured and did not return to baseline level indicating severely impaired 
glucose tolerance (p<0.01). Two hour blood glucose of GK rats at 8 weeks was <200 
mg/dL and when coupled with fasting blood glucose values (Fig 4.1 A), satisfied 
criteria for a diagnosis of IGT in accordance with  current guidelines (WHO, 2006). 
Mean plasma insulin levels were not assessed in this study but glycemic status in GK 
animals were consistent with impaired secretion of insulin and peripheral insulin 
resistance previously reported in this model (Portha et al., 1991).  
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Fig 4.1: Glucometry data. Fasting Blood glucose (1A) and GTT (1B) demonstrating 
elevated fasting glucose and impaired glucose tolerance in GK rats compared to controls 
1B 
* 
** 
** 
** 
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at 8 weeks (n=8/group). Data expressed as Mean+SEM. *p < 0.05, **p< 0.01, unpaired 
t test. 
 
2. Histopathology, gross morphology and gravimetry 
Body weight (BW), whole heart weight (HW) and LV weight (LVW) was assessed in 
prediabetic GK and age-matched control animals at 8 weeks. No significant differences 
were found in BW among groups, whereas HW and LVW normalized to BW showed a 
modest but significant increase within the GK group (Table 4.1). Small increases in 
thickness of the LV free wall were also evident in GK rats (Fig 4.2 B) compared to age-
matched controls (Fig 4.2 A) but this difference did not reach statistical significance 
(p>0.05). At the cellular level however, a conspicuous increase in cardiomyocyte width 
was apparent in the GK group that was further confirmed by quantifying Lectin staining 
(Fig 4.2 D, Table 4.1).  No major ultrastructural alterations were apparent on 
comparison of control and GK groups (Figs. 4.2 E and 4.2 F) and both groups showed 
comparable preserved sarcomeric structure within cardiomyocytes (i.e. within 
sarcoplasma, contractile apparatus and organelles). A subtle differentiating feature in 
prediabetic rats was the recurrent finding of altered intercalated disk presentation. 
Intercalated discs in the GK group frequently presented with dilation of fascia adherens 
and a zig-zag configuration (Fig 4.2 H) opposed to normal sinuous appearance within 
control animals (Fig 4.2 G). It has been suggested that this feature represents the brisk 
pace of sarcomerogenesis in the adapting myocardium much of which takes place at the 
intercalated disc and is reminiscent of normally growing hearts (Legato et al., 1984)   
 
Table 4.1:   General characteristics of control and GK rats at 8 weeks. Values are 
expressed as mean±SEM.  * unpaired t Test p<0.05 versus age-matched control.  BW: 
body weight; HW: heart weight; LVW: left ventricle weight                                                                                        
 
Animals BW 
(g) 
HW   (g) Hw/BW Ratio 
g/100g BW 
LVW/BW 
(mg/g) 
LV 
thickness 
(mm) 
Myocyte 
Diameter 
(µm) 
Control 
(n=8) 
325±1.49 0.80±0.01 0.24±0.441 1.76±0.42 2.98±0.20
7 
9.11±2.55 
GK 
(n=8) 
329±0.43 0.92±0.008* 0.28±0.002* 1.98±0.80
* 
3.15±0.46 9.93±2.69
* 
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Fig 4.2: Left ventricle Hypertrophy and Myocyte Ultrastructure. Representative 
photomicrographs from 4-5 hearts showing slight increase in LV wall thickness in GK 
(2B) rats compared to controls (2A). Scale bar=3 mm. Typical FITC-conjugated Lectin 
staining showing increased myocyte diameter in GK rats (2D) vs. Control (2C) 
Magnification X400. Representative transmission electron micrographs of the LV in 
control and GK rats (n=4) (2E & 2F) showing comparable cytoarchitecture. Normal 
aspects of the A and I bands, M and Z discs, densely packed mitochondria and regular 
arrangement of sarcomere (Magnification x14, 000). Representative intercalated disc in 
control and GK rats (2H, 2G). Control showing characteristic sinuous aspect (2G), 
adherens junctions evidenced by arrow whereas typical intercalated disk in GK cell; 
note dilatation of fascia adherens indicative of sarcomerogenesis (*) (2H) 
(Magnification x18, 000).  
 
The density of collagen protein was evaluated by Picrosirius Red staining in control and 
GK rats (Fig 4.3). In control animals, fibrosis in the LV was negligible. Within the GK 
group, ECM proliferation was still limited but significantly more pronounced, wherein 
accretions were evident throughout the interstitium and distributed evenly throughout 
the thickness of the myocardium. Quantitatively, there was a 1.43-fold increase in 
collagenous matrix accumulation, occupying 1.44±1.02% of the LV in GK animals vs. 
1.006±0.13% in controls p<0.05 (Fig 4.3 C). 
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Fig 4.3: Collagenous matrix proliferation in the interstitium. Increased picrosirius red 
staining was evident in GK (3B) compared to control animals (3A) Magnification X400. 
Collagen protein area fraction quantified by image analysis (3C). Data presented as 
Mean+SEM. * unpaired t test p<0.05, n=37-41 fields from 5-6 rats in each group. 
3. Molecular events characterising extracellular matrix proliferation in the 
prediabetic LV 
a. Increased active TGFΒ1 levels and  mRNA expression in the prediabetic GK rat 
Plasma and LV samples from GK and control rats were used to evaluate total and active 
TGFβ1 concentration by ELISA (Fig 4.4).  Active TGFβ1 levels increased in GK 
Plasma and LV relative to control animals (plasma: 2.55±0.55 vs. 1.67±0.11 ng/ml, 
p<0.05; LV: 5.47±1.48 vs. 2.89±0.60 pg/mg of total protein, p<0.05). Total TGFβ1 
protein levels were also increased in the LV of GK rats relative to controls (10.32±1.99 
* 
(C) 
A B 
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vs. 7.38±0.50 pg/mg of total protein, p<0.05) but remained largely unchanged in plasma 
(4.87±0.84 vs. 4.46±0.46, p>0.05).  Increased LV TGFβ1 in was accompanied by a 1.4 
fold transcriptional upregulation of TGFβ1 mRNA in GK LV relative to controls, as 
determined by quantitative RT-PCR (Fig 4.4 D).  
 
 
4. Gene expression profile of the intersitium and connective tissue growth 
factor 
Both HG and TGFβ1 activity are known to regulate gene expression of the ECM. Using 
RTqPCR, this study investigated whether fibrotic deposition in GK rats was paralleled 
by an altered ECM gene
 
expression phenotype.  
Collagen type 1α (Co1α) and fibronectin (Fn) expression were significantly increased in 
GK rats (Fig 4.5 A), whereas collagen type 3α (Col3α) expression was not altered 
(p>0.05). Message levels for regulators of the ECM also changed in prediabetes. 
Notable increases in the expression of connective tissue growth factor (CTGF), a key 
mediator of fibroblast differentiation and activity (Fig 4.5 B) was found in GK LV. 
Metalloproteinases represent a group of enzymes that catalyze ECM degradation and in 
this study we found significant upregulation of MMP2 and MMP9 in GK rats compared 
to controls (Fig 4.5 B). Finally, mRNA expression levels of tumour necrosis factor α, 
elastin, vimentin, integrin α1 and integrin α5 were also assessed but no significant 
differences were detectable in GK rats vs. controls. 
 
Table 4.2: Total and active TGFβ1 in plasma of control and GK rats. Data expressed as 
Mean+SEM. * unpaired t test, p<0.05. (n=3) 
 
 
 
 
 
 
 
 Total  PlasmaTGFβ1 
(pg/ml) 
Active Plasma TGFβ1 
(pg/ml) 
Control 4.46±0.35 1.67±0.09 
GK 4.87±0.65 2.55±0.21* 
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Fig 4.4: TGFβ1 protein level and expression.  Results of ELISA showing increased 
ratio of active: total TGFβ1 protein (4A), total TGFβ1: total extracted LV protein (3B) 
and active TGFβ1: total extracted LV protein (4C) in LV samples of GK vs. control 
animals (n=3/group). LV mRNA expression of TGFβ1 (4D). RT-PCR amplification 
was normalized to that of GAPDH (n=8/group). Table showing Experiments for both 
ELISA and RTqPCR were conducted in triplicate. Data expressed as Mean+SEM. * 
unpaired t test, p<0.05.  
 
 
Plasma TGFβ1 Total LV TGFβ1 
Active LV TGFβ1 TGFβ1 LV gene expression 
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Fig 4.5: Gene expression profile of the extracellular matrix. Increased message levels 
for ECM components Col1α and Fn (5A) and regulators MMP2, MMP9 and CTGF 
(5B). RT-PCR amplification was normalized to that of GAPDH (n=8/group). Data 
expressed as Mean+SEM.  * unpaired t test, p<0.05.  
Molecular events underlying left ventricle hypertrophy in prediabetes 
 
5. Recapitulation of a foetal gene phenotype 
Increased expression of the natriuretic peptides ANP and BNP and of myofibrillar 
protein αSKA are considered sensitive biomarkers for cardiac hypertrophy.  
Furthermore, TGFβ1 has been demonstrated to stimulate recapitulation of fetal cardiac 
genes. Therefore, to investigate whether histologically-determined myocyte hypertrophy 
was concurrent with induction of corresponding molecular markers, this study 
quantified ANP and BNP mRNA by RTqPCR (n=8/group) and cellular αSKA by 
indirect immunofluorescence labelling. Cardiac hypertrophy in GK rats was 
accompanied by significant upregulation of cardiac BNP transcripts in the LV whereas 
ANP mRNA was unchanged (Fig 4.6 A).  In this study, normalized pixel intensity 
measurements obtained by confocal imaging were used to determine cellular αSKA1 
protein levels. This method demonstrated a significant increase in signal intensity of 
Anti–αSKA1 immunostaining in GK rats relative to age-matched control animals 
(24.12±1.06 vs. 14.24±1.42, arbitrary units) (Fig 4.6 D) The distribution
 of αSKA1 
immunostaining in GK rats was of a focal pattern similar to that in control animals, but 
both density and staining intensity of reactive fibres were greater in GK (Fig 4.6 C) vs. 
normal myocardium (Fig 4.6 B).  
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Fig 4.6: Expression of biomarkers for cardiac hypertrophy. mRNA expression of 
natriuretic peptides ANP and BNP (6A). RT-PCR amplification was normalized to that 
of glyceraldehyde-3-phosphate dehydrogenase (GAPDH). Data expressed as Mean+ 
SEM. *p<0.05. Representative confocal photomicrographs demonstrating increased 
anti–α-SKA1 (green) immunoreactivity in GK LV (6C) relative to control (6B). 
Magnification X400. Quantitatively, α-SKA1 protein level (pixel intensity from 
immunofluorescence images) was consistently elevated in GK rats compared to controls 
(6D). Data expressed as Mean+SEM. * unpaired t test, p<0.05  
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6. Activation of Akt-p70S6K signaling in the prediabetic LV 
 To investigate hypertrophic signaling mechanisms possibly underlying myocyte 
hypertrophy in the prediabetic LV, this study focused on those pathways which are 
known targets of TGFβ1. A recent study has demonstrated that the capacity of HG to 
induce cellular hypertrophy in vitro is dependent upon MMP-dependent activation of 
TGFβ1 that regulates the activity of the akt-mTOR-p70S6K axis, a key cascade in 
protein synthesis upregulation (Wu and Derynck, 2009).  
It was of particular relevance to test this theory, as all other determinants of this 
mechanism (i.e. HG, myocyte hypertrophy, increased circulating TGFβ1 and increased 
MMP expression in the LV) occurred simultaneously in this study. Thus, levels and 
activation (phosphorylation) of Akt (Ser473) and p70S6K (Thr389), a downstream 
marker of TOR activation were measured by immunoblot (Fig 4.7 A). The latter 
phosphorylation site is well-recognized to reflect actual mTOR activity (Wang et al., 
2005). Results indicate that that there were significant increases in both Akt  (Fig 4.7 D) 
and p70S6K phosphorylation (Fig 4.7 E) in GK relative to Wistar control hearts at 8 
weeks (n=3/group). No differences in total Akt or total p70S6K were detectable within 
groups (Figs. 4.7 B, 4.7 C). Accordingly, ratio of normalised phosphorylated Akt:Total 
Akt  and normalised phosphorylated p70S6K:total p70S6K were significantly increased 
in GK rats relative to age-matched controls (pAkt:Akt - 0.99±0.02 vs 0.74±0.06, t test, 
p<0.05; pp70S6K:p70S6K – 1.33±0.80 vs. 0.98±0.98 t test, p<0.05).  
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Figure 4.7: Activation of Akt-p70S6K signaling. Representative immunoblots of total 
LV protein extracts showed increased levels of phosphorylated Akt and phosphorylated 
p70S6K in GK hearts relative to controls (C in 7A). β-actin served as a loading control 
(7A). There were no significant differences in levels of total Akt (7C) or total p70S6K 
(7B) in either group. Quantitative densitometric analysis corrected for protein loading 
showed increased Akt phosphorylation normalized to total Akt in GK rats (7E) and 
p70S6K phosphorylation normalized to total p70S6K (7D). Values in graphs represent 
the average data obtained from 3 separate experiments from each group conducted in 
duplicate. Data expressed as Mean+SEM. * unpaired t test, p<0.05  
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4.5 Discussion 
In this study, the morphological and molecular consequences of prediabetes on the LV 
in the GK rat have been characterised. This is the first report of LV structural 
remodelling and underlying molecular events, in a state of IGT that precedes onset of 
T2DM in the GK rat.  LV remodelling in the prediabetic GK rat presented with marked 
hypertrophy of cardiomyocytes and increased ECM deposition that altogether translated 
into increased heart size in the absence of ultrastructural changes, fibre disarray or wall 
thickening. Molecular derangements in this model of prediabetes included recapitulation 
of foetal gene phenotype markers BNP and αSKA, activation of the pro-hypertrophic 
Akt-p70S6K pathway and altered gene expression profile of key components (Col1, Fn) 
and modulators (MMP2, CTGF, MMP9) of the ECM.  Finally, these changes were 
correlated with parallel findings of increased TGFβ1 transcription in the LV and 
elevated circulating active TGFβ1. Taken together, these findings are significant in that 
they demonstrate a possible role for the dysglycemia of IGT in the pathophysiology of 
developing cardiac complications via early effects on ventricle structural remodelling. 
This concept finds resonance in recent clinical reports of concentric remodelling and 
LVH in IGT (Fujita et al., 2007; Schainberg et al., 2010).  
The GK rat as a model of prediabetes:  
To the best of current knowledge, this is the first study to establish the utility of the 
adult GK rat as a model of prediabetes. For the duration of the experimental period, GK 
rats consistently demonstrated mild basal HG and IGT. Moreover, in the literature (and 
in previous experience), GK rats are described as non-obese, normotensive and 
normolipidemic (Gupte et al., 2010) providing the valuable advantage of examining the 
effects of mild HG per se on development of cardiac hypertrophy and remodelling in 
the absence of the confounding effects of obesity/ hypertension that tend to cluster with 
glucose abnormalities in a clinical setting. 
TGFβ1 in cardiac pathology 
It is becoming increasingly apparent that TGFβ1 represents a key mediator of cardiac 
adaptation to a dysmetabolic environment and/or hemodynamic overload. An 
established effector of the detrimental outcomes of experimental and clinical HG, 
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TGFβ1 activation also has consistent implications in diabetic cardiomyopathy, MI, 
hypertension and HF  pathogenesis accountable in the most part due to direct and potent 
actions in myocyte hypertrophy and matrix metabolism  (Matsumoto-Ida et al., 2006; 
Wu and Derynck, 2009)). Pharmaceutical intervention to antagonize the effects of 
TGFβ1 is therefore an important therapeutic target in heart disease. In this regard, it is 
notable that the in vivo inhibition of TGFβ by Tranilast administration reverses myocyte 
hypertrophy and fibrotic deposition of DCM (Kelly et al., 2007)  
In this study, an overall increase in TGFβ1 activity in the LV of prediabetic GK rats was 
manifested by increased active TGFβ1 and upregulated TGFβ1 gene expression in the 
LV, consistent with previous studies describing elevated TGFβ1 at translational and 
protein levels, also correlated therein with  hypertrophic growth, fibrosis and 
recapitulation of foetal cardiac genes (Schultz et al., 2002). Increased circulating active 
TGFβ1 reported in this study is also particularly relevant considering the use of TGFβ1 
as a risk stratification tool for myocardial fibrosis in HF pathogenesis post MI has been 
recently advocated (Sovari et al., 2010). However, the correlation between events 
within the myocardium and markers in the circulation requires further clarification 
before the prognostic value of a snapshot measurement of TGFβ1 can be determined.  
TGFβ1 in Fibrotic Remodelling:  
In this work, exaggerated LV deposition of collagenous matrix that characterised the 
fibrotic process in GK rats was concomitant with the upregulation of Col1α, Fn and 
CTGF transcription. These results are comparable to previous observations of the ECM 
in prediabetes preceding onset of the metabolic syndrome (Yagi et al., 1997) and T2DM 
(Kaminski et al., 2009). Several lines of evidence suggest that an elevated LV TGFβ1 
may underlie these findings; In vitro and gene transfer studies have demonstrated that 
TGFβ1 can stimulate myocardial fibrosis by increasing abundance of Col1α mRNA 
through intermediate Smad protein signalling (Verrecchia and Mauvel, 2007). 
Conversely, inhibition of myocardial fibrosis was observed on antagonism of TGFβ1 
gene expression In vivo, providing further proof that increases in matrix protein 
production may indeed be mediated by TGFβ1 modulated gene expression (Lijnen et 
al., 2000). Additionally, both in vitro and in vivo work demonstrates the ability of 
TGFβ1 to induce increased matrix production in fibroblasts. TGFβ1 activation may 
exert this pro-fibrotic influence by mediating C-TGF activation, considered a critical 
downstream mediator of fibroblast activation and proliferation (Leask, 2010).  
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TGFβ1 also exerts transcriptional control over endogenous collagenases of the LV 
including collagenase 1 and is intimately involved in MMP-2 and 9 activities although 
the latter associations appear to be reciprocal and are currently unclear (Van Linthout et 
al., 2008; Wu and Derynck, 2009). Paradoxical findings of increased 
metalloproteinase(s) (i.e. MMP2, MMP9) transcription and MMP substrate, collagen, in 
this work maybe a direct reflection of a complex metabolic profile in the 
hyperglycaemic milieu. Upregulation of MMP2 has been previously reported in 
ischemic and dilated cardiomyopathies (Seeland et al., 2002; 2009). Justification of this 
phenomenon is based on the premise that total matrix collagen content is a function of 
synthesis and degradation, and degraded products of matrix proteins may in turn 
stimulate collagen synthesis and deposition of poorly structured fibrotic tissue in the 
myocardium (Li et al., 2000). 
 Altogether, current data are in agreement with a model wherein TGFβ1 activity is a 
major regulator of fibrosis in the myocardium. This postulation is confirmed and 
extended to a prediabetic setting wherein it appears that even the mild HG of IGT is 
capable of stimulating a pro-fibrotic phenotype in the LV possibly through increased 
TGFβ1 expression and activity which in turn could affect gene expression of ECM 
components and also ECM production by fibroblasts, the latter very likely through C-
TGF activation. 
 TGFβ1 in hypertrophic remodelling:   
Topical evidence from in vitro and transgenic studies suggests a pivotal role for TGFβ1 
in mediating the association between hypertrophy and HG (Gorksha-Hicks and 
Rathmell, 2009; Wu and Derynck, 2009). In particular, a recent in vitro study 
demonstrated that hypertrophy in HG could be blocked by inhibiting TGFβ1 receptor 
signalling. Furthermore, HG strongly enhanced metalloproteinase2-and 9 mediated 
TGFβ1activation which in turn activated the Akt-TOR-p70S6K pathway. Finally, HG-
induced cell hypertrophy was inhibited by preventing MMP-2/9 activation or TGF 
induced Akt downstream signalling (Wu and Derynck, 2009). This study now reports 
that the genetically defined GK model faithfully recapitulates several features of this 
paradigm in the prediabetic stage, wherein increased TGFβ1 activity was coincident 
with myocyte hypertrophy, increased MMP2 & 9 gene expression and activation of 
Akt-p70S6K signalling in the LV. In such a perspective, it is possible to speculate that 
the mild HG of prediabetes can induce myocyte hypertrophy by the activation of TGFβ1 
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via increased MMP activity which in turn activates the Akt-mTOR-S6k pathway- a key 
regulator of protein synthesis (Manning and Cantley, 2007).  
Undeniably, some considerations limit the literal interpretation of this theory- First, at 
present, it is not possible to exclude the possibility that TGFβ1 mediates parallel or 
proximal events that may govern the hypertrophic response of the LV in prediabetes. 
Second, the mitogenic actions of hyperinsulinemia also merit consideration as insulin 
stimulation is a known activator of Akt-p70S6K signalling. While this study did not 
evaluate incidence of hyperinsulinemia (HI), its contribution to Akt-p70S6K activation 
is possibly minimal given that insulin signaling through the
 
PI3K /Akt-1 pathway, 
upstream of mTOR and p70S6K is impaired in HI (Poornima and Parikh, 2006). 
 
 
In this study, IGT was sufficient stimulus for the induction of a foetal gene program, i.e. 
upregulation of BNP mRNA and cellular αSKA – both features typically seen in TGFβ1 
over-expression (Parker et al., 1990) and also in pathological hypertrophy arising from 
hypertension or DM (Matsumoto-Ida et al., 2006). The prevailing view is that 
recapitulation of foetal gene phenotype in HG reflects a compensatory adaptation of the 
stressed heart in response to altered metabolic flux to maintain the economy of muscular 
contraction (Taegtmeyer et al., 2010). Differential expression of BNP and ANP, i.e. no 
change in ANP message levels observed in this work is comparable to previous studies 
of DCM (Fredersdorf et al., 2004) as well as decompensated experimental HF 
(Langnickel et al., 2000). Upregulation of BNP mRNA is regarded as a sensitive marker 
of hypertrophy, left ventricular dysfunction and is an approved marker for the detection 
of acutely decompensated HF (Lukowicz et al., 2005). The significance of increased 
natriuretic peptide transcription is currently unclear in the clinical context. A recent 
study has shown a long-term, dose-dependent benefit of BNP administration in 
reversing cardiac hypertrophy in vivo with simultaneous TGFβ1 downregulation and 
disrupted downstream signalling (He et al., 2010). An increased LV cellular αSKA is a 
phenomenon that has not been previously described in the prediabetic rodent.  
Upregulated αSKA is a prominent feature of the foetal gene phenotype and represents a 
well-accepted marker of myocyte hypertrophy. It has been postulated that the increased 
αSKA during hypertrophy reflects a temporary requirement for large quantities of 
striated muscle actin when muscle volume is increasing rapidly (Clement et al., 1999). 
Concluding remarks and clinical perspectives 
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Simultaneous myocyte hypertrophy and fibrosis proliferation usually represent the 
morphological correlate of LV functional insufficiency.  Moreover, reactivation of the 
foetal cardiac gene programme is also considered a hallmark for progressive decline in 
cardiac function and poor prognosis (Stilli et al., 2006). Nonetheless, data presented 
here do not allow us to conclude that hypertrophy, matrix deposition, altered signal 
transduction and gene expression are events in the development or progression of 
altered ventricle function in a dysglycemic milieu, warranting further functional 
assessments of the LV and an extended time-course study in the GK rat. 
In summary, this work highlights the possibility that ventricular decompensation 
frequently reported in HF of diabetic origin may be linked to an early remodelling of 
cardiac parenchyma triggered by the cardiotoxic effects of moderate, early changes in 
glucose metabolism and presents the likelihood of TGFβ1 involvement in this process. 
From a clinical standpoint, the findings presented in this work are corroborated by 
emerging current recommendations encouraging a stringent degree of glycemic control 
to compensate for the low threshold of glucose perturbation that apparently engenders 
the onset of cardiac consequences (Nielsen and Lange, 2005; Bergman, 2010; 
Schainberg et al., 2010). Finally, it is estimated that patients may be exposed to a 
decade of mild-moderate HG before a diagnosis of overt DM is made (Schainberg et al., 
2010). The potential pathological implications of the preceding provide considerable 
incentive for further experimental delineation of the singular role of early dysglycemia 
in promoting the adverse myocardial sequelae of T2DM.  
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 5 
 
 
 
CHRONIC EFFECTS OF MILD HYPERGLYCEMIA ON 
LEFT VENTRICLE TRANSCRIPTIONAL PROFILE AND 
STRUCTURAL REMODELLING IN THE 
SPONTANEOUSLY DIABETIC GOTO-KAKIZAKI RAT 
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5.1 Abstract 
Background: HF in chronic T2DM may be partly due to adverse structural remodelling 
of the LV
 
but the contribution of HG per se in this process is controversial.  
Methods: In this study, the LV from 18 month old, mildly diabetic, male GK rats and 
age-matched male Wistar controls was analysed with respect to remodelling processes 
and cognate transcriptional profile.  
Results: Chronic mild T2DM produced LV hypertrophy in GK rats, underscored by 
increased myocyte size, expression of natriuretic peptides and Akt phosphorylation. In 
the absence of caspase-3 mediated apoptosis, fibrosis proliferation in the GK LV 
paralleled increased transcriptional and biologically active pro-fibrogenic TGFβ1 in the 
LV with upregulated mRNA abundance for key ECM components such as fibronectin, 
collagen type(s) 1 and 3α and regulators including MMP 2 and 9, and TIMP4, Cx43 and 
integrin α5. GK rats also presented with altered mRNA expression for cardiac 
SERCA2a, Na
+
/Ca
2+
 exchanger and the L-type Ca
2+
 channels which may contribute to 
the altered Ca
2+
 transient kinetics previously observed in this model at 18 months of age 
(t test, p<0.05 vs. age-matched Wistar control for all parameters).  
Conclusions: The results indicate that chronic mild HG can produce a hypertrophic 
myopathy that recapitulates several aspects of the failing heart. Diffuse fibrotic 
deposition in this model is possibly a product of HG-induced TGFβ1 upregulation and 
altered transcriptional profile of the ECM.  
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5.2 Introduction 
The aging diabetic patient is a potential case of CHF, (Verny, 2007; Jugdutt 2010) due 
in part to a decompensated myopathy characterised principally by progressive structural 
remodelling of the LV. As chronic HG may drive adverse tissue remodelling by 
inducing cardiotoxic effects, routine treatment for T2DM often targets tight glycemic 
control to delay and/or allay cardiac complications including DCM. However, in spite 
of robust epidemiological links substantiating the correlation between T2DM, 
advancing age and HF (Verny, 2007; Jugdutt 2010), the contribution of a milieu 
dominated by HG per se in HF pathogenesis is questionable for several reasons.  
Cardiac involvement in the elderly diabetic is usually multifactorial, frequently arising 
from co-morbid conditions including hypertension, obesity, ischemic events etc. Further 
ambiguity on the effect of HG proper on myocardial complications arises from 
incongruent epidemiological findings. While early data have suggested a protective 
effect of improved glucose control on cardiovascular-related mortality (UKPDS group, 
1998) recent trials have reported no effect (Duckworth et al., 2009) or increased risk 
(ACCORD study group, 2008) with intensive glucose control on major cardiovascular 
events. Finally, much of what is known of a DCM comes from experimental work 
utilizing models rendered diabetic with STZ/alloxan. Interpretations of studies 
employing this phenotype are rarely tempered by the fact that the degree of HG is very 
often supra-physiological, rarely encountered in clinical practice and that the diabetogen 
itself may exert direct cardiotoxic effects (Wold and Ren, 2004). 
 
Of the several proposed mechanisms whereby HG may induce LV remodelling, the 
activity of pro-fibrotic and pro-hypertrophic cytokine TGFβ1 in the pathogenesis of 
cardiac complications has been the subject of much recent inquiry. The ability of 
TGFβ1 to induce an adverse remodelling in the LV appears to stem from (but not 
limited to) a capacity to provoke a pro-fibrotic programme in the heart. This in turn  
negatively affects the transcriptional profile of the ECM and key mediators of 
intracellular calcium [Ca
2+
]i  (Ramos-Mondragon et al., 2008), which  regulate 
expression of foetal genes (Kapoun et al., 2004), including  natriuretic peptide 
expression (Parker et al., 1990) and also provoke pro-hypertrophic signalling via the 
akt-mTOR-p70S6K axis (Wu and Derynck, 2009). However, sufficient information on 
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these events in the long-term diabetic myocardium, uncomplicated by associated 
features of the metabolic syndrome is not available.  
In such a perspective, the effects of chronic mild HG that represents an important and 
predictable metabolic derangement of this disease on ventricle structure are unknown. 
The non-obese, spontaneously diabetic GK rat is ideally suited to address this issue as it 
represents an aetiology dominated by mild HG. Much akin to the typical clinical 
presentation of T2DM, disease pathogenesis in this model includes a reduced β cell 
mass, hepatic and peripheral insulin resistance altogether culminating in mild basal HG, 
marked glucose intolerance that deteriorates over time to frank T2DM (Howarth et al., 
2007) Accordingly, this work examined fibrotic, hypertrophic and apoptotic events in 
the long-term GK myocardium to test the hypothesis that a modest elevation in HG is 
sufficient stimulus for the sustenance of geometric, cellular and molecular remodelling 
in the heart. 
5.3 Methods  
As described in chapter 3. 
 
5.4  Results 
1. General Characteristics of the Diabetic GK rat: 
At 18 months, measurement of fasting blood glucose indicated that GK rats were mildly 
hyperglycaemic compared to Wistar control rats (Table 5.1). Glucose clearance capacity 
was significantly affected in diabetic GK animals as blood glucose levels following 
glucose tolerance tests were higher at all time points measured (p<0.01) and did not 
return to baseline level within 3 hours (Fig 5.1). Mean plasma insulin levels were not 
assessed in this study, glycemic status in GK animals being consistent with impaired 
secretion of insulin and peripheral insulin resistance previously reported in this model 
(Portha et al., 1991). GK rats presented with lower BW compared to controls but 
significantly higher but HW/BW ratio (Table 5.2). No obvious differences in 
subcutaneous fat distribution were evident between groups, nor were there any 
indications of overt congestive heart failure such as hepatomegaly, pleural effusion, or 
ascites on gross examination. Incidence of hypertension was not evaluated as previous 
studies have demonstrated that GK rats are normotensive and have slightly reduced 
resting heart rates at 18 months of age (Howarth et al., 2007). No overt differences in 
the distribution of epicardial fat were noted.  
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Table 5.1 General Characteristics of GK and age-matched Wistar control rats at 18 
months. Values are expressed as Mean±SEM.  * unpaired t Test p < 0.05 versus age-
matched control. 
 
Animals BW (g) HW 
(g) 
HW/BW 
ratio 
g/100g BW 
Fasting blood 
glucose 
(mg/dL) 
Control 
(n=8) 
418±6.07 1.22±0.2 0.21±0.01 95±0.30 
GK 
(n=8) 
413±3.36 1.41±0.16* 1.41±0.16* 131±0.22* 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.1: Oral glucose tolerance test. Impaired glucose tolerance in GK rats following 
intraperitoneal glucose challenge compared to age matched wistar controls at 18 months 
(n=8/group). Data expressed as Mean+SEM. **unpaired t test, p<0.01for GK compared 
to Wistar controls. 
 
2. Histopathology of the LV:  Chronic diabetes affected the weight and gross 
appearance of the LV. The analysis of surfaces of ventricular cross-sections with  Image 
J demonstrated significantly increased wall thickness in diabetic animals relative to 
control (Fig 5.2 A, top left panels). LV wall thickness was 3.08±2.39 mm in control vs. 
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3.35±0.17 mm in GK rats, p<0.05 (Fig 5.2 B). Masson’s trichrome, Sirius red, Lectin 
and H/E staining were used to examine LV morphological changes. At the cellular 
level, LV wall thickness translated into increased cardiomyocyte diameter in GK rats 
(Fig 5.2 A, top right panels). Morphometric analysis of Lectin stained sections revealed 
a 20.25 % increase in myocyte diameter in GK rats (11.34±0.54 µm) compared to age-
matched controls (9.43±0.35 µm) (Fig 5.2 C, p<0.05). Quantitatively, GK rats presented 
an increased ECM deposition in interstitial spaces, as stained by Sirius red (red-
staining) and Masson’s trichrome (green-staining) compared to controls (Fig 5.2 A, 
middle panels) and evaluated on Sirius red sections (5.87±0.54 % in control vs. 
7.38±0.50 % in GK LV, Fig 5.2 D, p<0.05).   
Overall, the myocardium from control animals showed normal structure (Fig 5.2 A, 
lower left panel).   In addition to diffuse accumulation of fibrotic material and 
hypertrophic cardiomyocytes, myofibre disarray was also occasionally evident in GK 
rats (Fig 5.2 A, lower left panel). The effects of DM upon myofibre disarray were 
difficult to assess as it was largely non-uniform and frequently shared the same 
microscopic section with regions showing preserved architecture, (albeit with increased 
fibrosis). On H&E stained sections from GK rats, signs of impending cell death, marked 
by spongy and vacuolated cytoplasm, (arrows, Fig 5.2 A, lower left panel) were 
occasionally apparent. Therefore, this study investigated whether fibrosis proliferation 
and myocyte hypertrophy were related to HG-induced cell death by caspase-3 
dependent mechanisms. Highlighted by cleaved (active) caspase-3 staining (Fig 5.2 A, 
lower right panels), long-standing mild DM produced small changes in apoptotic cell 
death in GK vs. control animals but incidence of apoptotic cardiomyocytes was low in 
both groups and the relation did not reach statistical significance. (1.84±1.29 in control 
LV vs. 2.31±1.66 positive myocytes/mm
2   
in GK LV, Fig 5.2 E, p>0.05)  
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Fig 5.2: Structural remodelling of the Left Ventricle 
Representative ventricular cross-sections from control and GK rats (A, top left panels) 
and graph illustrating quantitatively increased wall thickness in GK rats vs. control (B). 
Scale bar indicates 3 mm.   At the cellular level, FITC-conjugated Lectin staining 
demonstrated increased cell diameter in GK rats vs control (A, top right panels), and 
graphically represented in (C). Representative photomicrographs demonstrating 
increased collagenous matrix deposition on Masson’s trichrome (green) and Picrosirius 
red (red) stained sections in GK rats relative to age-matched controls (A, middle 
panels). Quantitative analysis of collagen deposits calculated from Sirius red stained 
sections after allowing specific separation of collagen fibres (red) against background 
(yellow) indicates significant elevation of cardiac collagen deposits in GK vs. control 
mice (D). At 18 months of age, control Wistar rats showed relatively normal myocardial 
architecture with preserved cross striation patterns (lower left panel), whereas GK rats 
occasionally presented with a disordered and irregular pattern of myofibrillar 
arrangement (A, lower left panel, arrow). Caspase-3 immunohistochemistry (brown 
staining) in the left ventricle of control and GK rats (A, lower right panels). Sections are 
counterstained with Haematoxylin (blue). Original magnification X400. Quantitatively, 
cleaved caspase-3 activity was unchanged in GK relative to age-matched Wistar control 
animals (E). Data in graphs expressed as Mean+SEM. * unpaired t test,  p<0.05; unless 
otherwise indicated, scale bar in panels indicate 20 μm and accounts for all 
photomicrographs. n=4-5 rats/group 
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3. Molecular events underlying structural remodelling 
a. TGFβ1 levels and gene expression 
Increasing evidence indicates that TGFβ1 induction by HG stimulates and sustains pro-
hypertrophic and pro-fibrotic mechanisms in the heart. As such plasma and LV samples 
from GK and control rats were used to evaluate differences in total and biologically 
active TGFβ1 protein levels by ELISA and TGFβ1 gene expression in the LV by q 
RTPCR (Fig 5.3). Long standing DM produced a significant increase in mRNA 
abundance of TGFβ1 (0.97±0.14 in control vs. 1.92±0.17 in GK LV, ratio units, Fig 5.3 
D, p<0.01) in the LV of diabetic rats and this change paralleled an increased bioactive 
TGFβ1 protein level in the LV (5.4±0.74 and 2.12±0.54 pg/mg Total TGFβ1 protein, 
respectively, vs. control, Fig 5.3 C, p<0.05) although total LV TGFβ1protein levels 
remained comparable (Fig 5.3 B, p>0.05,). No changes in the ratio of active: total 
TGFβ1 levels were observed in GK plasma relative to control (0.46±0.11 in control and 
0.63±0.17 in GK, ratio units, Fig 5.3 A, p>0.05) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5                                        LV REMODELLING IN CHRONIC DIABETES 
 
115 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 5.3: TGFβ1 protein level and gene expression 
Summarised data from ELISA showing unchanged ratio of active: total TGFβ1 protein 
(A) and total TGFβ1: total extracted LV protein (B) in plasma of GK vs. control animals 
and increased active TGFβ1: Total extracted protein (C) in the LV of GK vs. control 
animals (n=3/group). mRNA expression of TGFβ1 (D). qRT-PCR amplification was 
normalized to that of glyceraldehyde-3-phosphate dehydrogenase (GAPDH) 
(n=8/group). The results of both ELISA and qRT-PCR are representative of 3 individual 
experiments conducted in triplicate. Data expressed as Mean+SEM. * unpaired t test,  
p<0.05. 
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b. Altered LV Gene Expression Profile in the Long-term diabetic GK  
Transcriptional profile of the ECM 
A putative mechanism whereby HG (and TGFβ1) can induce a pro-fibrotic programme 
in the LV is via transcriptional regulation of key components of the ECM. Investigation 
of this effect in the long term diabetic GK LV by qRT-PCR demonstrated that increased 
ECM deposition and TGFβ1 were concurrent with transcriptional upregulation of 
Collagen type 1α (Co1α), collagen type 3α (Col3α) and fibronectin (Fn) expression 
(Co1α: 0.66±0.99  in control vs. 1.37±0.17 in GK LV, Col3α: 0.67±0.11 in control vs. 
1.22±0.16 in GK LV, Fn: 0.68±0.12 vs. 1.36±0.091, Ratio units, Fig 5.4 A,  p<0.05) but 
unaffected Elastin mRNA abundance relative to control (0.64±0.56 in control and  
0.82±0.15 in GK LV, ratio units, Fig 5.4 A,  p>0.05). Moreover, these changes were 
accompanied by distinct alterations in transcriptional activity of the regulators of the 
ECM. Notably, message levels for CTGF, the key downstream effector of TGFβ1 on 
fibroblast activity was significantly increased in the GK myocardium (1.55±0.19 in GK 
LV compared to 0.61±0.12 in control LV, ratio units, Fig 5.4 B,   p<0.01). Diabetic 
animals also presented with increases in mRNA abundance of the MMP2 and 9 that 
catalyze ECM degradation (MMP2: 0.60±0.07 in control vs. 0.98±0.094 in GK; MMP9: 
1.20±0.11 in GK LV vs. 0.68± 0.09 in Control, Fig 5.4 B, p<0.05). Interestingly, mRNA 
abundance of endogenous MMP inhibitor, TIMP4 was also upregulated in the diabetic 
heart (GK: 1.46±0.14 vs. 0.68± 0.08 in control, ratio units, Fig 5.4 B, p<0.05) whereas 
TIMP1 levels were unaffected by the disease (1.27±0.12 in control vs. 1.45±0.22 in GK 
LV, ratio units, p>0.05). A significant increase in message levels for gap in junctional 
protein Cx43 was also evident in diabetic rats (1.93±0.23 vs. 1.29±0.56, Fig 5.4 B, 
p<0.05). Cx43 is the dominant connexin in ventricular myocytes and activity and 
maintenance of the ECM in the ventricle are functionally coupled to its expression 
levels (Zhang et al., 2008). Message levels for the integrins, a family of cell surface 
receptors known to attach cells to the ECM and involved in fibrotic protein deposition 
and proliferation were also altered by chronic mild HG (Hescheler and Fleischmann 
2000). The α1 and β1 integrin heterodimers bind myocardial collagen to 
cardiomyocytes whereas α5 binds fibronectin. Integin α5 mRNA was upregulated in 
diabetic rats (1.38±0.10 vs. 0.64±0.08 in controls, Fig 5.4 B, p<0.05), whereas levels of 
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integrins α1 and β1 remained unaffected (p>0.05). Taken together, long term mild HG 
appeared to stimulate a complex gene expression profile in the ECM where alterations 
in message levels for secondary regulators (Integrin α5, Cx43), were concomitant with 
increased ECM components (Co1α, Col3α, Fn ) and paralleled by increased 
transcription of ECM breakdown agents (MMP2 and MMP9)  and their inhibitiors 
(TIMP4) likely representing compensatory mechanisms in the LV. Finally, mRNA 
expression levels of pro-inflammatory marker tumour necrosis factor α and vimentin (a 
marker for fibroblasts), were also assessed but no significant differences were detectable 
in GK rats vs. controls (p>0.05).   
 
Recapitulation of a foetal gene phenotype 
Gene expression of natriuretic peptides ANP and BNP, key indicators of hypertrophy 
and quantitiative biomarkers for heart failure, was measured in GK and control LV (Fig 
5.4 C). mRNA levels of ANP rose significantly in GK animals (10.15±3.70 ratio units) 
compared to control (1.47±0.28 ratio units, p<0.05). BNP that has been shown to be 
independent risk marker for diastolic dysfunction and CHF in diabetic patients (Gaede 
et al., 2005) was also significantly upregulated relative to controls (0.70±0.07 vs. 
1.23±0.16, ratio units, p<0.05). 
 
Gene expression of [Ca
2+
]i mediators  
Myocyte remodelling and contractility are known to be intimately interrelated and 
impaired Ca
2+
 handling is implicated as a fundamental mechanism for myocardial 
dysfunction, following pathological hypertrophy (Houser et al., 2000). As these changes  
encoding key mediators of [Ca
2+
]i i.e. sarcoplasmic reticulum Ca
2+
 ATPase (SERCA2a), 
phospholamban (Pln), ryanodine receptor (RyR2), Na
+
/Ca
2+
 exchanger (NCX), and 
voltage-gated L-type calcium channels CaV1.2 and CaV1.3 were investigated. At 18 
months of age, abundance of SERCA2a mRNA was significantly increased in GK 
hearts (0.99±0.07 vs. 0.68±0.10, ratio units, Fig 5.4 D, p>0.05). As is usually expected 
of a hypertrophic phenotype, NCX transcription was upregulated (1.77±0.10 vs. 
1.15±0.11) as were genes encoding L-type calcium channels CaV1.2 (1.50±0.16 vs. 
0.90±0.11, Fig 5.4 D, p<0.05), CaV1.3 (1.11±0.19 vs. 2.40±0.51) and finally, expression 
levels of Pln (1.50±0.18 vs. 1.64±0.16 in GK, Fig 5.4 D, p>0.05) and RyR2 (1.61±0.24 
in control vs. 2.06±0.06 in GK, Fig 5.4 D, p>0.05) were unaffected by the disease 
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Fig 5.4: Transcriptional profile of the Left ventricle in chronic mild T2DM 
Relative abundance of mRNA for various components (A) and regulators (B) of the 
interstitium, natriuretic peptides ANP and BNP (C) and mediators of [Ca
2+
]i  (D) in the 
C 
D 
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LV of control and GK animals. RT-PCR amplification was normalized to that of 
GAPDH. Bars indicate Mean+SEM, n =7-8, of 2–3 independent experiments. *p<0.05 
 
 
c. Akt activity  
To determine HG-sensitive signalling events in myocyte hypertrophy, this study 
investigated activation of the Akt-mTOR-p70S6K axis by western blotting. p70S6K, 
activated by upstream mTOR, is known to phosphorylate the ribosomal protein S6 
enabling the up-regulation of TOP mRNA for encoding translational machinery and 
ribosomal proteins (Alessi et al., 1998). Of particular interest, the Akt- mTOR-p70S6K 
axis is also a known target of HG-induced TGFβ1 activation and the association appears 
metalloproteinase (MMP2 and 9) -dependent (Wu and Derynck, 2009). Thus, levels and 
activation (phosphorylation) of Akt (Ser473) and p70S6K (Thr389), were measured by 
immunoblot (Fig 5.5 A). The latter phosphorylation site is well-recognized to reflect 
actual mTOR activity (Wang et al., 2005).  
Phosphorylated (Ser 437) Akt protein, indicative of  functional activation, was increased 
significantly in GK rats relative to controls (0.23±0.03 vs. 0.39±0.03 ratio units, 
p<0.05). p70S6K phosphorylation was not similarly influenced (0.31±0.13 in control 
LV vs. 0.49±0.19 in GK, ratio units,  p>0.05). Furthermore, as total protein levels of 
Akt and p70S6K were comparable in GK and control animals (p>0.05), ratio of 
normalised pAkt:Total Akt was significantly increased in GK rats relative to age-
matched controls (pAkt:Akt: 0.68±0.99 vs. 1.06±0.02, Fig 5.5 B,  p<0.05;) but 
normalised pp70S6K:total p70S6K remained unchanged  (pp70S6K:p70S6K,  
1.55±0.48 in GK vs. 0.60±0.08 in control, Fig 5.5 C,  p>0.05). 
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Fig 5.6: Akt-p70S6K signalling. Representative immunoblots of total cardiac protein 
extracts showed increased levels of phosphorylated Akt in GK hearts relative to controls 
(C in 5.6 A). β-actin served as a loading control (A). There was no significant difference 
in levels of total Akt or total p70S6K. Quantitative densitometric analysis corrected for 
protein loading demonstrated  increased Akt phosphorylation normalized to total Akt in 
GK rats (B) whereas p70S6K phosphorylation were not statistically significant between 
groups (C). Values in graphs represent the average data obtained from 3 separate 
experiments from each group conducted in duplicate. Bars indicate Mean+SEM, * 
unpaired t test, p<0.05 
 
 
 
 
Phosphorylated:Total Akt Phosphorylated:Total p70S6K 
Total p70S6K 
    Control                   GK                                                          Control                    GK 
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5.5 Discussion 
Despite the prevalence of HF in the aging T2DM population, the influence of mild HG 
per se on long-term structural remodelling in the heart is not well established. The 
present study demonstrates that a milieu dominated by chronic mild HG is sufficient 
stimulus for the sustenance of a cardiomyopathic phenotype that recapitulates several 
molecular and structural aspects of the failing heart.  These include myocyte 
hypertrophy and an increased ventricle wall thickness, natriuretic peptide expression 
with activation of Akt, diffuse fibrotic deposition in extracellular spaces, pro-fibrotic 
cytokine induction with altered transcriptional activity of the ECM and mediators of 
[Ca
2+
]i. Alterations of these key elements intrinsic to the normal function of the 
myocardium likely represent the structural and molecular substrates of electrical 
anisotropy and myocardial heterogeneity that accompany altered diastolic LV function 
frequently observed in chronic T2DM (Van Kujik et al., 2010).  
Caspase-3 Activity 
LV hypertrophy and fibrosis proliferation are recurrent findings in ventricular 
decompensation of diabetic origin and are often associated with increased apoptotic cell 
death in the myocardium (Francis et al., 2001; Chatham et al., 1996). A critical step in 
the execution of the apoptotic program eliciting DNA fragmentation is cleavage of 
caspase-3 into 19 and 17 kDa fragments. In this study, the LV exposed to chronic mild 
HG did not present with altered caspase-mediated apoptosis. The apparent discrepancy 
between the present findings and those reporting increased apoptosis in experimental 
diabetic cardiomyopathy may reflect the severity of HG in those studies,   often in the 
range of 250-650 mg/dL in the T1DM rat (Kajstura et al., 2001; Fiordaliso et al., 2000; 
Cai et al., 2002). As such, current findings support the notion that severity of HG may 
be an important determinant in apoptotic responses evoked by the caspases. In 
addressing the limitations of this finding, it cannot be ruled out that apoptosis may have 
occured independent of caspase-3 activation. Although histological signs of necrosis 
were not apparent, ubiquitin-related autophagic cell death still remains a possibility 
(Diwan and Dorn, 2007). However, likelihood is advanced that inconspicuous apoptosis 
in the mildly diabetic LV may be related to the obvious absence of LV dilation.  Several 
lines of evidence indicate that caspase-mediated cardiac myocyte apoptosis is 
unambiguously the cause of transitioning from compensated hypertrophy to 
decompensated dilated cardiomyopathy (Diwan and Dorn, 2007) that is typically 
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antecedent to overt HF. Conversely, inhibition of apoptosis by pharmacological caspase 
inhibition prevents cardiomyopathic degeneration and reverses dilated cardiomyopathy 
(Hayakawa et al., 2003). Nevertheless, whether unaffected caspase-3 activity is a direct 
indication of a compensated myopathy in the chronically diabetic GK rat is difficult to 
envision at the present time. 
TGFβ1 and the extracellular matrix 
In the relative absence of apoptotic cell death, an HG- upregulated TGFβ1 may underlie 
increased ECM proliferation in the long term T2 diabetic GK myocardium. Several 
mechanisms by which HG may activate TGFβ1 expression have been previously 
demonstrated. Of these, activation of a HG-sensitive glucose response element 
identified in the TGFβ1 promoter region and HG-activated Protein kinase C induced 
expression of TGFβ1 via thrombospondin (TSP-1) may act upstream of TGFβ1 in HG-
induced fibrosis proliferation (Smoak, 2004). Once upregulated, the ability of TGFβ1 to 
exert profibrotic effects in the myocardium is well described and often via 
transcriptional control over the fibrillar collagens and fibronectin (Ramos-Mondragon et 
al., 2008). Furthermore, TGFβ1 self amplifies its expression in myofibroblasts and can 
trigger fibroblast proliferation and phenotypic conversion to myofibroblasts that 
synthesize collagen types I and III (Berk et al., 2007). This effect is often by induction 
of the key TGFβ1 downstream effector, CTGF, by acting on TGFβ1 response elements 
localized in the CTGF promoter site (Ramos-Mondragon et al., 2008). The present 
study observed an upregulated TGFβ1 and CTGF mRNA in long-standing experimental 
DM and enhanced TGFβ1 LV activation concomitant with an increased collagenous 
matrix deposition, and transcriptional upregulation of major fibrillar collagens and FN. 
As such, it is possible to infer that activation of TGFβ1 may underlie the extracellular 
matrix deposition in the long-term mildly diabetic myocardium. It is noteworthy that in 
this study, plasma TGFβ1 levels were unaffected by diabetes and did not parallel 
transcriptional activity or biologically active TGFβ1 in the GK LV. As the use of 
TGFβ1 as a risk stratification tool for predicting the development of myocardial fibrosis 
resulting in heart failure has recently been advocated (Sovari and Dudley, 2010), current 
findings advice a degree of caution in assessing cardiac pathology based solely upon 
blood TGFβ1, which appears to be differentially regulated within the myocardium and 
in the circulation, at least in the diabetic milieu. 
A co-ordinated response of opposing elements in cellular and stromal compartments 
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maintains the integrity of the remodelling programme in the heart. In this regard, cell 
surface bound and soluble MMPs, their natural tissue inhibitors (TIMPs) constitute 
important systems for regulating ECM turnover. In investigating the effect of chronic 
HG on the transcriptional profile of the regulators of the ECM, the present results 
indicate that collagen deposition in the LV was paralleled by transcriptional 
upregulation of MMP2 and 9 and attendant increase in endogenous MMP inhibitor 
TIMP4, which is the dominant cardiac isoform of the TIMPs. The exact role of the latter 
in the remodelling heart is presently unclear, as TIMPs can also facilitate MMP 
activation by stabilisation and/or localisation (Kurrelmeyer et al., 1998). Interestingly, 
the activities of TGFβ1 and MMPs are known to be intertwined; Experimental evidence 
points towards the possibility that TGFβ1 can up-regulate MMP-2 and its cell surface 
activator MT-MMP in fibroblasts (Manso et al., 2006). The reverse is also documented 
(Wu and Derynck, 2009), and moreover, Col type I, whose production is regulated by 
TGFβ1, may result in increased MMP-2 activity (Kurrelmeyer et al., 1998). Regardless 
of activating processes, the net result of cardiac MMP activation is loss of the normal 
interstitial supporting structure (Francis, 2001), and upregulated MMP transcription 
observed in this study mirrors previous findings in severe congestive HF and in human 
cardiomyopathic hearts (Kurrelmeyer et al., 1998; Manso et al., 2006).  
Additionally, data presented in this study indicate that long-term mild HG may 
influence expression pattern of the major ventricular transmembrane gap junction 
protein Cx43 and the membrane-spanning integrins, both of which co-ordinate ECM-
myocyte interaction (Hescheler and Fleischmann, 2000; Manso et al., 2006; Zhang et 
al., 2008). Given the roles of integrins and Cx43 function on electrical integrity and 
ECM homeostasis in the myocardium, it is conceivable that HG-associated 
abnormalities in the expression of these molecules may be important in the pathogenesis 
of a DM-specific cardiomyopathy. Where dysregulated transcription may be the result 
of a complex interplay of mechanical/chemical signals in diabetic tissue 
microenvironment, consideration is given to the role of TGFβ1 in mediating this effect. 
In relation to Cx43, a recent in vitro study demonstrated HG-evoked TGFβ1 mediated 
increase in Cx43 expression and gap-junction mediated cell-cell communication (Hills 
et al., 2009). Finally, TGFβ1 stimulation increased expression of α5β1 integrins in 
fibroblasts and in turn, overexpression of the same integrin heterodimer increased TGFβ 
expression (Manso et al., 2006).  Altogether, the present results have implicated a 
complex interplay of MMPs, integrins, cytokines and ECM components in the heart 
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exposed chronically to mild HG. While further comprehensive and temporal analyses 
are required to delineate causative from compensatory adaptations, translational 
upregulation of ECM components and regulators described in this study are a likely 
reflection of altered local synthesis response to chronic HG.  It is also feasible that the 
alterations represent a response to the generation of inappropriate isoforms of the 
molecule (s), if DM were to alter alternative splicing patterns of specific genes (Roy et 
al., 1990). Both these possibilities are hypothetical but realistic and warrant further 
experimental enquiry.   
 
LV Hypertrophy 
 
Coupled with ECM deposition, the finding of LV hypertrophy in GK rats parallels 
previous experimental (Arres-Carrasco et al., 2009; Falcao-Pires et al., 2009) and 
clinical (Fujita et al., 2007; Van Heerebeek et al., 2007) reports of the decompensating 
T2DM heart. The molecular basis of specific patterns of cardiac remodelling in DM 
(and the involvement of apoptotic processes herein) is uncertain as of this writing, but 
much evidence has extended the regulatory portfolio of HG-upregulated TGFβ1 to 
include cellular hypertrophy. In keeping with the phenotype observed in this study, 
TGFβ1 overexpression resulted in cardiac hypertrophy that was characterized by both 
interstitial fibrosis and myocyte hypertrophy (Rosenkranz et al., 2002). In the same 
vein, expression of mRNA encoding TGFβ1 is increased in the LV myocardium of 
patients with LVH (Li et al., 1997) and it is known to be specifically expressed in 
hypertrophic myocardium during the transition from stable hypertrophy to overt HF 
(Berk et al., 2007).  
 Recent work underscores the pathophysiological significance of increased MMP-
activated TGFβ1 induction as a contributing factor in the onset of HG-induced 
hypertrophy, mediated via modulation of Akt-mTOR-p70S6K axis (Wu and Derynck, 
2009). However, increased Akt activity (phosphorylation) but unaffected 
phosphorylation of Akt target protein p70S6K in the chronically diabetic GK heart does 
not fully supplement this in vitro finding. In explanation, two inter-related possibilities 
that could contribute to this phenomeno are presented: Firstly, the hypertrophic targets 
of Akt and mTOR may not be uniquely restrained to p70S6K activation, and additional 
targets may be involved (Mc Mullen et al., 2004; 2004). Moreover, previous work 
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demonstrates that short term Akt activation, deemed essential for physiological growth 
of the heart, activates mTOR and downstream p70S6K. On the contrary, chronic Akt 
activation was associated with a transition to decompensated myocyte hypertrophy and 
downregulation of signalling to S6K (Mc Mullen et al., 2004; 2004b; O’Neill and Abel, 
2005). Although this hypothetical effect has not yet been investigated in the diabetic 
milieu, the current findings provide strong indication of such an effect when coupled 
with previously presented observations in the prediabetic GK rat wherein myocyte 
hypertrophy and TGFβ1 increase were concomitant with upregulated activity of both 
p70S6K and Akt (unpublished data). Given this, the relation between Akt signal 
intensity and/or duration in determining early vs. late hypertrophic remodelling in the 
diabetic heart merits further enquiry.  
The molecular signature of pathological hypertrophy was recapitulated in the long term 
diabetic GK rat, manifested by quantitative changes in gene expression of key mediators 
of [Ca
2+
]i and the natriuretic peptides, the latter presumably upregulated as a 
compensatory mechanism to promote natriuresis and suppress myocyte hypertrophy, 
altogether aimed at reducing load (Olson and McKinsey, 2005). Once again, the 
involvement of upregulated TGFβ1 in these transcriptional changes cannot be 
disregarded. Of note, Kapoun et al. (2004) reported that BNP treatment produced a 
remarkable inhibition of TGFβ1-induced effects on human cardiac fibroblasts and 
opposed TGFβ1-regulated genes related to fibrosis including Col1, Fn, CTGF, and the 
TIMPs. Similarly, TGFβ1 activation has implications in ionic remodelling of the failing 
ventricle, capable of altering myocyte shortening and Ca
2+
 kinetics and also NCX 
mRNA expression, that was observed in this study (Ramos-Mondragon et al., 2008)  
TGFβ1 involvement notwithstanding, cardiac hypertrophy is associated with marked 
changes in myocardial contractility. These contractile abnormalities are frequently 
accompanied by alterations in [Ca
2+
]i transient that have been previously reported in 
myocytes isolated from GK rats at 18 months of age (Howarth et al., 2007). By means 
of extension, the results presented in this section indicate that increased [Ca
2+
]i transient 
amplitude in the long term diabetic GK LV (Howarth et al., 2007) may be due in part to 
increased transcription of the L-type calcium channels resulting in elevated Ca
2+
 influx 
at systole.  
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Concluding Remarks: 
This study has demonstrated that cardiac remodelling in a diabetic setting can be 
viewed, at least in part, as a transcriptional disorder. As such, normalization of the gene 
expression patterns of through transcriptional therapies may represent a promising 
interventional approach in the treatment of DCM. The extents to which the remodelling 
changes described here contribute to LV functional impairment are the subject of 
ongoing enquiry. In the absence of apoptotic cell death, LV dilation and increased 
amplitude of the calcium transient associated with a compensated stage of hypertrophy 
(Wickenden et al., 1998), it is perhaps to be expected that available data indicate 
preserved cardiac function in this model even at 18 months of age (Howarth et al., 
2007). In this sense, it is tempting to speculate that the addition of another stressor such 
as obesity/hypertension that frequently cluster with DM, especially in the elderly, may 
‘tip-the-balance’ in favour of a dilated cardiomyopathy coupled with an overt decline in 
LV mechanical performance.   
In its entirety, this study represents an exploration of the clinical relevance and 
suitability of the mildly diabetic GK rat for experimental delineation of HG-induced 
chronic cardiac remodelling and a cardiomyopathic phenotype. It is especially notable 
that the model that emerges from this
 
study implicates complex interactions between the 
matrix and the
 
myocyte, cytokine induction and potential electrical remodelling at 
fasting blood glucose levels that very closely skim the upper limit of optimal HbA1c 
goals for T2DM patients with persistent HG, as outlined by current consensus 
guidelines (Fasting glucose 70-130 mg/dL to achieve HbA1c of <7%) (McCulloch,  
2010). Finally, when compared to results of Chapter 3, the relation between the severity 
of DM and the development of myocardial sequelae is especially highlighted as chronic 
HG of 131.4±0.22 mg/dl (compared to a normoglycemia of 95.2±0.3 mg/dl in control 
animals) produced remodelling changes in the LV that are identical in several respects 
to those reported in the short term, severely diabetic T1 model of the disease. In this 
regard, HG being the principal marker of DM in experimental studies, this work also 
emphasizes the importance of specifically defining disease severity in studies of the 
heart. 
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6.1   Introduction 
The cardiac effects of T2DM are known to be most pronounced in the elderly (Verny, 
2007).  Chronic HG may underlie this process, by producing structural changes that 
alter LV compliance and by extension, function.  However, major difficulties arise in 
studying DM-related complications in the ageing heart. Ageing imposes unique 
conditions on cardiac adaptation to cardiac stress and cardiac involvement in the ageing 
is usually multi-factorial, with increased frequency of arterial hypertension and 
coronary damages due to accumulation of vascular risk factors. Beyond these issues, 
how chronic HG affects the heart specifically and potentially accelerates the effects 
proper to ageing are relatively unknown. In the laboratory, the STZ-induced type 1 rat 
model remains the „work horse‟ for studying cardiomyopathic changes in the diabetic 
heart, in spite of obvious limitations in translational value and relatively short study 
periods. Because the HG that dominates the pathophysiology and clinical course
 
of 
T2DM is potentially modifiable, information concerning how increased glucose may 
contribute to other risk factors for HF, notably advanced age, is of particular clinical 
consequence as no effective treatment serves to reverse HF once established 
(Strahrenberg et al., 2010). In response to these issues, this study represents an 
investigation of the effect of ageing on dysglycemia-related myocardial remodelling 
changes, based on the hypothesis that chronic mild HG accentuates the effects of ageing 
in the heart. In examining the additive effects of HG and cardiac ageing, an 
experimental protocol was chosen in which each of these two conditions in isolation 
were likely to produce only modest remodelling changes. As such, GK rats were 
examined at 2 ends of the dysglycemia continuum to allow comparison across a wide 
age range while also approximating the typical clinical course of the disease during 
progression from IGT to overt T2DM.  
6.2 Methods 
 As described in Chapter 2 
6.3 Results 
Data described in graphs below are from young Wistar (young control), young GK, old 
Wistar (old control) and old GK groups as outlined in Chapter 2 and as given in 
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Chapters 4 and 5 respectively. The letter „a‟ indicates a significant ageing effect, 
*significant dysglycemia effect, a* indicates interaction of ageing and T2DM.  2-way 
ANOVA, level of significance is set at p<0.05. 
Represented in Fig 6.1, mean HW/BW ratio (A), LV wall thickness (B) and myocyte 
diameter (C) demonstrated a trend towards greater LV hypertrophy with ageing, and the 
effect was accentuated by the presence of T2DM. (HW/BW ratio: F(3,32)=66.8, 
p<0.05; LV wall thickness: F(3,17)=17.86, p<0.01; myocyte diameter: F(3,82)=14.39,  
p<0.05). A significant consequence of age-induced remodelling of the heart is the 
accumulation of connective tissue and old Wistar rats also displayed markedly higher 
ECM deposition in interstitial spaces than the LV from young control animals (D) 
(F(3,153)=67.712, p<0.05). 
Mechanisms that possibly underlie remodelling changes in the LV were also compared 
across groups for age-related interactions. A positive correlation between level of  HG 
and TGFβ1 activity was observed with levels of active protein increasing in parallel 
with HG increase (Fig 6.2 C). An interesting observation was that although Total 
TGFβ1 protein levels in the LV were significantly reduced with ageing in GK groups 
(Fig 6.2 A, F(3, 17), p< 0.05), active LV TGFβ1 showed a significant increase (Fig 6.2 
B). This suggests that the mechanisms that mediate TGFβ1 activation in the LV, notably 
HG and MMP induction (Wu et al., 2009) may be upregulated in the GK myocardium, 
as is the case in the present study. Within the control group, age-related effects were not 
statistically significant for either parameter (p>0.05).Finally, phosphorylation levels of 
Akt protein (and p70S6K in the prediabetic group) were only significantly upregulated 
by dysglycemia (F(3, 35), p<0.05) and there was no apparent trend towards alteration 
with increasing age in both control and GK groups (p>0.05), (Fig 6.3).  
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Fig 6.1: Age-dependent structural remodelling in the LV. HW/BW ratio (A),  LV wall 
thickness (B) Myocyte diameter (C) and ECM (interstitial) area fraction (D) were 
determined using LV histological sections from young and old diabetic and age-
    a* 
                               LV free wall thickness 
mm 
    a* 
* 
(D) 
Interstitial fibrosis area fraction 
                    Prediabetes                                                                       Chronic Diabetes 
                    Prediabetes                                                                       Chronic Diabetes 
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matched Wistar control groups. n= 4-5 in each group. The letter „a‟ indicates a 
significant ageing effect *significant dysglycemia effect. 2-Way ANOVA, p<0.05 
 
Fig 6.2 
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(C) 
 
 
 
Fig 6.2: Age-related effects on LV TGFβ1 concentration. Total TGFβ1 (A) and Active 
TGFβ1 protein  (B) in control and GK rats determined by ELISA. The letter „a‟ 
indicates a significant ageing effect *significant dysglycemia effect. 2-Way ANOVA, 
p<0.05. n= 3 in each group. Correlation between blood glucose and active TGFβ1 in the 
LV. 
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Fig 6.3 
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Fig 6.3:  Effect of age on Akt (A) and p70S6K (B) phosphorylation  in the LV. 
*significant dysglycemia effect. 2-Way ANOVA, *p<0.05. n=3 in each group
 
 
6.4 Discussion 
 Ageing is often associated with a progressive decline of the cardiovascular system, 
characterized in part by an increase in wall thickness of the ventricles (Burgess et al., 
2001). Aged rodents are also known to present with ventricular hypertrophy in 
association with excess ECM accumulation (Thomas et al., 1992; Lin and Bissell, 1993; 
Seccia et al., 1999). In concord, from the combined results of this study, it can be 
inferred that ageing results in structural remodelling of the LV in the Wistar heart.  As 
given, modestly increased HW in ageing control rats was reflected by a small increase 
in LV mass and significantly increased myocyte dimensions. Moreover, differences in 
ECM accumulation between young and ageing Wistar control rats also reached 
statistical significance, further suggesting a qualitative loss of structural integrity at 18 
months of age, in keeping with clinical observations at comparable age groups (Lakhan 
and Harle, 2008). This work also demonstrates that chronic but modest elevations in HG 
can aggravate age-induced remodelling changes in the GK heart. As hypothesised, the 
effects of ageing on structural remodelling were far more prominent in the GK 
myocardium, presenting with significantly elevated wall thickness, myocyte size and 
ECM deposition relative to younger GK rats as well as age-matched Wistar controls. 
Since myocardial architecture accounts for efficient pump function
 
at the global level of 
the heart, distribution of interstitial
 
fibrosis and myocyte hypertophy during LV 
remodelling are critical factors for adverse prognosis
 
in heart diseases and often 
represent the structural correlate of LV functional deficit (Buckberg et al., 2008). It is 
particularly noteworthy that this marked remodelling occurred in response to fasting 
blood glucose levels (131mg/dL) that very closely skim the upper limit of optimal 
HbA1c goals for T2DM patients with persistent HG, as outlined by current consensus 
guidelines. Indeed, the American Diabetes Association and the European Association 
for the Study of Diabetes consensus guidelines for pharmacotherapy to control HG in 
T2DM recommends fasting glucose values of  70-130 mg/dL to achieve an optimal 
HbA1c treatment goal of <7% (McCulloch, 2010). Moreover, fasting plasma glucose 
has recently been shown to be prognostic of incident HF in a large randomised trial of 
patients at high CV risk (Held et al., 2007) and worryingly, epidemiological studies by 
Poirier and colleagues (2001) and Redfield et al., (2003) have reported that the 
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prevalence of asymptomatic diastolic dysfunction in patients with type 2 diabetes to be 
between 52 and 60%, despite meeting clinical criteria for acceptable glycemic control.  
Taken together, it can be argued that present definitions for dysglycemic states may be 
inadequate and thereby underestimate the implications of the disease, supplementing 
recent articles addressing the need to redefine optimal HbA1c levels (Bergman et al., 
2010; Schainberg et al., 2009), and perhaps „individualise‟ targets in patient populations 
that may require special considerations, especially those with other risk factors for HF. 
On the flipside, another line of reasoning is that if HG drives the pathogenesis of a 
diabetes-specific cardiomyopathy, one would expect intensive glycemic control in 
diabetic patients to translate into meaningful morbidity and mortality benefits. 
However, as mentioned previously, it is disconcerting to note that recent clinical trials 
targeting tight glycemic control have indicated no such effect or the possibility of 
worsening results (Montori et al., 2009). The answer to this conundrum may lie in a 
better understanding of the relationship between dysglycemia and cardiac structure with 
an emphasis on the importance of early subtle changes in glucose levels, as provided by 
the preceding chapters and discussed in the next section. 
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7.1 Perspectives 
It is stressed that a majority of studies dealing with LV remodelling changes in DM are 
focussed primarily at the end point of what is undoubtedly a dynamic process of change, 
with likely origins in prediabetes and IGT as given in Chapter 4. Therefore, 
morphological/functional assessment of remodelling changes in response to HG 
following several weeks of exposure provides a description „after the fact‟, in the 
process missing the temporal relation of the remodelling process that may perhaps be all 
important. Such information can only be obtained from studies like the present, of 
which there is sparsity.   
As described in Chapter 4, T2DM in the GK rat was preceded by a prediabetic phase 
during which cardiomyocyte hypertrophy and modest fibrosis proliferation were already 
apparent in the LV. This finding provides novel experimental support for the clinical 
contention that HG may reflect a risk for HF even in the absence of DM, at least in part, 
by initiating early LV structural remodelling. It is well established that in the longer 
term, hypertrophy and fibrosis progress to a maladaptive state, and become important 
blood pressure-independent predictors of myocardial infarction, HF and cardiovascular 
mortality (Cohn, 2000; Lips et al., 2003) Although association does not equate 
causality, the data presented in Chapter 3 are corroborated by robust epidemiological 
evidence suggesting that IGT and IFG are not only indications of risk for progression to 
T2DM, but also to have independent pathophysiologic significance that includes 
mortality and cardiac functional deficit (Neilsen and Lange, 2005). It has been 
previously hypothesised that the structural manifestations of DCM consist of two major 
components; the first being a compensatory adaptation to HG-related metabolic 
alterations, while the other represents degenerative changes for which the myocardium 
may have only a limited capacity for repair (Thompson, 1988). Underlying this 
supposition is the fact that compensatory mechanisms activated during the initial 
remodelling process have the paradoxical role of serving simultaneously as adaptive, 
compensatory changes, and as major contributing elements to the progression of CHF 
(Cohn, 2000). When supplemented with previous work, the same concepts may also be 
applied to remodelling changes as described in this work, in the GK rat. As such, in the 
following section it is argued that initial compensatory molecular adaptations triggered 
in response to the mild dysglycemia of prediabetes may have become deleterious when 
sustained in the long term and may underscore the worsening phenotype as the T2DM 
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progressed untreated. Comments are limited to molecular events in hypertrophy and 
fibrosis proliferation relevant to data presented in the preceding chapters. 
 First, early transcriptional remodelling of the ECM in the GK rat was characterised by 
increased message levels of the gelatinases MMP 2 and 9. These changes in MMP 
expression,  likely indicators of activity, were further sustained in the long-term, an 
effect that has been previously correlated with onset of apoptotic processes, defective 
angiogenesis and contractile dysfunction (Reinhardt et al., 2002; Yaras et al., 2008). 
Previous work has demonstrated the temporal role of MMPs in which MMP2 levels 
were increased on compensatory concentric remodelling as a protective response to 
ECM proliferation. However, in decompensation and eccentric remodelling, MMP2 and 
9 are known to remain activated, suggesting a role for the MMPs in the teleological 
function of the heart‟s structure (Nishikawa et al., 2003).  
Second, another key example is that of TGFβ1, potent stimulus for hypertrophy, 
collagen synthesis, matrix accumulation and organization, that was found to be 
upregulated in both pre-and overt T2DM in the GK myocardium. Several lines of 
evidence confirm that continuous over-expression of pro-inflammatory cytokines 
including TGFβ1 within the myocardium contribute to the progression of cardiac 
remodelling, the hallmark of heart failure by sustaining cardiac hypertrophy, cardiac 
fibrosis and cell death (Sivasubramanian et al., 2001; Dai et al., 2004). While excessive 
TGFβ1 may be deleterious by promoting collagen deposition, increased myocardial 
stiffness and diastolic dysfunction, how acute activation of TGFβ1 impacts the 
myocardium is less well established. A baseline level of TGFβ signalling has been 
deemed necessary to preserve cardiac structure and to protect the pressure-overloaded 
myocardium from uncontrolled matrix degradation that could result in cardiac dilation 
(Dobaczewski et al., 2010). Furthermore, short–term cardioprotective effects may be is 
associated
 
with the preservation of endothelium-dependent relaxation, prevention
 
of free 
radical generation, a decrease in TNF-  release and attenuation of ischemia-reperfusion 
injury (Lefer et al., 1990; 1993).   
 
Third, involvement of Akt, a protein kinase that regulates
 
a broad range of physiological 
responses in the heart, including metabolism,
 
gene transcription, cell size and survival 
(O‟Neill and Abel, 2005) cannot be discounted. The finding that Akt- and p70S6K 
phosphorylation were increased in prediabetic GK rats in association with LV 
hypertrophy is mirrored in previous work in cardiac-specific doxycycline–dependent 
inducible Akt1–transgenic mice that developed adaptive hypertrophy following short-
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term induction that was reversible on doxycycline treatment (Shiojima et al., 2005). 
Akin to the chronic T2DM rat described in this study, long term sustained Akt 
activation induced extensive hypertrophy. Furthermore, prolonged induction led the 
progression to a dilated phenotype and cardiac dysfunction that was not attenuated but 
further exacerbated by transgene repression with doxycycline. Interestingly, rapamycin 
treatment that inhibits MTOR signalling inhibited Akt-mediated cardiac growth in both 
acute and chronic stages. However, in direct concurrence with the results of this work, 
phosphorylation levels of S6K in DTG hearts were not altered in the chronic phase of 
Akt induction, corroborating the supposition that Akt to S6K signaling is impaired 
following prolonged Akt.  Altogether, these findings reiterate the supposition that the 
fine-tuning of the Akt signalling pathway, reflected in level and duration of Akt 
signaling may modulate compensated vs. decompensated remodelling (Nagoshi et al., 
2005) and current data extend this postulation to the HG-stressed heart.  
Altogether, these alterations at the level of the genome/proteome may represent early 
adaptations in the HG-stressed heart that have the capacity to become deleterious in the 
long term and adversely affect myocardial structure and function. The possibility exists 
that the molecular changes described above may not only persist in response to 
uncontrolled HG like in the present study, but also with glucose control becoming 
myocardial representations of the „legacy effect‟ or „metabolic memory‟ of HG, (DCCT 
Research group, 1993; Nathan et al., 2005) a concept that has arisen from evidence of 
ongoing vascular
 
injury as a result of prior transient episodes of poor glycemic control, 
that is today gaining momentum in pathogenesis of diabetic complications. Very briefly, 
the prevailing view in this fledgling field is that that gene–environment interactions not 
only represent current glycemic status, but also include precedent HG, which could 
transmit conserved epigenetic fates that are spatially and temporally consistent with 
persistent
 
gene activities (Cooper and El Osta, 2010). Occurrence of a HG-mediated 
metabolic memory was documented over 20 years ago in a series
 
of cell culture 
experiments where transient exposure of endothelial
 
cells to HG followed by a return to 
normoglycemia was
 
associated with persistent upregulation of various ECM proteins 
including fibronectin and type IV collagen (Roy et al., 1990). When applied to the 
vasculature, epigenetic changes as a result of HG are held accountable a structural 
fixation due to endothelial damage up to a “point of no return”, when a regression of 
vascular disease progression is no longer possible (Jax, 2010). Extrapolated to the 
present setting, the possibility arises that the myocardium exposed to early transient HG 
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may also present with limited capacity for repair owing not only to the metabolic 
memory in endothelial cells but in the myocardium itself? However, as of this writing, 
an in-depth understanding of the genomic effects of HG and how epigenetic pathways 
may be interrupted for therapeutic benefit is far from realised and the onus is still on the 
early identification and treatment of DM as opposed to intensification at a later stage to 
achieve any meaningful long-lasting cardio-therapeutic benefit.  
 
7.2   Limitations and future scope of the study 
In addressing the limitations of the findings reported in this thesis, the following 
admonishments are due, but in the process have also raised several clinically relevant 
questions worthy of further experimental pursuit.  
First, this work is primarily descriptive by design, the overall outcome being the 
assessment of the interactive effects of ageing and chronic uncontrolled HG on 
remodelling processes in the LV. While the demonstration of HG-related cellular and 
molecular perturbations provides insight into the nature of disease, the data presented do 
not allow us to conclude that hypertrophy, matrix deposition, altered signal transduction 
and gene expression are events in the development or progression of altered ventricle 
function in the diabetic milieu uncomplicated by traditional cardiovascular risk factors. 
The true test for determining compensated vs. decompensated remodelling lies in the 
assessment of LV function that was outside the remit of the present thesis. However, 
previous functional data in the GK rat provide some insight: In GK rats upto 12 weeks 
of age, cardiac function appears to be preserved at resting physiological conditions, 
wherein diastolic dysfunction was undetectable without an added insult of salt overload 
and could be corrected by pharmacological intervention directed at the renin-
angiotensin and the neutral endopeptidase system (Gronholm et al., 2005). Using 
isolated Langendorff-perfused hearts, El-Omar et al. (2004) demonstrated that no 
significant functional changes can be found in GK rat hearts under normoxic conditions 
while after a brief exposure to hypoxia a marked contractile defect could be seen both in  
systolic and diastolic LV function. Reports of LV function at later stages of T2DM in 
the GK rat are not directly forthcoming.  On the one hand, the structural phenotype is 
reminiscent of chronic mechanical stress with pressure overload where cardiomyocyte 
hypertrophy is often observed in association with myocardial fibrosis. The LV 
undergoes concentric hypertrophy without chamber dilatation, and cardiac function is 
usually preserved. The global accumulation of collagen alters the material properties of 
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the myocardium, resulting in a stiffer, less compliant chamber. In some cases, LV filling 
and diastolic function are reduced. DHF ensues, accompanied with progression of ECM 
accumulation in the absence of LV dilatation (Mandinov et al., 2000). Direct evidence 
is lacking however and the contention can only be affirmatively resolved with measures 
of diastolic function. In the absence of the latter, other indices are perhaps suggestive of 
unaffected mechanical activity that is associated with a compensated remodelling 
phenotype even at 18 months of age; These include unaltered resting heart rate and LV 
action potential duration, normal heart rate variability, QRS and QT duration and 
preserved contractile kinetics in isolated ventricular myocytes (Howarth et al., 2004; 
2007). Moreover, unchanged apoptosis index and absence of LV dilation may be 
interrelated findings that further supplement this stance as transition to CHF have been 
associated primarily with an elevated degree of apoptosis (Fedak et al., 2005).  
Although focussed investigation into LV function in this model is warranted, and is a 
key avenue of future exploration, the available data encourages the possibility that mild 
HG elevation and moderately deranged carbohydrate metabolism alone may not be 
sufficient to produce overt changes in cardiac function. By extension, a paradigm arises 
wherein HG in DM potentially promotes a setting in which addition of another stressor 
(obesity, hypertension, hypoxia) is poorly tolerated and „tips the balance‟ in favour of a 
cardiomyopathy with well recognized anatomic, molecular and functional landmarks 
reminiscent of the failing heart. This perspective is reiterated in numerous reports of the 
combined effects of DM and hypertension and/or obesity, ischemic events etc in 
experimental T2DM. At this juncture, the utility of the GK rat comes to the fore as it 
represents a clinically relevant HG-dominated aetiology, providing a tabula rasa setting 
onto which additional „stressors‟ or comorbidities can be added and cumulative CV 
outcomes measured. As such, the present study has presented an important rationale for 
the commencement of experiments wherein adult diabetic GK rats are fed a high 
sucrose diet, to assess the combined effects of mild T2DM and diet-related obesity on 
cardiac function, structure and remodelling.   
Second, in the absence of an interventional approach, this study is by necessity, 
correlative in nature. The demonstration that the myocardial bioactive TGFβ1 is 
upregulated in early in T2DM and can potentially result in many of the features of 
myocardial remodelling that are associated with HF (e.g., myocyte hypertrophy, 
interstitial fibrosis, and induction of a foetal pattern of gene expression) suggests that 
TGFβ1 signalling  plays a central role in the pathophysiology of myocardial failure. 
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However, at present it remains to be determined whether myocardial TGFβ1 mediates 
(or modulates) remodeling of the myocardium in response to a dysglycemic 
environment.  Moreover, where experimental evidence has demonstrated that the 
TGFβ1-inhibitor Tranilast  can reverse the diastolic dysfunction and histopathological 
features of DCM in T1DM (Kelly et al., 2007), translation of these findings in diabetic 
patients is currently hampered by challenges arising from an incomplete understanding 
of TGFβ1 activation patterns and dissection of fibrogenic vs. immunomodulatory or 
homoeostatic effects of TGFβ1 signalling (Dobacewski et al., 2010), altogether 
representing an exciting area of future research with several unanswered questions. 
These include addressing whether TGFβ1 simply represents one of several peptides 
activated in response to HG that act in concert, or does it occupy a particularly focal 
position as a distal convergence point for other pathways? Where most experimental  
observations of TGFβ1 in diabetes are derived from studies performed in young 
animals, current demonstration of upregulated TGFβ1 in the ageing  T2DM rat 
highlights the importance of understanding the consequences of ageing on the TGFβ 
system. Dissection of the relative roles of TGFβ1, β2 and β3 and receptor subtypes and 
their activation effects on different cell types in the myocardial remodelling process will 
further determine whether inhibition of TGFβ1 signalling proves to be an effective 
therapeutic intervention for preventing and ameliorating the development of myocardial 
failure in DM. In the same vein, analysis of the pro-hypertrophic Akt signalling 
pathway  as an offshoot of TGFβ1 activation in the present study also highlights gaps in 
present understanding of  the that signals converge on such a nodal control point and 
what HG-sensitive effector pathways may operate downstream. Advancements in the 
field are not at a stage to allow the full comprehension of how closely related, HG-
sensitive kinases such as PKC, AMPK interact or whether their individual properties 
may be exploited clinically. Nevertheless, the results of the present study do implicate 
the activation of Akt and its downstream effector p70 in association with a hypertrophic 
phenotype, proffering the theoretical basis for such a demand.  
Third, the primary focus of this work has been on molecular events triggered by HG as 
an endpoint. While HG is clearly an important prognostic indicator of poor clinical 
outcome, it may ultimately represent but one proponent of the remodelling process in 
DM. The same theme is reiterated in previous work suggesting that the direct metabolic 
changes caused by diabetic HG may not be the only targets in the treatment of DCM 
(Falcão-Pires et al., 2009).  In interpreting the results of this or any other study of DM, 
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it is important to bear in mind that sequelae, including cardiomyopathy, must be 
considered a mosaic of both primary and secondary alterations (Thompson, 1988).  In 
this sense, insulin resistance and hyperinsulinemia are key mechanisms outside HG-
conditional events in the onset of remodelling changes if the direct actions of insulin 
upon such processes as the transport of glucose and amino acids across cellular 
membranes, the regulation of both anabolic and catabolic enzymes, and the stimulation 
of DNA translation and mRNA transcription are taken into account.  Nevertheless, one 
must appreciate that the involvement of T2DM in HF pathogenesis is associated with a 
panoply of complementary and intricately interrelated triggers not limited to the effects 
of HG and altered insulin signalling resulting in oxidative stress, nitrosative stress, 
signal transduction defects, alterations in [Ca
2+
]i handling and mitochondrial 
dysfunction often acting on a substrate of inherited mutations. As such, it is unlikely 
that a series or a series of series of experimental studies can fully encompass disease 
pathophysiology. However, by focussing on the most practical options for intervention, 
studies like the present have important implications for understanding the basic 
mechanisms responsible for the myocardial response to HG and for the development of 
new treatment strategies for DCM and HF. These are briefly summarised below. 
7.3 Concluding remarks  
Clinical Perspectives 
Previous studies have linked favourable changes in ventricular geometry to improved 
survival (Packer et al., 1991; Pfeffer et al., 1992; Waagstein et al., 1993; Colucci et al., 
1996; MERIT-HF study group, 1999; Konstam et al., 1992;1993; Cohn and Ferrari, 
2000; Linde and Daubert, 2010), suggesting that remodelling may be a suitable 
surrogate endpoint for intervention. Although the issue of whether the ageing GK rat 
represents a decompensated functional phenotype cannot be affirmatively resolved at 
the present time, the results are of this study are still significant in as much as they 
demonstrate the remodelling effects of chronic HG per se. Extrapolated to the clinic 
where HG almost always clusters with features of the metabolic syndrome, it is likely 
that the impact of DM on ventricle structure is amplified by high blood pressure and 
dyslipidemia, compounded by an accelerated atherosclerosis and impaired collateral 
formation that together exacerbate the existing phenotype. In this regard, further 
delineation of the role HG as a fundamental cause of nonischemic cardiomyopathy 
should
 
allow for the development of new therapies aimed at metabolic modulation. The 
transcriptional alterations that underscored the remodelling phenotype in this study may 
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also be of particular therapeutic importance. Transcriptional reprogramming has been 
shown to correlate with loss of cardiac function and, conversely, improvement in 
cardiac function in response to drug therapy or implantation of a left ventricular assist 
device is accompanied by normalization of cardiac gene expression (Abraham et al., 
2002; Lowes et al., 2002; Blaxall et al., 2003; McKinsey and Olson, 2005). Strategies 
to control cardiac gene expression, therefore, represent attractive, albeit challenging, 
approaches for HF therapy in T2DM. 
The study design employed here demonstrated that remodelling changes originate in the 
prediabetic phase that is today understood to be typical of the clinical course of T2DM 
and for which greatest uncertainty exists regarding impact on the heart and the need for 
intervention. The results described in this thesis demonstrate that prediabetes represents 
a morphological intermediate between normal and diabetic states, highlighting a graded 
effect of IGT on ventricle structure along the type 2 diabetic continuum. When coupled 
with recently published studies demonstrating an increased prevalence of diastolic 
dysfunction in prediabetic participants (Stahrenberg, 2010), current data favour the 
assumption that early preventive measures for good metabolic control may mediate a 
long term benefit in the diabetic patient. As a corollary, targeting HG and HG-sensitive 
remodelling mechanisms may represent one possible approach to combat diastolic 
dysfunction and diastolic heart failure.  Ultimate proof-of-concept is a
 
test of blood 
glucose lowering and is the subject of ongoing trials.  A trial of great interest in this 
perspective is the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) 
due to end in late 2011, that has recruited 12,612 patients with type 2 DM or impaired 
glucose tolerance and concomitant CVD, randomizing them to insulin glargine (and 
omega 3-fatty acids) with the dose titrated to achieve normoglycaemia to assess effects 
on 5 year incidence of CV events (Gerstein et al., 2008). Another awaited trial is the 
Acarbose Cardiovascular Evaluation (ACE) trial (Holman and Pan, 2007),   a 
randomised, placebo-controlled trial that investigates the effect of anti-diabetic 
medication acarbose on secondary prevention of cardiovascular events in approximately 
7,500 prediabetic patients with established CVD for a minimum of 4 years. It is 
anticipated that analyses of these trials may demonstrate that restoration of 
normoglycemia in prediabetes allays development of remodelling in the myocardium, 
thus consolidating the present argument for early tight glycemic control.  
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Conclusion 
In conclusion, this study endorses the likely detrimental influence of long-term subtle 
glucose abnormalities on HF pathogenesis, and extends these observations to the 
prediabetic range. Because prevention of HF is a major public health goal and no clear 
improvement in event rates have been noted in the recent past (Recchia and Lionetti, 
2010), the present work presents another basis to suggest that targeting HG at early 
stages is a medical imperative. Further elucidation of the information
 
generated from 
cellular and molecular models like the present may result in the provision of optimal 
therapy at an appropriate time to retard HF progression in the dsyglycemic patient. 
Future work with judicious use of experimental models and parallel studies of the 
human disorder holds great promise in this regard
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